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The detection of oligomers and aggregates formed by two amyloid proteins, insulin and 
amyloid-β (Aβ), is of particular importance due to the role which these species play in Diabetes 
and Alzheimer’s disease, respectively. However, existing techniques are limited in the ability to 
detect insulin and Aβ oligomers due to the fact that these early aggregates are transient, present 
at low concentrations, and difficult to isolate. Improvements must be made to existing techniques 
or alternative techniques must be explored in order to identify and quantify the size of these 
oligomeric and aggregate species without disrupting their structure. 
Capillary and microchip electrophoresis (CE and ME) are two promising electrophoretic 
methods for amyloid oligomer and aggregate detection. The present work demonstrated the 
potential for CE and ME to detect native aggregation of insulin and Aβ proteins, in particular the 
formation of oligomers and aggregates. Furthermore, the effect of hydrodynamic size on 
separation was increased through the use of a highly entangled polymer matrix introduced into 
the capillary, thus offering the potential to resolve populations of amyloid species. Using this 
novel separation, we investigated variables such as sample salt concentration, sample preparation 
method, and fluorescent dye structure. We demonstrated the ability of CE with ultraviolet 
detection (UV-CE) to detect native insulin aggregates estimated to range in size from 30 – 100 
kDa and native Aβ1-40 aggregates estimated to range in size from 10 – 30 kDa, 10 – 300 kDa and 
> 300 kDa. These studies demonstrated the successful detection of physiological concentrations 
(pM) of monomeric fluorescein isothiocyanate labeled insulin (FITC-insulin) and carboxy-
fluorescein labeled Aβ (FAM-Aβ) using CE with laser induced fluorescence detection (LIF-CE). 
However, the detection of oligomeric and aggregate species was altered from unlabeled samples, 
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The detection of oligomers and aggregates formed by two amyloid proteins, insulin and 
amyloid-β (Aβ), is of particular importance due to the role which these species play in Diabetes 
and Alzheimer’s disease, respectively. However, existing techniques are limited in the ability to 
detect insulin and Aβ oligomers due to the fact that these early aggregates are transient, present 
at low concentrations, and difficult to isolate. Improvements must be made to existing techniques 
or alternative techniques must be explored in order to identify and quantify the size of these 
oligomeric and aggregate species without disrupting their structure. Capillary and microchip 
electrophoresis (CE and ME) are two promising electrophoretic methods for amyloid oligomer 
and aggregate detection. The present work demonstrated the potential for CE and ME to detect 
native aggregation of insulin and Aβ proteins, in particular the formation of oligomers and 
aggregates.  
During the earliest portion of this doctoral research (Fall 2009), a literature review was 
conducted by the author in order to determine alternative techniques suitable for the detection of 
amyloid oligomers and aggregates, in particular Aβ. Furthermore, this literature review was 
published in Spring 2012 in the International Journal of Molecular Sciences as a review paper. 
Since this publication gave a good outline for the techniques utilized to detect Aβ oligomeric 
size, this publication was reproduced in Chapter 1 as a part of the literature review for this 
dissertation. The author of this dissertation contributed to writing over 50% of this literature 
review. Furthermore, Chapter 3 outlines studies conducted using CE to detect insulin oligomers 
and aggregates. This information was published in Fall 2011 in the International Journal of 
Molecular Sciences. Again, since this author contributed to writing over 50% of this publication, 





Chapter 1:  Unraveling the Early Events of Aβ Aggregation:  Techniques for the 
Determination of Aβ Aggregate Size 
Pryor, E.; Moss, M. A.; Hestekin, C. N. Int. J. Mol. Sci. Unraveling the Early Events of Aβ 
Aggregation: Techniques for the Determination of Aβ Aggregate Size 2012, 13, 3038-3072 
Abstract 
The aggregation of proteins into insoluble amyloid fibrils coincides with the onset of 
numerous diseases. An array of techniques is available to study the different stages of the 
amyloid aggregation process.  Recently, emphasis has been placed upon the analysis of 
oligomeric amyloid species, which have been hypothesized to play a key role in disease 
progression. This paper reviews techniques utilized to study aggregation of the amyloid-β 
protein (Aβ) associated with Alzheimer’s disease. In particular, the review focuses on techniques 
that provide information about the size or quantity of oligomeric Aβ species formed during the 
early stages of aggregation, including native-PAGE, SDS-PAGE, Western blotting, capillary 
electrophoresis, mass spectrometry, fluorescence correlation spectroscopy, light scattering, size 
exclusion chromatography, centrigugation, enzyme-linked immunosorbent assay, and dot 
blotting. 
Keywords  
amyloid, capillary electrophoresis, centrifugation, dot blotting, enzyme-linked immunosorbent 
assay, fluorescence correlation spectroscopy, light scattering, mass spectrometry, native-
polyacrylamide gel electrophoresis, oligomer, size exclusion chromatography, sodium dodecyl 






 1.  Introduction 
Protein aggregation leads to the formation of insoluble fibrous aggregates, termed 
amyloids, which are commonly associated with disease. However, understanding of the 
mechanism by which proteins aggregate has remained elusive. Although larger aggregates, 
including fibrils, remain important for clinical determination [1,2], small oligomeric aggregates 
are of interest due to their potentially toxic nature and hypothesized role in disease progression. 
However, the study of oligomers is complex due to the fact that these early aggregates are highly 
unstable, present at low concentrations, and difficult to isolate.  
Among the diseases to which amyloids contribute are Alzheimer’s disease (AD), 
Parkinson’s disease, prion diseases, Type II diabetes mellitus, Huntington’s disease, as well as 
many others [3]. The clinical presentation of each amyloid disease is very different, yet the 
presence of amyloid fibrils is a common characteristic of each disease. These amyloid fibrils 
exhibit a cross β-sheet structure in which the β-strands are oriented perpendicular to and 
hydrogen bonding is oriented parallel to the long axis of the fibril [4-9]. In addition, it has been 
shown that the amyloidogenic proteins amyloid-β (Aβ), α-synuclein, huntingtin, prion, and islet 
amyloid polypeptide (IAPP) form structurally similar soluble oligomeric species, which share an 
epitope recognized by oligomer-specific antibodies [10,11]. The commonalities shared by each 
amyloid disease protein suggest that studying the aggregation of one amyloid protein could 
provide insight into the general aggregation mechanism of other amyloid proteins.  
AD is the most common cause of dementia and the most prevalent neurodegenerative 
disorder [12,13]. The neurodegenerative effects of AD are hypothesized to arise from Aβ, a 
partially folded protein that aggregates during the disease process. Aβ was first identified by 





its monomeric form, this protein may be harmless [15].  However, Aβ monomer can self-
assemble via a nucleation-dependent pathway into Aβ oligomers, larger Aβ aggregation 
intermediates, and eventually the fibrillar aggregates that deposit in the brain (Figure 1) [5,16-
18]. Steps within the Aβ aggregation pathway are reversible, such that deposited fibrils could 
give rise to soluble oligomers and intermediates. Soluble aggregate species that appear between 
monomer and insoluble fibrils have been termed within the literature as oligomers [19], micelles 
[20], amyloid-derived diffusible ligands (ADDLs) [21,22], βamy balls [23], amylospheroids 
(ASPDs) [24], and protofibrils [25,26], and the aggregate sizes associated with these definitions 
overlap in range. Smaller species are most commonly referred to as oligomers, including both 
low molecular weight and high molecular weight species, while larger intermediates are often 
referred to as protofibrils. Controversy exists concerning the exact size of the nucleus formed 
within the rate-limiting step of the aggregation pathway; however, most reports speculate that the 
nucleus is oligomeric in nature [27-29]. In addition to oligomers formed along the aggregation 
pathway, off pathway oligomers and higher order assemblies, which fail to give rise to an 













Figure 1: The Aβ aggregation process.  Aβ monomer self-assembles into low 
molecular weight oligomeric species that can give rise to either off-pathway 
oligomers or nuclei of an undetermined size.  Nuclei, which arise within the rate-
limiting step of the Aβ aggregation pathway, will increase in size to form high 
molecular weight oligomers, soluble aggregation intermediates, and finally the 
fibrillar aggregates that deposit in AD brain to yield amyloid plaques. 
 














Aβ proteins comprised of either 40 or 42 amino acids, termed Aβ1-40 and Aβ1-42, are the 
major components found in amyloid plaques [31]. Aβ1-42 has implications for the formation of 
initial aggregates, while Aβ1-40 is more soluble and is the main circulating form in normal plasma 
and cerebrospinal fluid (CSF) [32]. Controversy currently exists over the direct effect Aβ has on 
neurodegeneration, but it is theorized that soluble aggregates of Aβ, rather than monomers or 
insoluble fibrils, may be responsible for the cellular pathology associated with AD [33-35]. This 
hypothesis is supported by experimental observations in vitro which show that soluble 
aggregates formed by synthetic Aβ1-40 and Aβ1-42 can induce cellular dysfunction and toxicity in 
cultured cells [21,36,37] and in vivo where Aβ dodecamers (Aβ*56) have been isolated from the 
brains of transgenic mice and shown to induce memory deficits [38]. In addition, soluble Aβ 
aggregates generated in cell culture drastically inhibit hippocampal long-term potentiation in rats 
[39]. Furthermore, data from mouse models show a poor correlation between the levels of 
insoluble Aβ fibrils and disease severity [40]. It is now more widely accepted that soluble Aβ 
oligomers impair cognitive function and, in addition to synapse loss, correlate most accurately 
with the stage of neurological impairment [11,41-43]. However, the progression from monomer 
to oligomer to insoluble Aβ aggregates is not well understood. Therefore, it is important to 
develop an analytical tool that is suitable for analysis of the Aβ aggregation process. 
A range of techniques are available to study the different stages of the Aβ aggregation 
process. These techniques fall into three main categories: 1) Methods for the quantitative 
detection of monomeric and oligomeric Aβ sizes; 2) Methods for the qualitative detection and 
characterization of oligomeric Aβ species; 3) Methods for the qualitative detection of Aβ fibrils. 
As a result of the imminent need to understand oligomerization events, the focus of this review is 





species formed during aggregation. Accumulating evidence suggests that these Aβ oligomeric 
species play a role in AD progression and severity. Therefore, it is important to gain a better 
understanding of the formation of smaller Aβ species in order to halt the progression of AD. The 
ability to identify and quantify the size of these Aβ oligomeric species without disrupting their 
structure is of utmost importance in order to effectively study the aggregation process and 
develop treatments that target these pivotal oligomerization events. Accordingly, this review 
focuses primarily upon techniques that have been employed in the study of in vitro aggregation 
of Aβ. Currently, a commonly used technique for the quantification of Aβ oligomer sizes within 
in vitro studies is polyacrylamide gel electrophoresis (PAGE). Other techniques that have been 
applied for determining the size of Aβ oligomers include Western blotting, capillary 
electrophoresis, mass spectrometry, fluorescence correlation spectroscopy, light scattering, 
centrifugation, and size exclusion chromatography (SEC). Furthermore, techniques including 
enzyme-linked immunosorbent assay (ELISA) and dot blot have been applied to identify Aβ 
oligomers, but give no size estimates. In the subsequent sections, we will discuss the application 
of each of these techniques to study Aβ oligomers. 
2.  Electrophoretic Techniques for the Quantification of Aβ Oligomer Sizes 
2.1.  SDS- and Native-PAGE 
SDS-PAGE is the most common electrophoretic technique used for Aβ oligomer size 
determination in protein aggregation studies. Furthermore, a review by Bitan et al. cited SDS-
PAGE as the most common method used to characterize toxic protein oligomers [44]. SDS-
PAGE relies on the ability of SDS, a negatively charged detergent, to bind to the protein of 
interest. This binding typically results in the removal of secondary, tertiary, and quaternary 





gives the protein a charge approximately proportional to its length, thereby allowing for size 
based separations. Following the gel electrophoretic separation of proteins, the gel may be 
stained with a dye such as Coomassie Brilliant Blue or silver stain.   
Many research groups have utilized SDS-PAGE, as a standalone technique, to study the 
evolution of Aβ species over time. A study by Ying et al. used SDS-PAGE to separate oligomers 
formed by 100 µM Aβ1-42 incubated at 4°C for 1 day [45]. SDS-PAGE revealed bands for 
monomer (4.5 kDa), trimer/tetramer (16.5 kDa), and higher molecular weight intermediates (>83 
kDa) that appeared as a smear. The oligomer pattern of freshly dissolved Aβ peptides and Aβ 
peptides after a 7 day incubation have been observed by Satoh et al. [46]. Both Aβ1-40 and Aβ1-42 
peptides incubated for 7 days as well as the freshly dissolved Aβ1-42 peptide exhibited a range of 
species from 5 - 20 kDa (Figure 2). However, the resolution of these species was low due to gel 
smearing. Smearing in these gels may be due to the resolution limitations of the gel or could be 
due to continuous associations and disassociations of the aggregating species occurring during 
the electrophoresis analysis. Whatever the cause, gel smearing interferes with the ability to 
identify a particular species and is often overcome by combining SDS-PAGE with another 











Figure 2:  Tricine-SDS-PAGE analysis of the aggregation states of Aβ peptides 
freshly dissolved or incubated for 7 days. Aβ1-42 exhibits bands at 5 - 20 kDa in both 
freshly prepared samples and samples incubated for 7 days. Aβ1-40 incubated for 7 
days also exhibits a smear at higher molecular weights, which is absent in freshly 
prepared samples. Reprinted from [46], with permission from Elsevier. 
 
Figure 2 Tricine-SDS-PAGE analysis of the aggregation states of Aβ peptides freshly dissolved or 
















Although the anionic micelles formed by SDS enhance separation, they can also induce 
non-native behavior. SDS has been reported to accelerate the generation of Aβ fibrils. 
Sureshbabu et al. have shown that Aβ1-42 freshly prepared in phosphate buffered saline exhibits 
monomer, trimer (~13.5 kDa), and tetramer (~18 kDa) bands when analyzed via Western 
blotting [47]. The addition of 1.5 mM SDS to the sample produced bands at 20 and 50 kDa. They 
proposed that the addition of 1.5 mM SDS causes Aβ1-42 to develop a partial helical structure 
whose hydrophobicity induces aggregation. One way to counter this phenomenon is to add urea 
to the sample to further denature the peptide and prevent aggregation. However, the migration 
behavior of Aβ peptides in urea SDS-PAGE is inconsistent. A study by Kawooya et al. showed 
that the Aβ peptide exhibits an unusual electrophoretic mobility in urea SDS-PAGE that is 
proportional to the sum of the hydrophobicity consensus of the peptide rather than the number of 
amino acids in the peptide [31]. Therefore, under these conditions SDS-PAGE may provide 
information about the hydrophobicity of the peptide and not the size. The drawbacks of SDS-
PAGE may be overcome by using native-PAGE to separate various Aβ sizes under conditions 
that allow the protein to remain in a native state. 
Native or “non-denaturing” gel electrophoresis is similar to SDS gel electrophoresis, 
except this technique is run in the absence of SDS. With native-PAGE, protein mobility depends 
on both charge and hydrodynamic size. This differs from SDS-PAGE, where protein mobility 
depends primarily on molecular mass. Since Aβ aggregation is a process that involves changes in 
protein conformation, native-PAGE is often a suitable technique to detect various sizes of Aβ 
species. A study by Iurascu et al. used both SDS-PAGE and Tris-tricine PAGE to analyze the 
species formed by a solution of Aβ1-40 solubilized in fibril growth buffer at pH 7.5 for 5 days at 





oligomeric species of 20 kDa, and high molecular weight aggregates >98 kDa. In contrast, Tris-
tricine PAGE was able to separate these Aβ oligomers into monomer, dimer, trimer, and high 
molecular weight Aβ sizes. Klug et al. have also compared native and SDS-PAGE analyses of 
Aβ aggregation [49]. They observed the presence of oligomers and high molecular weight 
species using native-PAGE with the majority of Aβ species observed in the high molecular mass 
region of the gel. In contrast, SDS-PAGE showed lower molecular weight species (<14 kDa) 
with only trace amounts of high molecular weight species (>50 kDa), suggesting that the 
removal of higher order protein structures by SDS may destabilize aggregates. The differences 
between native-PAGE and SDS-PAGE highlight the importance of examining more than one 
method for studies of the various Aβ aggregate sizes formed throughout the aggregation process.  
2.2  SDS-PAGE in Combination with Western Blotting 
Western blotting is a popular technique used to further process samples after 
electrophoretic separation. This technique provides a more sensitive detection of separated 
proteins. This detection is achieved by transferring separated proteins to a membrane where they 
are detected using antibodies specific to the protein of interest. Antibodies may be either 
monoclonal or polyclonal and are typically specific for a particular part of the Aβ sequence or a 
particular amyloid conformation. Some common antibodies and their recognition motifs are 
listed in Table 1. Selecting the proper antibody is an important consideration in order to achieve 
detection of the desired Aβ species or aggregation state.  
Numerous research groups have utilized Western blot analyses of SDS-PAGE separations 
to characterize SDS-stable Aβ assemblies [21,39,45,50-54]. Ryan et al. analyzed Aβ1-42 oligomer 
preps via silver staining and immunoblot with the 6E10 antibody [53]. The band intensity for 





intermediate sized oligomers were more apparent in the immunoblot analysis. Moore et al. have 

























Table 1:  Antibodies used for Aβ detection in Western blot analysis and their 
respective Aβ recognition motifs.  
Table 1 Antibodies used for Aβ detection in Western blot analysis and their respective Aβ 
recognition motifs 
Antibody Recognition Motif Monoclonal/Polyclonal References 
6E10 Aβ1-17 Monoclonal [50,52-54] 
Ab9 Aβ1-16 Monoclonal [55] 
6C6 Aβ1-16 Monoclonal [50] 
4G8 Aβ17-24 Monoclonal [50] 
2G3 Aβ31-40 Monoclonal [51] 
BA-27 Aβ1-40, C-terminal Monoclonal [56] 
BC-05 Aβ1-42, C-terminal Monoclonal [56] 
A8 amyloid oligomers Monoclonal [45] 
A11 amyloid oligomers Monoclonal [10,57,58] 
NU-4 amyloid oligomers Monoclonal [59] 














SDS-PAGE with Western blotting has also been used to monitor the formation of Aβ 
oligomers in cell culture. A study by Walsh et al. employed SDS-PAGE followed by Western 
blotting to probe the formation of Aβ oligomers in APP-expressing Chinese hamster ovary 
(CHO) cells [50]. Bands corresponding to ~4, 6, 8, and 12 kDa were obtained using the 
monoclonal antibody 6E10. However, it was necessary to concentrate the Aβ protein via 
immunoprecipitation with an Aβ-specific antibody prior to performing electrophoretic 
separation.  
Within in vitro studies of Aβ aggregation, Aβ is typically solubilized in 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP) to break up any residual aggregates that may be present in 
solution [61]. The HFIP is allowed to evaporate, and the peptide film is either resuspended in an 
organic solvent such as dimethyl sulfoxide (DMSO) and diluted into culture media or 
resuspended in a buffer solution such as phosphate buffered saline (PBS). Following incubation, 
samples are analyzed to detect the presence of oligomeric species. Dahlgren et al. utilized such 
an Aβ1-40 oligomer preparation employing DMSO and F12 culture media with incubation at 4°C 
for 24 hours [52]. Western blot analysis using the 6E10 antibody showed bands corresponding to 
monomer and tetramer. Similar results were obtained by Stine et al. using the same sample 
preparation [54]. Walsh et al. utilized an Aβ1-40 oligomer preparation in PBS (pH 7.4) at 37°C 
[51]. After 5 days, Western blot analysis using the antibody 2G3 showed bands corresponding to 
monomer, dimer, and tetramer. However, intermediate sizes of oligomeric species >20 kDa were 
not obtained.  
In addition to Aβ1-40, oligomeric Aβ1-42 species formed in vitro have been well 
characterized using Western blot analyses. Stine et al. studied the formation of Aβ1-42 oligomers 





faint tetramer band were obtained. After 24 hours, these bands were more intense and a smear 
corresponding to oligomeric species ranging from 30 to 70 kDa was present. Furthermore, no 
differences in the band patterns obtained using the 6E10 and 4G8 antibodies were observed. 
Dahlgren et al. obtained comparable 24 hour incubation results using the same oligomer 
preparation as Stine et al. [52]. In addition, similar 0 and 24 hour results were obtained by Ryan 
et al. using a monomer preparation with dilution into PBS and an oligomer preparation with 
dilution into cold PBS+0.05% SDS [53]. Stine et al. also examined the effect of temperature and 
ionic strength on the oligomeric band pattern obtained after incubation of 100 μM Aβ1-42 for 
24 hours. An increase in temperature from 4 to 37°C resulted in a decreased intensity of 
monomer and trimer bands and an increased intensity of the tetramer band. In addition, a smear 
for oligomeric species ranging from 30 to 70 kDa appeared at 25°C with increased intensity at 
37°C. The effect of ionic strength was probed using the oligomer preparation at 37°C with 
incubation for 24 hours in either 10 mM Tris (pH 7.4) or 10 mM Tris supplemented with 150 
mM NaCl. Both preparations yielded bands for monomer, trimer, and tetramer. However, the 
oligomer preparation in 10 mM Tris gave an intense oligomer smear from 30 to 97 kDa while the 
preparation in 10 mM Tris supplemented with 150 mM NaCl showed a less intense oligomer 
smear from 40 to 50 kDa. Ying et al. have also utilized the same Aβ1-42 oligomer preparation as 
Stine et al. but employed for detection the monoclonal antibody A8, which is specific for 
oligomers [45].  A smear for oligomeric species ranging from 16.5 to 25 kDa was observed with 
antibody A8 (Figure 3, lanes 2 and 3). A poorer resolution of oligomers and larger species were 
obtained using the 6E10 antibody (Figure 3, lane 4). These results show that 6E10 may be 
reacting more strongly with higher molecular weight oligomers or that these antibodies bind 





detection of intermediate Aβ oligomers, the presence of a gel smear in many of the studies 
outlined above indicates that this technique does not allow quantification of individual sizes of 
























Figure 3:  Aβ1-42 oligomers obtained upon incubation at 4°C for 24 hours. A 5 mM 
Aβ1-42 sample was prepared in DMSO and diluted to 100 µM in Ham’s F12 medium 
without phenol red. Oligomer mixture was separated by 15% SDS-PAGE, 
transferred to nitrocellulose membranes, and probed with monoclonal antibody A8 
(Lanes 2 and 3) or 6E10 (Lane 4). Sample in Lane 2 was heat denatured prior to 
analysis, while sample in Lane 3 was untreated. Reprinted from [45] with 
permission. The publisher for this copyrighted material is Mary Ann Liebert, Inc. 
publishers. 
 
Figure 3 SDS-PAGE with Western Blotting Analysis of Aβ1-42 oligomers obtained upon 











2.3  SDS-PAGE in Combination with Other Techniques 
SDS-PAGE has been used in combination with oligomer stabilization techniques. One 
such technique that has been applied by Bitan et al. is Photoinduced Cross-Linking of 
Unmodified Proteins (PICUP) [62]. PICUP was developed in the Kodadek laboratory in 1999 to 
study proteins that naturally form stable homo- or heterooligomers [63]. This technique provides 
a snapshot of different oligomer species present in solution at different times. Protein cross-
linking is achieved via the visible light excitation of a tris(2,2’-bipyridyl)dichlororuthenium(II) 
complex which, through a series of steps, leads to the generation of a free protein radical [62,64]. 
This radical can attack an unmodified neighboring protein and form a covalent bond. Therefore, 
PICUP can be used to covalently freeze components of the sample, and these components may 
be separated and analyzed via techniques such as SDS-PAGE [62].  
Bitan et al. have applied PICUP to compare low molecular weight fractions of Aβ1-40 and 
Aβ1-42, where these fractions were isolated by SEC and analyzed via SDS-PAGE [65]. Aβ1-40 
exhibited bands for monomer, dimer, trimer, and tetramer with more faint bands for pentamer 
and heptamer (Figure 4, lane 2). A distinctly different low molecular weight Aβ1-42 oligomer size 
distribution, consisting of three groups of oligomers of varying band intensity, was obtained 
(Figure 4, lane 4). This pattern led to the conclusion that the initial phase of Aβ1-42 
oligomerization involves the formation of pentamer/hexamer subunits which then associate to 
form larger oligomers and intermediates, or protofibrils [65]. Furthermore, they found that for 
Aβ1-40, monomer through tetramer were preexisting species in solution, while pentamer through 
heptamer were formed via a diffusion-dependent reaction of these preexisting species with free 
monomer. Their results verified that PICUP was capable of “freezing” preexisting oligomers but 





conditions, thereby misrepresenting the true Aβ1-40 oligomerization pattern. In addition, this 
study examined samples that were not cross-linked via PICUP before separation by SDS-PAGE. 
A single monomer band was obtained for Aβ1-40 (Figure 4, lane 1), while Aβ1-42 exhibited only 
bands for monomer and trimer (Figure 4, lane 3).  These results indicate that oligomers not 






















Figure 4:  SDS-PAGE analysis of non-cross-linked (lanes 1 and 3) and cross-linked 
(lanes 2 and 4) Aβ1-40 and Aβ1-42. Densitometric intensity profiles of lanes 2 and 4 
are shown on the right and left sides of the gel, respectively. Molecular weight 
standards are shown on the left in kDa. Reprinted with permission from [62].  
 














SDS-PAGE has also been combined with SEC to investigate Aβ aggregation [25,66,67]. 
A study by Podlisny et al. used SDS-PAGE and SEC to observe the aggregation process of Aβ1-
40 secreted from CHO cells [66]. Soluble, SDS-stable aggregates of 6 - 25 kDa, were detected 
during the first 4.5 hours of incubation at 37°C via added radioiodinated synthetic Aβ1-40 at low 
nanomolar concentrations. These 6 – 25 kDa Aβ oligomers represented ~18% of the total Aβ 
signal via SDS-PAGE and ~31% of the total Aβ signal via SEC. This low conservation of the Aβ 
gel signal over time to oligomeric species again indicates that SDS-PAGE underestimates the 
amount of aggregation.  A study by Walsh et al. compared size estimations via SEC to those 
obtained by analyzing these SEC fractions by SDS-PAGE [25]. Aβ1-40 and Aβ1-42 were dissolved 
in Tris-HCl (pH 7.4) and incubated for 48 and 6 hours, respectively, at room temperature. SEC 
fractions corresponding to Aβ1-40 dimers, protofibrils, and fibrils produced a single band at ~4 
kDa on SDS-PAGE. The SEC fraction for Aβ1-42 dimers produced a single SDS-PAGE band at 
~4 kDa, while the SEC fraction for Aβ1-42 protofibrils and fibrils produced a ladder of sizes 
ranging only from monomer to pentamer. These results suggest that SDS-PAGE may not 
accurately detect Aβ aggregate sizes produced throughout aggregation.   
2.4.  Summary of SDS-Based Methods  
As a standalone technique, SDS-PAGE is able to detect Aβ1-42 species ranging from 
monomer to tetramer. Native-PAGE has been used to separate Aβ1-40 species ranging from 
monomer to pentamer. However, for higher order oligomers, these techniques only give a range 
of sizes that appear as a smear on the gel. SDS-PAGE is often coupled with other techniques 
such as Western blotting and PICUP to enhance the resolution of Aβ sizes. By coupling SDS-
PAGE to these techniques, a better resolution of Aβ1-40 species which appear as individual gel 





individual gel bands corresponding to monomer, trimer, tetramer, and hexamer has been 
obtained. However, the resolution of intermediate sized Aβ oligomers ranging from 30 - 70 kDa 
by PAGE remains a significant challenge.  The addition of SDS may also lead to complications 
including the acceleration of aggregation and the increased instability of oligomers, thereby 
misrepresenting the distribution of Aβ oligomeric species.     
2.5.  Capillary and Microfluidic Capillary Electrophoresis  
Capillary electrophoresis (CE) is another electrophoretic technique employed for size 
based separations of Aβ. CE offers a fast and highly efficient separation of molecules with a 
broad range of properties thereby making it well suited for the separation of different sizes of 
protein aggregates [68]. CE separates molecules based on electrophoretic mobility, which results 
from differences in charge, shape, and/or size, and may be used either with or without SDS. 
Thus, CE allows a highly efficient separation and resolution of native forms of Aβ species, 
thereby overcoming the problem of gel smearing in many SDS and native-PAGE gel separations. 
CE detection typically uses either ultraviolet (UV) absorbance or laser induced fluorescence 
(LIF) to detect proteins. UV can detect proteins without any additional labeling, but typically has 
a lower sensitivity than LIF. LIF usually requires labeling of the molecules, but is highly 
sensitive, with previous reports of CE-LIF detection of double-stranded DNA down to the pg/μL 
range [69,70]. The ability to detect biomolecules at these low concentrations is necessary for the 
analysis of physiologically relevant protein concentrations. 
CE with UV detection has been utilized by various researchers to detect Aβ species from 
monomers to large aggregates. Verpillot et al. used CE-UV to separate monomeric Aβ ranging in 
size from 37 - 42 residues and differing in length by a single residue, however they did not 





detection of Aβ1-40 and Aβ1-42 oligomers formed in PBS (pH 7.4) at room temperature [72]. At 0 
hours, peaks for Aβ1-42 oligomers in a size range from monomers to undecamers (~50 
kDa)/dodecamers (~54 kDa) and larger aggregates were obtained (Figure 5, t0). A similar peak 
pattern was obtained over an incubation time period of 24 hours with an increase in intensity of 
the higher molecular mass (>50 kDa) oligomer peak (Figure 5, t = 1440 minutes). However, 
resolution of individual species, especially in the larger aggregate peak, was not achieved. 
Compared to Aβ1-42, the peaks for Aβ1-40 were better resolved, but a drastically different peak 
pattern was observed. At 0 hours, three peaks ranging in size from 3 to 30 kDa were obtained. A 
decrease in the intensity of the 10 to 30 kDa peak was observed over an incubation period of 24 
hours with the disappearance of all peaks after 48 hours. This result shows that CE-UV is 
capable of detecting small Aβ1-40 species and intermediate oligomeric Aβ1-42 species. In addition, 
the CE electrophoretic profiles of Aβ1-40 and Aβ1-42 differ significantly, supporting observations 














Figure 5:  Electropherograms for Aβ1-42 species formed in room temperature PBS 
(pH 7.4) at different elapsed aggregation times from t0. CE was performed with 50 
mbar pressure injection for 8 s with separation at 16 kV. Molecular weights 
corresponding to each peak were determined using Microcon centrifugal filter units 
with molecular weight cutoffs of 3, 10, 30, and 50 kDa. Peaks with migration times 
of 5 – 10 min represent monomers to undecamers/dodecamers (3 – 50 kDa) and 
peaks with migration times of 10 – 15 min represent larger aggregates (>50 kDa). 
Reprinted from [72] published by John Wiley and Sons, © 2004 WILEY-VCH 
Verlag GmbH & Co. KGaA.   
 
Figure 5 CE Electropherograms for Aβ1-42 species formed in room temperature PBS (pH 7.4) at 








A study by Picou et al. also observed substantial differences in the CE-UV 
electrophoretic profiles of Aβ1-40 and Aβ1-42 [73]. Two different preparations typically employed 
to form Aβ monomer or fibril were used. The Aβ1-40 monomer preparation yielded a single 
monomer peak with a molecular weight of 4.3 kDa. In contrast to Aβ1-40, the Aβ1-42 monomer 
preparation gave peaks for both monomer and fibrillar species. A peak pattern similar to the Aβ1-
42 monomer preparation was also obtained for the Aβ1-40 fibril preparation. The Aβ1-42 fibril 
preparation produced multiple aggregate peaks and no monomer peak. Although this study was 
able to separate Aβ monomer from mature fibrils, the detection of oligomeric Aβ species was not 
achieved.  
LIF detection has also been utilized as a more sensitive means of identifying lower 
concentrations of Aβ aggregate species separated using CE. A study of the aggregation patterns 
of Aβ1-42 using CE-LIF was conducted by Kato et al. [74]. The fluorescent dye thioflavin T 
(ThT) was used to detect two different Aβ1-42 aggregate sizes with a 5 minute analysis time [74]. 
In addition, this study examined the effect of seeding a freshly prepared Aβ1-42 sample with a 
fibrillar Aβ1-42 seed. For samples without a seed, a broad peak was observed with CE-LIF as 
opposed to seeded samples that contained both a sharp and broad peak, although no specific sizes 
were determined. 
In addition to CE-LIF, microfluidic capillary electrophoresis (MCE) has been used to 
study Aβ. MCE is similar to CE except operates on a much smaller scale. The advantages of 
MCE over conventional electrophoresis methods include low sample consumption and a strong 
potential for automation and integration [75,76]. MCE has been utilized to study Aβ monomeric 





(Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-40, and Aβ1-42) [77]. However, MCE has yet to be applied for the 
study of Aβ oligomers. 
CE as a technique for the detection of Aβ species formed throughout aggregation is still 
in its early stages. CE-UV has been utilized to detect small Aβ1-40 species ranging from 3 - 30 
kDa as well as to separate Aβ1-40 monomer from fibrillar species. Aβ1-42 species ranging from 3 - 
50 kDa and >50 kDa have been detected using CE-UV. In addition, the separation of Aβ1-42 
monomer from fibrillar species has been achieved using CE-UV, and the separation of two 
different Aβ1-42 fibrils has been accomplished with CE-LIF. The development of MCE has 
prompted researchers to apply this technique to the study of Aβ, with initial investigations 
demonstrating the separation of five Aβ isoforms differing in length by a single residue. The 
ability of CE to detect sizes from monomers to fibrils offers the potential to monitor the amyloid 
aggregation process over time, and the use of LIF provides the potential for examining 
physiologically relevant concentrations.  However, further improvements to this technique must 
be made in order to enhance the resolution of intermediate sized Aβ species. 
3.  Spectroscopic Techniques for the Quantification of Aβ Oligomer Sizes 
3.1  Mass Spectrometry 
Mass spectrometry (MS) is a widely used technique for the detection of monomeric and 
oligomeric Aβ. In MS, the sample undergoes vaporization, and components are ionized by 
impacting them with an electron beam. Ions are separated by their mass-to-charge ratio using 
electromagnetic fields, and the ion signal is processed into a mass spectrum characteristic of the 
analyte. MS uses a variety of ionization sources depending on the sample state. For vapor 
samples, the most common source used to generate gas-phase ions is a radioactive ionization 





[80,81], photoionization (PI) [80,82], and secondary electrospray ionization (SESI) [83-86] have 
been used as well. The most commonly used ionization source for liquid samples is electrospray 
ionization (ESI) [83-86], and for solid samples matrix assisted laser desorption ionization 
(MALDI) [87-90] and laser desorption ionization (LDI) [91-93] are widely used ionization 
sources. In addition, there are various types of mass analyzers that process the ion signal into a 
mass spectrum. These include time-of-flight, quadrupole, ion trap, Fourier transform ion 
cyclotron, magnetic sector, and tandem instruments as recently reviewed by Kanu et al. [94]. The 
most common MS techniques used for protein analyses are MALDI-MS and ESI-MS.  
3.2  Matrix-Assisted Laser-Desorption Ionization (MALDI)-MS 
MALDI-MS may be combined with other separation techniques such as SDS-PAGE to 
provide more quantitative size estimates. Iurascu et al. utilized SDS-PAGE in combination with 
MALDI-MS to analyze a solution of Aβ1-40 solubilized in fibril growth buffer at pH 7.5 for 5 
days at 37°C [48]. MALDI-MS indicated that the soluble fraction contained two different ion 
mobilities, indicative of oligomerization. Parallel analysis using SDS-PAGE and Tris-tricine 
PAGE revealed the presence of oligomeric Aβ1-40 of ~20 kDa (pentamer). A study by Maji et al. 
subjected wild-type and tyrosine substituted Aβ1-40 and Aβ1-42 to PICUP and quantified the 
resulting aggregate sizes via MALDI-MS and SDS-PAGE [95]. SDS-PAGE yielded wild-type 
Aβ1-40 bands for monomer through hexamer. However, MALDI-MS was only able to attain 
masses for the monomer through tetramer bands, while masses for the pentamer and hexamer 
bands could not be measured. This inconsistency could be attributed to the presence of very 
small quantities of pentamer and hexamer. Alternatively, these species may not be desorbed from 
the MALDI matrix as readily as smaller oligomers. In addition, MALDI-MS spectra of tyrosine 





be incorporated into the MALDI matrix due to their exceptional hydrophobicity or their covalent 
or weak noncovalent interactions were disrupted by the desorption/ionization process. These 
results show that although MALDI-MS may be used to quantify Aβ oligomers, this technique 
does have drawbacks including limited matrix interactions as well as the inability to distinguish 
molecules with overlapping charge-to-mass ratios, expense, and labor intensive analyses [96,97]. 
In addition, since MALDI is typically coupled with a pre-separation step such as SDS-PAGE, its 
detection capabilities may vary depending on the pre-separation technique used.  
3.3  Electrospray Ionization (ESI)-MS 
ESI-MS has been used to analyze liquid Aβ samples. Palmblad et al. have utilized ESI-MS 
to study the effect of Met-35 oxidation on the formation of Aβ1-40 oligomers [98]. They found 
that freshly dissolved Aβ1-40 and Aβ1-40Met35(O) both exhibited monomers and dimers (Figure 6, 
panels a and b). In addition, Aβ1-40 and Aβ1-40Met35(O) incubated for 41 minutes exhibited 
similar monomer and dimer signals (Figure 6, panels e and f). In contrast, trimers and tetramers 
were detected for freshly dissolved Aβ1-40 (Figure 6, panel c) whereas these species were not 
detectable for freshly dissolved Aβ1-40Met35(O) (Figure 6, panel d). However, after >95 minutes 
of incubation, Aβ1-40 and Aβ1-40Met35(O) exhibited similar trimer and tetramer signals (Figure 6, 
panels g and h). These results suggest that Met-35 oxidation slows a conformational change that 
may be necessary for early formation of Aβ1-40 trimers. Although ESI-MS can be used as a way 
to freeze protein oligomers in time, complications arise when a protein could simultaneously 
populate a number of states with the same mass-to-charge ratio [97]. This complication makes it 






Figure 6:  ESI-Mass spectra of 4.0 µM freshly dissolved Aβ1-40 (panels a and c), 
freshly dissolved Aβ1-40Met35(O) (panels b and d), Aβ1-40 and Aβ1-40Met35(O) 
incubated for 41 minutes (panels e and f), and Aβ1-40 and Aβ1-40Met35(O) incubated 
for >95 minutes (panels g and h). Aβ1-40 samples were dissolved in H2O and Aβ1-
40Met35(O) samples were dissolved in H2O and 2.7% H2O2. Reprinted with 
permission from [98]. Copyright (2002) The American Society for Biochemistry and 
Molecular Biology. 
 
Figure 6 ESI-Mass spectra of 4.0 µM freshly dissolved Aβ1-40, freshly dissolved Aβ1-40Met35(O), 
Aβ1-40 and Aβ1-40Met35(O) incubated for 41 minutes, and Aβ1-40 and Aβ1-40Met35(O) incubated 





3.4  Ion Mobility (IM)-MS 
IM-MS is capable of separating ions by both their shape and charge, which has rendered 
it a successful technique for the separation of conformers of various shapes arising from a single 
protein [94,99-101]. Ions are separated in time according to their cross sections by passing them 
through a drift cell containing helium gas under the influence of a weak electric field [102]. The 
flight times are combined with the drift times to yield the mass-to-charge IM distributions for all 
ions in the sample. The ability of IM-MS to separate species that differ in shape or size but have 
the same mass-to-charge ratio has made this technique a powerful tool for analyses of the early 
stages of Aβ oligomerization. 
Various research groups have utilized IM-MS to gain a better understanding of the early 
events of Aβ aggregation. Aβ1-40 conformational states in freshly dissolved and aggregated 
solutions have been studied by Iurascu et al. [48]. Two different conformational states were 
obtained for freshly dissolved Aβ1-40 and the soluble fraction obtained by Aβ1-40 incubation for 5 
days at 37°C and pH 7.5. Bernstein et al. used IM-MS to study the aggregation of Aβ1-42 versus 
Aβ1-42 with a Phe19→Pro19 substitution [103]. Monomers and large oligomers were produced 
by unfiltered Aβ1-42, while protein passed through a 10,000 amu filter yielded monomer, dimer, 
tetramer, hexamer, and an aggregate of two hexamers.  In contrast, the Pro19 alloform produced 
monomer, dimer, trimer, and tetramer but no large oligomers. In a more recent study by 
Bernstein et al., a mechanism for Aβ1-40 and Aβ1-42 oligomerization and eventually fibril 
formation was postulated [104]. Using IM-MS, this group was able to determine the shape and 
size of Aβ1-40 and Aβ1-42 oligomers. Aβ1-40 oligomerization proceeded via the formation of dimer 
and tetramer followed by the very slow formation of fibrils containing a β-sheet structure. In 





followed either by the formation of dodecameric species or the slow conversion into fibrils 
containing a β-sheet structure. Representative IM-MS data obtained by Berstein et al. for Aβ1-42 
and Aβ1-40 are shown in Figure 7. Similar findings about the early oligomerization behavior of 
Aβ1-40 and Aβ1-42 were obtained by Murray et al. using IM-MS [102]. In addition, these 
researchers found that in an equimolar mixture of Aβ1-40 and Aβ1-42, Aβ1-40 inhibited the 
formation of higher molecular weight oligomers by Aβ1-42. This result suggests that Aβ1-40 could 




















Figure 7:  IM-MS arrival time distributions for (a) 30 µM Aβ1-42 in 49.5% H2O, 
49.5% acetonitrile, and 1% NH4OH and (b) 30 µM Aβ1-40 in ammonium acetate (pH 
7.4). D = dimer, Te = tetramer, H = hexamer, Do = dodecamer with a z/n = -5/2. 
Figure 7a adapted with permission from [103]. Copyright (2005) American Chemical 
Society. Figure 7b adapted by permission from Macmillan Publishers Ltd.: Nature 
Chemistry [104], copyright (2009). 
 
Figure 7 IM-MS arrival time distributions for (a) 30 µM Aβ1-42 in 49.5% H2O, 49.5% 
acetonitrile, and 1% NH4OH and (b) 30 µM Aβ1-40 in ammonium acetate (pH 7.4). D = dimer, Te 












3.5 Fluorescence Correlation Spectroscopy 
Fluorescence correlation spectroscopy (FCS) has also been utilized to gain information 
about the size of Aβ species formed throughout aggregation [24,105-107]. FCS was originally 
developed by Eigen and Rigler in the early 1990s [108]. In FCS, unlabeled protein is combined 
with fluorescently labeled protein and, at various times throughout aggregation, the fluorescent 
dye is excited by a sharply focused laser beam. The emitted fluorescence of a small number of 
molecules in solution is observed. The fluorescence intensity fluctuates due to Brownian motion 
of the particles, and an intensity correlation function can be used to determine the average 
number and average diffusion time (ie. molecular size) of molecules. Advantages of FCS include 
high sensitivity (nM range and below), ability to examine a wide range of molecular sizes (ie. 
monomer, oligomer, fibrils) [109], fast analysis times [109], and small sample volumes 
(femtoliter) [110]. In addition, no pre-separation step is required for the determination of particle 
radius via FCS. However, assumptions must be made about the kinetics of the aggregation 
process as well as molecular shape in order to determine molecular weight. 
Various researchers have employed FCS to monitor Aβ aggregation. A study by 
Matsumura et al. utilized FCS to monitor the aggregation of Aβ1-40 and Aβ1-42 and observed 
distinct aggregation pathways, dependent upon incubation conditions, that resulted in the 
formation of either oligomeric species or fibrils [24]. Two different site-specific labels at either 
the N-terminus or Lys16 were used to monitor aggregation. One pathway involved the formation 
of 10 - 15 nm spherical Aβ1-42 assemblies of ~330 kDa, termed amylospheroids (ASPDs), 
appearing after 5 hours of gentle agitation of a 50 µM Aβ1-42 solution in F12 buffer at 4°C. These 
ASPDs were formed from Aβ species of ~12.7 kDa initially present in solution. In addition, the 





alternative pathway involved fibril formation from 100 µM Aβ1-40 solutions in Dulbecco’s PBS 
(pH 3.5) with gentle agitation at 4°C. This pathway began with dimer formation at 0 hours, 
followed by the formation of intermediate sized species of 15 - 40 nm after 2 - 9 hours. 
Eventually, larger molecular weight fibrils (14,000 kDa) were formed after 24 hours using Aβ 
labeled site-specifically at Lys16. However, much larger aggregates (120,000 and 3,900,000,000 
kDa) were formed after 24 hours using Aβ labeled site-specifically at the N-terminus. It was thus 
postulated that the Lys16 fluorescent probe interfered with aggregation into larger fibrils. By 
employing oligomer formation conditions, Cizas et al. used FCS to observe much smaller Aβ1-42 
oligomers [105]. They dissolved Aβ1-42 in HFIP with subsequent dilution into de-ionized water 
and incubation at 20°C with or without agitation (500 rpm) for 24 hours. The average radius 
observed for unagitated samples was ~3.4 nm while the radius for agitated samples was ~8 nm. 
Garai et al. have applied FCS to monitor the Aβ1-40 aggregation process when monomer is 
initially the predominant species present in solution (Figure 8, time = 0.05 hours) [107]. After 1 
hour, intermediate aggregates of 20 - 100 nm formed and grew to sizes >1000 nm after 24 hours 
(Figure 8, time = 2 – 24 hours). These Aβ1-40 intermediate sizes are larger than those observed by 
Mastmura et al. and could be due to different sample preparations or the presence of different Aβ 
species at 0 hours. These studies again show that although Aβ1-40 and Aβ1-42 differ by only two 









Figure 8:  Size distributions obtained via FCS for Aβ1-40 dissolved in 2.8 mM 
NaOH, diluted to 10 µM in HEPES (pH 7.4), and incubated at room temperature. 
Sample taken at  ~3 minutes shows predominantly monomeric species with the 
formation of intermediate aggregates of 20 – 100 nm after 1 hour and further growth 
into larger aggregates >1000 nm after 24 hours. Reprinted with permission from 
[107]. Copyright (2008), American Institute of Physics. 
 
 
Figure 8 Size distributions obtained via FCS for Aβ1-40 dissolved in 2.8 mM NaOH, diluted to 10 











3.6 Summary of Spectroscopic Methods 
MS is capable of detecting low oligomer concentrations but is expensive and has 
difficulty separating species with identical mass-to-charge ratios such as Aβ aggregates [96,97]. 
To address this problem, MS is often coupled with an upstream separation technique such as 
SDS-PAGE [48,95]. In addition, IM-MS has been utilized for the separation of different sizes 
and conformations of Aβ1-40 and Aβ1-42 with promising results for small oligomers. However, the 
addition of a step such as IM also increases the time needed for analysis and therefore decreases 
the chances of detecting transient species. Consistent results for Aβ1-40 and Aβ1-42 oligomer sizes 
formed during the earliest events of aggregation have been obtained using MS techniques. 
However, the detection of larger Aβ1-40 and Aβ1-42 oligomeric species ranging from ~32 - ~100 
kDa has not been achieved using MS. FCS does not require a pre-separation step to determine 
the particle radius of species in a sample. This technique has been successfully applied for the 
detection of small and intermediate sized Aβ oligomers as well as large Aβ fibrils. However, 
FCS yields average values of particle radius for a population of aggregates and not individual 
particle sizes or their distributions.  
4.  Additional Techniques Utilized for Aβ Aggregate Size Determinations 
4.1 Light Scattering Techniques 
Light scattering techniques have been used to measure Aβ aggregate sizes. Classical, or 
multi-angle, light scattering (MALS) employs a well collimated, single frequency light beam to 
illuminate a sample of macromolecules [111]. When incident light interacts with the 
macromolecules in solution, an oscillating dipole is induced and the light is re-radiated, or 
scattered [112]. Aggregated structures induce coherent scattering, and as a result the intensity of 





scattering that result from the independent scattering of individual molecular elements can give 
rise to an angular dependence of the scattered light, which is a function of the size of the 
molecule. Thus, the intensity of the scattered light is measured as a function of scattering angle, 
often referred to as Rayleigh scattering, to yield the molar mass and root mean square (rms) 
radius of the macromolecules [112]. MALS is ideal for characterizing larger assemblies 
(>10 nm). In contrast, for analyses in which smaller molecules are present in solution, dynamic 
light scattering (DLS), also known as quasi-elastic light scattering (QELS), is used. DLS 
employs a fast photon counter to measure time dependent fluctuations in scattered light at a 
single angle (usually 90°), which are related to the rate of diffusion of the macromolecules 
[112,113]. Measurement of diffusion rates allows calculation of the hydrodynamic radius (RH) of 
macromolecules using the Stokes-Einstein equation [113]. When used as standalone techniques, 
MALS yields the weight-averaged molar mass for all molecules in solution. While DLS can 
distinguish populations that differ in size by a factor of five or more, individual peaks exhibit a 
high degree of polydispersity. Therefore, it is often necessary to utilize a pre-separation step in 
conjunction with light scattering to obtain an accurate estimate of the relative amounts of 
individual aggregates present in solution. In addition, the exponential dependence of scattering 
on aggregate size prohibits the detection of low quantities of small aggregates in the presence of 
larger species. 
Various researchers have utilized MALS and/or DLS to characterize Aβ assemblies 
formed throughout aggregation [114-117]. Carrotta et al. utilized both MALS and DLS to 
monitor the aggregation of a 185 µM Aβ1-40 sample at pH 3.1 and 37°C [117]. DLS was used to 
characterize aggregate sizes formed during the early stages of aggregation up to ~38 hours, as 





distribution became more polydisperse over time and ranged from 10 - 52 nm after 37 hours 
(Figure 9f). However, only average size distributions could be obtained and no information was 
reported about the concentrations of each aggregate species (ie. monomer, dimer, etc.). Larger 























Figure 9:  Time evolution of RH for a 185 µM Aβ1-40 sample incubated at pH 3.1 and 
37°C.  Distributions were determined using a constrained regularization method. 
Reprinted with permission from [117]. Copyright (2005) The American Society for 
Biochemistry and Molecular Biology. 
 










Similar to these findings, Lomakin et al. observed using DLS the initial formation of a 
spherocylindrical micelle with average RH of 7 nm immediately following dissolution of Aβ1-40 at 
pH 2 [115]. In addition, they reported two different kinetic patterns for aggregation of Aβ1-40 
prepared at a concentration either above or below the critical micelle concentration (CMC) of 
100 µM [114] Complimentary DLS and MALS studies by Murphy and Pallitto also 
demonstrated an effect of Aβ concentration upon aggregate formation [118].  They demonstrated 
that dilution of Aβ1-40 from urea into PBS yielded larger aggregates at lower protein 
concentrations, while the increase in RH for aggregates was proportional to the protein 
concentration.  In addition, MALS data indicated that the linear density of aggregates increased 
with protein concentration. Thunecke et al. have utilized MALS and DLS to study the 
aggregation of Aβ1-40 and Aβ1-42 in acetonitrile-water mixtures [116]. At the onset of 
aggregation, Aβ1-42 was present as a 2 nm oligomer and rapidly formed fibrils with a length <50 
nm within 4.5 hours. In contrast, Aβ1-40 initially exhibited large aggregates that grew 70 times 
slower than aggregates of Aβ1-42. However, the presence of these large aggregates may preclude 
observation of a separate population of oligomers. These findings highlight differences in the 
dissolution and aggregation of Aβ1-40 and Aβ1-42. 
4.2 Light Scattering in Combination with Other Techniques 
Because light scattering techniques provide information about the weight-average molar 
mass and radius for all molecules in solution, they are often coupled with a pre-separation 
technique such as asymmetric field flow fractionation (AFFF) [119] or SEC [25,120,121] to 
better characterize individual Aβ oligomeric species. A study by Nichols et al. utilized MALS 
with SEC as well as DLS to characterize Aβ1-40 protofibrils following growth by monomer 





average RH of 51 nm and molecular weight, determined via MALS of 30,000 kDa. Protofibrils 
that had grown by monomer deposition had an average RH of 143 nm and molecular weight of 
57,000 kDa, while protofibrils that had grown by lateral association had an average RH of 104 
nm and molecular weight of 86,000 kDa. Furthermore, SEC-MALS revealed that the mass per 
unit length of protofibrils was unchanged during elongation, but was increased following 
association. The temporal change in size of Aβ1-40 protofibrils isolated by SEC has also been 
monitored via DLS by Walsh et al. [121]. The initial average RH for protofibrils isolated by SEC 
was ~27.8 nm, and protofibril size grew to 80.6 nm over a period of 9 days when 17 µM Aβ1-40 
in Tris-HCl (pH 7.4) containing 0.04% w/v sodium azide was incubated at room temperature. 
AFFF is another technique that has been coupled with light scattering to estimate the 
molecular weight of individual Aβ aggregates. AFFF exploits the parabolic flow profile created 
by the laminar flow of a sample through a thin, parallel plate flow channel, where the lower 
surface is solvent permeable [122]. A perpendicular force applied to the laminar flow stream 
drives molecules towards the permeable boundary layer of the channel [123]. Because Brownian 
motion of the particles creates a counteracting force, smaller particles localize higher in the 
channel leading to separation of different molecular sizes, with smaller molecules eluting first 
[122]. Rambaldi et al. utilized AFFF-MALS to monitor the aggregation of Aβ1-42 in PBS (pH 
7.4) at room temperature over 24 hours [119]. At 0 hours, two major peaks were obtained 
corresponding to molecular weights of ~60 kDa and ~1,000 - 100,000 kDa. In addition, the 
retention time of the ~60 kDa species decreased between 0  and 4 hours, corresponding to an 
increase in aggregate size of 6.5 - 4.7 nm. The intensity of the two peaks also decreased over 24 
hours, possibly due to irreversible adsorption of the sample to the permeable surface. Although 





improvements to the ultrafiltration membrane are critical to enhance analysis capabilities. In 
addition, the smallest molecular weight cutoff for membranes is 5 kDa, making detection of Aβ 
monomeric species difficult. 
4.3 Centrifugation 
Centrifugation has also been explored as a method for determining Aβ size. Here, 
sedimentation coefficient (s) values can be correlated with molecular weight. Mok and Howlett 
provide a nice overview of sedimentation velocity centrifugation in the context of Aβ analysis 
[124]. Ward et al. used density gradient centrifugation to fractionate Aβ1-40 samples incubated at 
pH 7.4, 35°C for 30 minutes, 18 hours, or 18 days [26]. Using SDS-PAGE with Western blotting 
to analyze sedimented samples, they found that Aβ1-40 incubated for 18 hours contained only 
small molecular weight oligomers (4 – 17 kDa), while Aβ1-40 incubated for 18 days showed the 
presence of a >250 kDa band as well as significant streaking, indicating other unresolved sizes. 
Huang et al. used analytical ultracentrifugation to compare Aβ1-40 samples prepared at pH 3, 5, 
and 7 [125]. They determined that at pH 5 there were no soluble aggregate species. At pH 7, they 
identified small oligomers with an average molar mass of 12.1 kDa, and at pH 3 they identified a 
range of aggregate sizes with an average molecular weight of 1 MDa. Nagel-Stefer et al. also 
used sedimentation velocity centrifugation for the analysis of Aβ1-42 samples after 5 days of 
agitation at room temperature and were able to detect “globular species” ranging in size from 
~270 kDa - 3.8 MDa as well as even larger aggregates [126].  Interestingly, they also compared 
three different simulation methods for determining molecular weight from sedimentation values 





4.4 Size Exclusion Chromatography 
SEC, a chromatographic technique, separates molecules based on molecular 
hydrodynamic volume or size. Molecules too large to penetrate the pores of the column packing 
material elute in the void volume, while smaller molecules travel through the pores and elute at 
later times. Globular proteins are often used as standards to estimate the size of Aβ oligomers. 
However, since Aβ is a linear, hydrophobic peptide, comparisons between the elution behavior 
of Aβ oligomers and size standards are difficult [127]. In addition, the sample is subjected to a 
several-fold dilution, which facilitates the dissociation of small unstable oligomers [128], thereby 
precluding the detection and size estimation of these species.  
Although SEC is typically utilized in conjunction with another technique, SEC as a 
standalone technique has been employed for the study of Aβ aggregates [129-131]. Englund et 
al. used SEC to detect low molecular weight Aβ aggregates, Aβ protofibrils, and Aβ fibrils 
formed using different Aβ sample preparations [130]. The size of low molecular weight Aβ 
aggregates ranged from 4 - 20 kDa (Figure 10, panel a), while Aβ protofibrils were >100 kDa 
(Figure 10, panel c). A more narrow size distribution of Aβ1-42 oligomers of 24 ± 3 kDa 
(pentamer - hexamer) has been obtained by Ahmed et al. with SEC [129]. This resolution was 
achieved by stabilizing Aβ1-42 oligomers at a low temperature (4°C) and low salt concentration 
(10 mM NaCl). Zheng et al. have analyzed via SEC freshly prepared 1 mg/mL Aβ1-40 in PBS 
(pH 7.4), diluted from DMSO, and achieved resolution of an Aβ1-40 trimer with molecular weight 
of 11.6 - 15.7 kDa [131]. The difference in sizes obtained by Ahmed et al. and Zheng et al. most 
likely result from differences in sample preparation. While these studies show promising results 





intermediate Aβ oligomeric sizes formed during aggregation has not been achieved using SEC as 

























Figure 10: HPLC-SEC chromatograms of Aβ aggregates produced using sample 
preparations of 50 µM synthetic Aβ designed to optimize (a) low molecular weight 
Aβ1-40 oligomers and (c) Aβ1-42 protofibrils. To ensure that insoluble fibrils were not 
present in solution, these species were removed via centrifugation prior to analysis, 
and this was confirmed by an absence of SEC signal in (b), a fibrillar Aβ1-42 
preparation. Absorbance at 214 nm is given on the y-axis and retention time is given 
on the x-axis. Reprinted from [130] published by John Wiley and Sons, © 2007 The 
Authors Journal Compilation © 2007 International Society for Neurochemistry.   
 
Figure 10 HPLC-SEC chromatograms of Aβ aggregates produced using sample preparations of 
50 µM synthetic Aβ designed to optimize (a) low molecular weight Aβ1-40 oligomers and (c) 
Aβ1-42 protofibrils 
sample preparations of 50 µM synthetic Aβ designed to optimize (a) low 





4.5 Summary of Additional Aβ Aggregate Size Determination Techniques 
Light scattering techniques, such as MALS and DLS, have been used to detect both small 
and large Aβ aggregates. DLS is more suitable for the detection of smaller aggregates and gives 
information about aggregate size, or RH, while MALS has been utilized for the detection of larger 
Aβ species, including fibrils, and can provide information about molar mass. MALS and DLS, 
however, give a weight-average molar mass or RH for all molecules in solution and must be 
coupled to another technique in order to increase the resolution of individual sizes. SEC as a 
standalone technique has been utilized to detect low molecular weight Aβ oligomers and 
protofibrils, and SEC-MALS has been used to characterize protofibrils formed via different 
growth mechanisms. However, due to the dilutions required by SEC, small unstable oligomers 
are often dissociated, thereby precluding their analysis. AFFF-MALS does not require a pre-
fractionation step and has been used to separate Aβ oligomers of ~60 kDa from larger species. 
This technique yields a gentle, non-destructive separation of molecules. However, further 
improvements to the ultrafiltration membranes must be made in order to reduce adsorption of the 
sample to the membrane. Centrifugation has also been explored for the separation of small 
oligomers (4 – 17 kDa) and larger species (>250 kDa) but requires an uncertain correlation of 
sedimentation coefficients with molar mass. Each of these techniques are suitable for the 
detection of a wide range of Aβ aggregates present throughout aggregation but present 
difficulties with respect to the resolution and quantification of individual Aβ aggregate sizes.  
5.  Techniques Utilized for Aβ Oligomer Identification 
While this review focuses primarily on techniques capable of qualitatively determining 
the size of Aβ oligomers, techniques that can identify the presence of oligomers, without 





have chosen to briefly discuss two of these techniques, dot blot and ELISA, as a result of their 
frequent use and emerging interest. 
5.1 Dot Blot 
Dot blots employ a protein captured upon a membrane as a spot, or dot. A primary 
antibody binds to the protein epitope of interest followed by the binding of a secondary antibody 
to facilitate detection. When dot blots are probed with antibodies that specifically recognize 
oligomeric Aβ, they can confirm the presence of oligomers but give no information about 
aggregate size. Three different Aβ antibodies, oligomer-specific A11 or sequence specific 4G8 
and 6E10 (see Table 1 for Aβ binding epitopes), were employed in conjunction with a dot blot 
assay for detection of aggregating Aβ by Wong et al. [57]. Aβ1-40 was diluted to 50 µM in PBS 
(pH 7.4) and incubated at 37°C. At times ranging from 0 - 3 days, a sample was analyzed via dot 
blot, as shown in Figure 11. A11 binding revealed the transient appearance of oliogmers in 
uninhibited samples, while detection via 4G8 and 6E10 remained constant until later times when 
signals decreased, presumably due to masking of binding sites following aggregation. Changes in 
these patterns in the presence of inhibitor demonstrated the ability of the inhibitor to prevent 
oligomer formation and slow the evolution of larger aggregates. Necula et al. used a dot blot 
assay to monitor the oligomerization of Aβ1-42 dissolved in 100 mM NaOH, diluted to 45 µM in 
PBS (pH 7.4), and incubated at room temperature for 10 days [132]. Similar to Wong et al., they 
probed the specificity of three different antibodies, oligomer-specific A11 and sequence specific 
6E10 and 4G8. At 0 days, 6E10 and 4G8 strongly reacted with Aβ1-42 aliquots, while A11 
reacted weakly, indicating that only monomeric species were present. A strong immunoreactivity 





results obtained by Wong et al. Again, this was accompanied by a decrease in immunoreactivity 

























Figure 11:  Aβ aggregation monitored via dot blot. A 50 µM Aβ1-40 sample was 
incubated in PBS (pH 7.4) at 37°C in the presence (+) or absence (-) 3 x Brilliant 
Blue G (BBG) inhibitor. Samples were taken on the indicated days and spotted on a 
nitrocellulose membrane. Oligomer-specific A11 antibody and Aβ-sequence specific 
antibodies 4G8 and 6E10 were used to detect aggregates. Reprinted with permission 
from [57]. Copyright (2011) American Chemical Society. 
 











5.2 Enzyme-Linked Immunosorbent Assay 
ELISA is a commonly used technique for the identification of Aβ oligomers. ELISA may 
be used in a traditional or sandwich assay format.  In the traditional format, protein adsorbed at a 
surface can be detected using a primary antibody that is specific for Aβ oligomers (see Table 1). 
This primary antibody can be directly linked to an enzyme that converts added substrate to a 
detectable signal (direct ELISA) or can be coupled with a secondary antibody containing the 
enzyme moiety (indirect ELISA).  The latter format serves to enhance the assay signal.  
Alternatively, in the sandwich ELISA format, a sequence-specific capture antibody (see Table 1) 
adsorbed onto the surface is used to capture Aβ protein, which is subsequently detected using the 
same sequence-specific antibody, such that only Aβ species containing multiple monomeric 
units, and therefore multiple epitopes, are detected [130,133]. Consequently, this sandwich 
ELISA will recognize only aggregated Aβ, but not Aβ monomer. Although ELISA can identify 
the presence of Aβ oligomers in a sample, this technique is not capable of determining sizes of 
these oligomeric species. Therefore, ELISA is most advantageous for the detection of oligomeric 
Aβ within a sample containing many different proteins.  
Various researchers have utilized ELISA for the detection of Aβ oligomers [128,130,133-
135]. A study by Englund et al. employed a sandwich ELISA with monoclonal antibody 158 for 
the detection of low molecular weight oligomeric Aβ1-40 produced by dissolving Aβ1-40 in 10 mM 
NaOH with dilution to 50 µM in 2 X PBS and Aβ1-42 protofibrils produced by dissolving Aβ1-42 
in 10 mM NaOH with dilution to 443 µM in 2 X PBS and incubation overnight at 37°C [130]. 
Gonzales et al. utilized a similar ELISA assay to detect low molecular weight Aβ1-42 formed by 
dissolving Aβ1-42 in HFIP with dilution to 200 nM in PBS (pH 7.2) and incubation at 37°C for 24 





however, the bands were very faint, indicating the superior sensitivity of the ELISA assay for 
these oligomeric species. A detection limit for Aβ1-40 oligomers of 80 nM was obtained in these 
studies.  
5.3 Summary of Aβ Oligomer Identification Techniques 
Dot blots and ELISAs have been employed to detect oligomeric Aβ assemblies. Dot blots 
have been used to observe the transient evolution of oligomers during aggregation, but provided 
no information about Aβ aggregate size. Low molecular weight Aβ oligomers and Aβ 
protofibrils have been detected via ELISA at nanomolar concentrations. However, PAGE was 
required to estimate the size of these species. Thus, these techniques can sensitively confirm the 
presence of oligomers but yield no size information.  
6.  Conclusions 
This review describes a variety of techniques, summarized in Table 2, that are currently 
utilized to determine the size or presence of Aβ aggregates, with a focus upon oligomeric 
species. These techniques have been explored for the quantitative detection of different 
aggregate sizes with various limitations to their resolution, dependence on pre-analysis 
procedures, sensitivity, cost, etc.  Electrophoretic techniques, such as SDS-PAGE, Western 
blotting, and CE, are widely used for size-based separations of Aβ aggregates. In particular, 
SDS-PAGE and Western blotting are suitable for the detection of monomeric and small 
oligomeric Aβ species. The separation of larger oligomers via SDS-PAGE is more difficult due 
to the sensitivity of these sizes to denaturing conditions, which can result in aggregate 
decomposition during analysis. The recent development of antibodies specific for Aβ oligomers 
has led to an increase in the application of Western blotting, dot blotting, and ELISA to study Aβ 





physiologically relevant Aβ concentrations. While more sensitive, ELISA is better suited for the 
identification of specific analytes, such as Aβ oligomers, present within a mixed population but 
cannot distinguish individual oligomer sizes. CE with LIF detection offers a highly sensitive 
detection of physiologically relevant concentrations, but the application of CE to amyloid 
aggregation analyses is still in the early stages. MS is another commonly used technique for Aβ 
aggregate size-based separations. MS has been successfully used to detect small oligomeric 
species (especially IM-MS) but quantitative analyses of aggregate size may be limited by the 
pre-separation step, the ability to differentiate species with highly similar charge-to-mass ratios, 
and high equipment costs. FCS, MALS, and DLS may be utilized for determination of Aβ 
aggregate size, but yield a weight-averaged molecular weight of species, thereby limiting the 
resolution of individual Aβ aggregate species. Centrifugation has been used to examine small 
oligomeric species up to large fibrils; however, selection of the method for determination of 
molar mass from sedimentation coefficients can play an important role in size estimation.  SEC 
may be coupled with these approaches or used as a standalone technique; however, SEC is 
complicated by dilution of the analyte during separation, inadequate resolution of intermediate 
oligomeric species, and limited utility of size standards. 
Although each of the methods discussed in this review has the capability to determine Aβ 
aggregate size, the pathogenic events that initiate the misfolding of Aβ and formation of 
aggregate species remain elusive. Hence, there is a continued need for improvement of these 
techniques in order to realize the effective detection of small size differences in Aβ oligomers. In 
order to leverage the advantages of each Aβ detection method, a combination of approaches must 
be utilized, allowing validation of findings from different techniques and a better understanding 





Table 2: Summary of techniques for the quantitative detection and/or identification of Aβ aggregate sizes formed throughout the 
aggregation process. process 
Table 2 Summary of techniques for the quantitative detection and/or identification of Aβ aggregate sizes formed throughout the aggregation process 
Technique Advantages Disadvantages Aggregate Sizes 
Detected 
References 
SDS-PAGE • SDS offers strong 
size-based 
separation 
• SDS may induce non-native 
behavior and destabilize 
oligomers 
• Gel smearing 
4.5 - 20 kDa, 
>83 kDa 
[45,46] 
Native PAGE • Ability to separate 
based on charge and 
hydrodynamic size 




Western Blotting • High sensitivity and 
specificity, 
• Requires specific and 
expensive antibodies 
• Incomplete transfer of 
proteins onto membrane 
• Technically demanding 
4 - 16 kDa, 
16.5 - 25 kDa, 







• Fast, highly 
sensitive separation 
of proteins based on 
charge and 
hydrodynamic size 
• Low sample volume 
• Low resolution of 
intermediate sized Aβ 
oligomers 
• Irreproducibility 






Mass Spectrometry • Fast data acquisition 




• Inability to distinguish 




• Labor intensive 
 

















• High sensitivity, 
ability to look at 
wide range of sizes 
within a sample 
• Fast analysis time 
• Low sample volume 
 
• Relies on assumptions 
about shape and kinetics of 
protein to determine 
molecular weight 












Light Scattering • Direct measurement 
of molar mass and 
radius (MALS) 
• Simultaneous 
detection of multiple 
populations within a 
sample (DLS) 
• Yields weight-average 
molar mass and not size of 
individual species or their 
distribution 
• Exponential dependence of 
scattering on aggregate size 
>10 kDa  
(MALS) 
 




Centrifugation • Ability to detect a 
wide range of sizes 
(oligomers – fibrils) 
• Fast analysis time 
• Theoretical size estimate 
depends on appropriate 
assumptions in the model 
4 - 17 kDa, 
>250 kDa, 




















• Leads to sample dilution 
which can dissociate 
unstable oligomers 
• Comparisons between 
elution behavior of 
oligomers and globular 
































• Highly sensitive and 
specific 
• Ability to measure 
specific analytes 




• Gives information about 
presence of oligomers and 
not size 












Dot Blot • Straight-forward, 
rapid technique 
• Gives information about 
presence of oligomers and 
not size 
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CHAPTER 2:  TECHNIQUES FOR THE DETERMINATION OF INSULIN 
AGGREGATE SIZE 
1.  Insulin protein 
 Human insulin is a 51-residue protein hormone which stimulates the transport of glucose 
from blood into cells [1]. In vivo, insulin exists as a Zn2+ containing hexamer and is stored in the 
pancreas [2]. Upon dilution in the bloodstream, insulin dissociates rapidly through dimers to 
biologically active monomers [2]. In vitro, insulin exists as a mixture of monomer and 
oligomers, including dimers and hexamers [3]. Insulin is prone to form amyloid fibrils under 
various conditions in vitro [4,5]. It has been postulated that insulin aggregation in vitro occurs 
due to the presence of a destabilized monomer that undergoes non-native self-assembly by 
overcoming the free energy barrier [6-8]. This self-assembly proceeds through the formation of 
high-order oligomeric species and culminates with the appearance of insoluble fibrillar 
aggregates. Insulin fibrillization poses a problem for the treatment of Type II diabetes where 
insulin amyloid deposits have been observed at sites of repeated insulin injection [9-11]. These 
amyloid deposits are associated with the clinical syndrome, injection-localized amyloidosis 
[9,10]. It has been proposed that insulin is destabilized in the presence of hydrophobic interfaces 
such as the solid-aqueous interface of insulin pumps [5,12], leading to its aggregation. The 
deposition of insulin aggregates can lead to injection site problems for Type II diabetes patients, 
such as infection, bleeding, bruising, irritation, and inflammation [13]. In addition, insulin 
fibrillization in vitro presents a problem for the quality control of pharmaceutical insulin 
production [5]. Therefore, it is important to elucidate the molecular mechanisms underlying 




 Similar to Aβ, a range of techniques are available to detect the insulin aggregate sizes 
formed throughout aggregation. Table 1 summarizes the advantages and disadvantages of these 
techniques as well as the insulin aggregate sizes which have been detected. In the subsequent 














Table 1: Summary of techniques for the quantitative detection and/or identification of insulin aggregate sizes formed 
throughout the aggregation process. 
Table 3 Summary of techniques for the quantitative detection and/or identification of Aβ and insulin aggregate sizes 
formed throughout the aggregation process. 





• SDS offers strong size-based 
separation 
• SDS may induce non-native 
behavior and destabilize 
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• Gel smearing 
 
6, 12 kDa [14] 
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charge and hydrodynamic 
size 
 
• Gel smearing 
 
 





• High sensitivity and 
specificity, 
• Requires specific and 
expensive antibodies 
• Incomplete transfer of 
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• High sensitivity, ability to 
look at wide range of sizes 
within a sample 
• Fast analysis time 
• Low sample volume 
• Relies on assumptions 
about shape and kinetics of 
protein to determine 
molecular weight 











• Direct measurement of 
molar mass and radius 
(MALS) 
• Simultaneous detection of 
multiple populations within 
a sample (DLS) 
 
• Yields weight-average 
molar mass and not size of 
individual species or their 
distribution 
• Exponential dependence of 
scattering on aggregate size 
 
 
6, 12 kDa (SEC-
MALS) [23] 
2.3 – 6.5 nm 
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• Ability to detect a wide 
range of sizes (oligomers – 
fibrils) 
• Fast analysis time 
• Theoretical size estimate 
depends on appropriate 
assumptions in the model 
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• Leads to sample dilution 
which can dissociate 
unstable oligomers 
• Comparisons between 
elution behavior of 
oligomers and globular 




















• Good information on surface 
features, structure, and shape 
• Results skewed toward 
species which adhere to the 
support 
• Inability to distinguish 
between similarly sized 
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5 – 15 nm (diameter) 
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• Ability to measure specific 




• Gives information about 
presence of oligomers and 
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• Straight-forward, rapid 
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• Requires expensive and 
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2.  Electrophoretic techniques for the quantification of insulin oligomer size 
2.1 Sodium dodecyl sulfate- and native-polyacrylamide gel electrophoresis (SDS- and native-
PAGE) 
 Compared to Aβ, fewer studies have been conducting which utilize SDS-PAGE to detect 
insulin aggregates. Low concentrations of SDS (0.1, 0.3, and 1 µM) have been reported to 
accelerate insulin aggregation while higher SDS concentrations (10 to 360 µM) led to a 
reduction in insulin aggregation [35]. One way to counter this phenomenon is to add urea to the 
sample to further denature the peptide and prevent aggregation. However, it has been shown that 
urea increases the rate of insulin fibrillation [5]. The drawbacks of SDS-PAGE may be overcome 
by using native-PAGE to separate various insulin sizes under conditions that allow the protein to 
remain in a native state.  
 Native-PAGE followed by Western Blotting has been applied to monitor the sizes of 
insulin oligomers formed at pH 2 and 60°C [16]. At 0 hours, insulin monomer (6 kDa) was 
present. After incubation for 24 hours, the appearance of ~12 and 18 kDa oligomers was 
observed. The formation of insulin species of ~24 kDa with a smear for sizes ranging from 30 to 
185 kDa was observed after 48 hours. The differences between native-PAGE and SDS-PAGE 
highlight the importance of examining more than one method for studies of the various insulin 
aggregate sizes formed throughout the aggregation process.  
2.2 Capillary electrophoresis (CE) 
 The utility of CE for the detection of insulin has been demonstrated by various 
researchers. Kunkel et al. have used CE with UV detection to analyze the degradation products 
formed by a 0.6 mg/mL human insulin solution in 0.9% NaCl (pH 7.8) which was incubated at 




study by Gao et al. determined the dimerization constant of bovine insulin at pH 8.4 using CE 
with UV detection [37]. However, the determination of changes in insulin size with incubation 
time was not accomplished in either of the above mentioned studies. A study by Iwasa et al. used 
UV-CE to monitor the aggregation of insulin dissolved in HCl and incubated at 60°C for 1 – 4 
days [38]. At 0 hours, a peak for native insulin was present. After 24 and 48 hours of incubation, 
this native insulin peak decreased in area and a new peak appeared with a faster migration time 
than the native insulin. After 96 hours, all peaks had essentially disappeared, indicating that 
insulin was fully aggregated into larger structures. Although this study looked at changes in the 
insulin peak pattern over time, no estimates of the sizes of these species were obtained. CE as a 
technique for the detection of insulin species formed throughout aggregation is still in its early 
stages. However, further improvements to this technique must be made in order to enhance the 
resolution of intermediate sized insulin species. 
3. Spectroscopic techniques for the quantification of insulin oligomer size  
3.1 Electrospray ionization mass spectrometry (ESI)-MS 
 ESI-MS has been used to analyze liquid insulin samples. Nettleton et al. studied  
the time course of insulin oligomer appearance using nano-ESI-MS. Oligomers exhibiting sizes 
up to 12 monomeric units were detected when insulin was aggregated at very high, millimolar 
concentrations [18]; however, large aggregates could not be studied using this technique. In 
addition, identification of insulin oligomers was complicated by the presence of overlapping 
charge states among the aggregates present. A study by Devlin et al. analyzed lower 
concentrations (0.44 mM) of insulin incubated at pH 2.0 and 60°C [19]. They found that insulin 
existed as a mixture of monomeric and dimeric species. These results are consistent with the 




3.2 Ion mobility mass spectrometry (IM)-MS 
 Various research groups have utilized IM-MS to gain a better understanding of the early 
events of insulin aggregation. Insulin monomer, dimer, and hexamer species formed at pH 7.4 
have been detected using IM-MS, but changes in insulin size with aggregation time were not 
conducted in this study [20].  
3.3 Fluorescence correlation spectroscopy 
 While FCS has been widely used in the literature as a way to estimate sizes of Aβ 
species, less work has been done using FCS to determine insulin sizes. The interaction between 
insulin and an inhibitory molecule p-FTAA has been characterized via FCS [22]. Furthermore, 
the association constant (Kass) between insulin and its membrane-bound receptor has been 
determined via FCS by Zhong et al [21]. These studies illustrate that while FCS is a useful 
technique for size estimates, this technique has not been used specifically to determine the sizes 
of insulin species formed throughout aggregation. 
4. Additional techniques utilized for insulin aggregate size determination 
4.1 Light scattering techniques 
 Light scattering techniques are the more widely used technique to characterize insulin 
aggregate sizes. A study by Sluzky et al. utilized DLS to determine the particle diameter of 
insulin species generated upon agitation at 37 °C and 80 rpm in PBS (pH 7.4) [7]. A range of 
insulin species with diameters from 2.5 to 10 nm were observed initially in solution. Upon 
agitation for 1 h in the presence of Teflon spheres, a second peak appeared corresponding to 
insulin particles ~150 nm in diameter. After aggregation for 21 h, three species of insulin were 
present: native molecules with sizes ranging from 2.5 to 10 nm, stable intermediates with sizes 




Sluzky et al. for the initial insulin sizes in solution, Kadima et al. observed species with a weight 
average molecular mass close to that of a hexamer (~5.6 nm) for a 12 mg/mL insulin solution at 
pH 7.5 with 100 mM NaCl [24]. Furthermore, they found that a 1.9 mg/mL insulin solution at 
pH 10.5 and 10 mM NaCl existed as primarily monomer (~3 nm).  
4.2 Light scattering in combination with other techniques 
 Oliva et al. utilized SEC in conjunction with MALS and DLS to determine the molecular 
weight and size of insulin solutions [23]. SEC-MALS detected the presence of monomeric and 
dimeric species with r.m.s. radius values of 20 and 40 nm, respectively. In contrast, SEC-DLS 
yielded RH values of 2.7, 3.8, and 5.5 nm which correspond to monomer, dimer, and hexamer, 
respectively.  
4.3 Centrifugation 
 Ultracentrifugation has been utilized by Whittingham et al. to determine the molecular 
mass of insulin species formed under different solution conditions [27]. Insulin dissolved in 
sulfuric acid, citric acid, and a pH 2.0 solution existed as a mixture of monomer and dimer. In a 
20% acetic acid solution insulin existed as monomer whereas in 0.1 M Tris-HCl at pH 8, insulin 
sizes ranging from dimer to tetramer were observed.  
4.4 Size exclusion chromatography 
 A study by Ahmed et al. utilized SEC to monitor the effect of Gdn-HCl on insulin sizes 
formed at pH 7.4 [30]. Native insulin eluted at a volume of 6.1 mL, corresponding to hexamer. In 
the presence of 0.5 – 3 M Gdn-HCl, insulin existed as a mixture of monomer and dimer while at 
Gdn-HCl concentrations > 3.5 M, insulin was primarily monomeric. Similar to Ahmed et al., 
Oliva et al. achieved separation of insulin dimer and monomer formed after incubation for 5 days 




4.5 Transmission electron microscopy 
Insulin protofibrils with a diameter of 5 nm and length of 4 – 5 µm have been observed 
by Whittingham et al [27]. Furthermore, the protofibrils sizes were found to be highly dependent 
on the type of acid used to dissolve insulin. Fibrillar insulin species with a diameter of ~14 – 15 
nm formed by twisting at least two protofibrils into a flat ribbon-like fibril have been detected 
using TEM by Bouchard et al [31]. Contrary to these findings, Liu et al. observed insulin fibrils 
with a width of 50 nm and length of 100s of nm [32]. These fibrils were formed in the presence 
of 100 mM NaCl and this most likely explains the differences in diameter obtained.  
5. Techniques utilized for amyloid oligomer identification 
5.1 Dot blot 
Studies utilizing dot blots for the detection of insulin monomer or fibrillar species have 
also been conducted, while studies on the detection of insulin oligomeric species are limited. The 
binding of aprotinin, an antiprotease which is known to be present in amyloid deposits, to insulin 
fibrils has been characterized via dot blots by Cardoso et al [34]. Dots were obtained for 100, 50, 
25, and 10 µg of insulin fibrils in the presence of iodinated-aprotinin. Stains used to image 
protein gels such as SYPRO Ruby have been used to detect insulin monomer via dot blots [33]. 
These studies illustrate that dot blots have not been extensively used in the literature for the 
detection of insulin oligomers.  
6. Summary of electrophoretic and non-electrophoretic based insulin and Aβ size detection 
methods 
 Chapters 1 and 2 describe a variety of techniques that are currently utilized to determine 
the size or presence of amyloid aggregates, with a focus upon oligomeric species. These 




various limitations to their resolution, dependence on pre-analysis procedures, sensitivity, cost, 
etc.  Electrophoretic techniques, such as SDS-PAGE, Western blotting, and CE, are widely used 
for size-based separations of Aβ aggregates. These techniques have been less widely used to 
detect insulin aggregates. In particular, SDS-PAGE and Western blotting are suitable for the 
detection of monomeric and small oligomeric insulin Aβ species. The separation of larger 
oligomers via SDS-PAGE is more difficult due to the sensitivity of these sizes to denaturing 
conditions, which can result in aggregate decomposition during analysis. The recent 
development of antibodies specific for Aβ oligomers has led to an increase in the application of 
Western blotting, dot blotting, and ELISA to study Aβ aggregation. However, the detection 
limits of Western and dot blotting prohibit study of physiologically relevant Aβ concentrations. 
While more sensitive, ELISA is better suited for the identification of specific analytes, such as 
Aβ oligomers, present within a mixed population but cannot distinguish individual oligomer 
sizes. CE with LIF detection offers a highly sensitive detection of physiologically relevant 
concentrations, but the application of CE to amyloid aggregation analyses is still in the early 
stages. MS is another commonly used technique for Aβ aggregate size-based separations and is a 
more widely used technique for the detection of insulin aggregates. MS has been successfully 
used to detect small oligomeric species (especially IM-MS) but quantitative analyses of 
aggregate size may be limited by the pre-separation step, the ability to differentiate species with 
highly similar charge-to-mass ratios, and high equipment costs. FCS, MALS, and DLS may be 
utilized for determination of insulin Aβ aggregate size, but yield a weight-averaged molecular 
weight of species, thereby limiting the resolution of individual Aβ aggregate species. 
Centrifugation has been used to examine small oligomeric species up to large fibrils; but, 




play an important role in size estimation.  SEC may be coupled with these approaches or used as 
a standalone technique. SEC is complicated by dilution of the analyte during separation, 
inadequate resolution of intermediate oligomeric species, and limited utility of size standards. 
TEM is widely used to estimate the size of insulin and Aβ aggregates. TEM is a technique which 
is more suited for the detection of protofibrils and fibrils and does not possess the ability to 
distinguish between small oligomeric species which differ in size by a single monomer unit. 
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CHAPTER 3:  MONITORING INSULIN AGGREGATION VIA CAPILLARY 
ELECTROPHORESIS 
Pryor, E.; Kotarek, J. A.; Moss, M. A.; Hestekin, C. N. Int. J. Mol. Sci. Monitoring Insulin 
Oligomer Formation Via Capillary Electrophoresis, 2011, 12, 9369-9388. 
Abstract 
Early stages of insulin aggregation, which involve the transient formation of oligomeric 
aggregates, are an important aspect in the progression of Type II diabetes and in the quality 
control of pharmaceutical insulin production. This study is the first to utilize capillary 
electrophoresis (CE) with ultraviolet (UV) detection to monitor insulin oligomer formation at pH 
8.0 and physiological ionic strength. The lag time to formation of the first detected species in the 
aggregation process was evaluated by UV-CE and thioflavin T (ThT) binding for salt 
concentrations from 100 mM to 250 mM. UV-CE had a significantly shorter (5–8 h) lag time 
than ThT binding (15–19 h). In addition, the lag time to detection of the first aggregated species 
via UV-CE was unaffected by salt concentration, while a trend toward an increased lag time with 
increased salt concentration was observed with ThT binding. This result indicates that solution 
ionic strength impacts early stages of aggregation and β-sheet aggregate formation differently. 
To observe whether CE may be applied for the analysis of biological samples containing low 
insulin concentrations, the limit of detection using UV and laser induced fluorescence (LIF) 
detection modes was determined. The limit of detection using LIF-CE, 48.4 pM, was lower than 
the physiological insulin concentration, verifying the utility of this technique for monitoring 
biological samples. LIF-CE was subsequently used to analyze the time course for fluorescein 




FITC label prevented incorporation of insulin into oligomers, cautioning against the use of this 
fluorescent label as a tag for following early stages of insulin aggregation. 
Keywords  
capillary electrophoresis; ultraviolet absorbance; laser induced fluorescence; thioflavin T; 
insulin; oligomer; amyloid 
1. Introduction 
Human insulin is a 51-residue protein hormone which stimulates the transport of glucose 
from blood into cells [1]. In vivo, insulin exists as a Zn2+ containing hexamer and is stored in the 
pancreas [2]. Upon dilution in the bloodstream, insulin dissociates rapidly through dimers to 
biologically active monomers [2]. In vitro, insulin exists as a mixture of monomer and 
oligomers, including dimers and hexamers [3]. Insulin is prone to form amyloid fibrils under 
various conditions both in vitro and in vivo [4,5]. It has been postulated that insulin aggregation 
both in vitro and in vivo occurs due to the presence of a destabilized monomer that undergoes 
non-native self-assembly by overcoming the free energy barrier [6–8]. This self-assembly 
proceeds through the formation of high-order oligomeric species and culminates with the 
appearance of insoluble fibrillar aggregates. Insulin fibrillization poses a problem for the 
treatment of Type II diabetes where insulin amyloid deposits have been observed at sites of 
repeated insulin injection [9–11]. These amyloid deposits are associated with the clinical 
syndrome, injection-localized amyloidosis [9,10]. It has been proposed that insulin is 
destabilized in the presence of hydrophobic interfaces such as the solid-aqueous interface of 
insulin pumps [5,12], leading to its aggregation. The in vivo deposition of insulin aggregates can 
lead to injection site problems for Type II diabetes patients, such as infection, bleeding, bruising, 




the quality control of pharmaceutical insulin production [5]. Therefore, it is important to 
elucidate the molecular mechanisms underlying insulin amyloid fibrillization to improve the 
treatment of diabetes.  
The visualization of oligomers, which appear in the early stages of aggregation, is one 
key to understanding the molecular mechanisms underlying amyloid formation. Various 
techniques have been utilized to detect soluble and low-molecular weight oligomeric species 
formed by amyloid proteins such as atomic force microscopy (AFM) [12,14], light scattering 
[12,14], hydrogen-deuterium exchange mass spectrometry [15,16], matrix assisted laser 
desorption ionization mass spectrometry (MALDI-MS) [17,18], electrospray ionization mass 
spectrometry (ESI-MS) [19], ion mobility mass spectrometry (IM-MS) [20–23], and oligomer 
specific antibodies [24–26]. A major analytical challenge is developing a technique which is 
capable of identification, quantification, and characterization of a wide range of amyloid species. 
Electrophoretic techniques can be used to detect soluble and low-molecular weight oligomeric 
species and provide a compliment for other traditional techniques. These electrophoretic 
techniques include sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) [27–
30], Western immunoblotting [27,29,31–37], and capillary electrophoresis (CE) [38–43]. SDS-
PAGE is a commonly used technique, but SDS has been reported to accelerate β sheet formation 
during amyloid aggregation [44,45], to induce and possibly stabilize aggregation [36], and to 
misrepresent the native species and their assembly [46]. Western blotting necessitates the  
use of expensive and specific antibodies and can also require a pre-concentration step such as 
immunoprecipitation [47,48]. In addition, these gel-based methods can produce smears making 
specific oligomer size determination impossible [29,30]. In contrast, CE provides the ability to 




Capillary electrophoresis (CE) offers fast and highly efficient separation of molecules 
with a broad range of properties thereby making it well suited for the analyses of biological 
samples, which contain different types and sizes of proteins [49]. CE separates proteins based on 
electrophoretic mobility, which is related to charge, shape, and/or size. Previous studies have 
demonstrated the utility of CE to detect low concentrations of insulin [50–52] and identify 
differences in insulin analogs [42]. In this work, we have extended CE to monitor the appearance 
of insulin oligomers over time when aggregation is carried out under varying solution conditions. 
In addition, we have probed the ability of CE to detect insulin at physiological concentrations. 
This study is the first report of the use of UV-CE to monitor insulin oligomer formation at pH 
8.0 and physiological ionic strength. Our results demonstrate the utility of CE as a 
complimentary technique for studying the early stages of insulin aggregation and define the 
hurdles that must be overcome before the aggregation of biological insulin concentrations can be 
explored. 
2. Results and Discussion 
2.1. Detection of Insulin Oligomers Using CE with UV Detection 
To explore the use of CE for the detection of insulin oligomers that appear during early 
stages of insulin aggregation, lyophilized insulin was solubilized in 5 mM NaOH, diluted into 40 
mM Tris (pH 8.0), subjected to 150 mM NaCl, and agitated at 185 rpm to promote amyloid 
assembly. The reaction was analyzed using UV-CE at early and late time points to assess the 
appearance of oligomers and progression into larger aggregate species. At 0 h, UV-CE 
demonstrated the presence of an early, broad peak in addition to a sharper peak migrating at ~70 
min (Figure 1A). The size of these species was probed using a filtration analysis similar to that 




β aggregation species detected via UV-CE. For our experiments, we used membranes with 
molecular weight cutoffs of 30, 50, and 100 kDa to determine that the species present at 0 h 
correspond to molecular weights <30–50 kDa, or oligomers of <5–8 monomer units. A similar 
peak pattern was obtained after 4 h with the appearance of another peak migrating at ~90 min 
(Figure 1B). At 8 and 12 h, broad peaks migrating at times >90 min appeared (Figure 1C,D). The 
size of these species was estimated by filtration analysis to be >50 kDa, or larger than 8 
monomer units, thus indicating the detection by UV-CE of the first species in the aggregation 
process. By 24 h, aggregate peaks of greater intensity appeared at migration times >150 min, 
indicating the formation of larger and more concentrated aggregate species, estimated via 
filtration analysis to be <100 kDa, or less than 17 monomer units (Figure 1E). Due to 
experimental time constraints, UV-CE runs for the 0, 4, and 8 h time points were terminated at 
180 min. Separate experiments with run times of 240 min were conducted for the 0, 4, and 8 h 
time points and confirm that no significant species (signal to noise or S/N >3) were present at 












Figure 1. Detection of insulin monomer, oligomer, and higher molecular weight 
aggregation states using UV-CE. Insulin was aggregated under agitation (185 rpm) at  
0.2 mg/mL in 40 mM Tris (pH 8.0) containing 150 mM NaCl and at 25 °C. At 0 h 
(panel A), 4 h (panel B), 8 h (panel C), 12 h (panel D), and 24 h (panel E), CE was 
performed in conjunction with UV detection with a 0.5 psi pressure injection for 8 s 
with separation at 15 kV using 0.5% PHEA separation matrix in a PHEA coated 
capillary. Results are representative of three independent experiments. 
Supplementary data confirms the absence of significant peaks at a migration time of 
>180 min for 0, 4, and 8 h time points. 
 





Other measurement techniques have been employed previously to characterize insulin 
oligomers. Quasi elastic light scattering (QELS) [7], high performance liquid chromatography 
(HPLC) [53], small angle neutron scattering (SANS) [54], and nanoflow electrospray (nano-ES) 
mass spectrometry [55] have been successfully used to detect oligomeric insulin species. A study 
by Sluzky et al. utilized QELS to determine the particle diameter of insulin species generated 
upon agitation at 37 °C and 80 rpm in PBS (pH 7.4) [7]. Similar to the UV-CE results at 0 hr, a 
range of insulin species with diameters from 2.5 to 10 nm were observed initially in solution. 
Upon agitation for 1 h in the presence of Teflon spheres, a second peak appeared corresponding 
to insulin particles ~150 nm in diameter. After aggregation for 21 h, three species of insulin were 
present: native molecules with sizes ranging from 2.5 to 10 nm, stable intermediates with sizes 
ranging from 150 to 190 nm, and fully aggregated particles >800 nm. Nayak et al. and 
Vestergaard et al. utilized SANS and SAXS to monitor the formation of insulin oligomers and 
proposed a model for nucleus formation and growth [54,56]. However, insulin oligomers were 
generated under extreme conditions (45–65 °C, pH = 1.6–2.0,  
5–10 mg/mL) which may not accurately reflect insulin aggregation in vivo. Nettleton et al. 
studied the time course of insulin oligomer appearance using nano-ES. Oligomers exhibiting 
sizes up to 12 monomeric units were detected when insulin was aggregated at very high, 
millimolar concentrations [55]; however, large aggregates could not be studied using this 
technique. In addition, identification of insulin oligomers was complicated by the presence of 
overlapping charge states among the aggregates present. The drawbacks of each technique listed 
above show that other complementary methods may be needed to verify the results obtained. The 
UV-CE method in the current study was able to detect insulin oligomers that appeared transiently 




highlights the potential for CE to be used as a complementary technique to follow the evolution 
of insulin oligomer appearance. 
2.2. Effect of Salt Concentration on the Time Course for Insulin Oligomer Formation  
Solution conditions such as protein concentration [5,57], pH [5], and ionic strength 
[5,58,59] have been reported to have a pronounced impact upon the rate at which insulin 
aggregates, and understanding these effects can provide insight into the mechanism of insulin 
aggregation. Here, CE was employed to study the effect of solution ionic strength on the early 
events of insulin aggregation by examining the time to appearance of oligomers formed when 
insulin is aggregated at 25 °C and pH 8.0 (40 mM Tris) in the presence of three different 
concentrations of NaCl: 100 mM, 150 mM, and 250 mM. Figure 2 illustrates the change in 
normalized migration time of the largest species present throughout the early stages of 
aggregation. During the first 5 h of aggregation, there was little change in the migration time at 
all three salt concentrations. After 5 h, oligomeric species began to form. While the time to 
oligomer appearance was unaffected by NaCl concentration (Table 1), the size of oligomers 
formed increased with salt concentration. At 10 h, oligomers formed in the presence of 150 and 
250 mM NaCl exhibiting significantly longer migration times than those formed in the presence 
of 100 mM NaCl (Figure 2). To our knowledge, no other studies have used methods focused on 









Table 1. Lag times observed at 100, 150, and 250 mM NaCl by CE versus ThT binding. 
Table 4 Lag times observed at 100, 150, and 250 mM NaCl by CE versus ThT binding 
NaCl concentration 
(mM) 
Lag time for CE 
(h) 1 
Lag time for ThT Binding  
(h) 2 
100 6.7 ± 1.7 16 ± 1.0 *** 
150 5.0 ± 0.0 15 ± 1.4 *** 
250 7.6 ± 1.3 19 ± 2.4 *** 
1 Results are reported as the mean ± SE, n = 3. 2 Results are reported as the mean ± SE, n = 4.  





Figure 2. Effect of solution ionic strength on the formation of insulin oligomers 
detected by UV-CE. Insulin was diluted to 0.2 mg/mL in 40 mM Tris (pH 8.0) 
containing 100 mM (), 150 mM (), or 250 mM () NaCl. Aggregation was 
induced at 25 °C by continuous agitation (185 rpm) and monitored using UV-CE. CE 
was performed with sample injection at 0.5 psi for 8 s with 15 kV separation using 
1% PHEA separation matrix in a PHEA coated capillary. Migration times were 
normalized to those observed prior to the onset of aggregation using the peak 
corresponding to monomer to facilitate comparison between individual runs. Error 
bars represent SE, n = 3. For the 10 h time point, the migration times of the 150 mM 
and 250 mM NaCl were both determined to be statistically different from the 100 
mM NaCl migration time with a p < 0.1. 
 







A traditional method of detecting amyloid aggregates containing a cross β-sheet structure 
is through the examination of thioflavin T (ThT) binding, which has been used to study insulin 
aggregation under a variety of solution conditions. ThT is an intercalating fluorescent dye that 
binds to the β-sheet structure within amyloid fibrils, giving rise to a shifted excitation maximum 
at 450 nm and a shifted and enhanced emission at 482 nm [5,60]. For our study, ThT was also 
used to follow insulin aggregation in order to compare the lag times obtained using ThT 
fluorescence with those observed using CE. When insulin was aggregated at pH 8.0 (40 mM 
Tris) and 25 °C with agitation (185 rpm) in the presence of 100 mM NaCl, 150 mM NaCl, or 250 
mM NaCl, the lag time, or initial increase in ThT fluorescence, was observed at 16 ± 1.0 h, at 15 
± 1.4 h, and at 19 ± 2.4 h, respectively (Figure 3, Table 1). These results demonstrate a trend 
toward a longer lag time at the highest salt concentration. 
Other researchers have examined the effect of ionic strength on insulin structure [58,59] 
and aggregation lag time, but under slightly different conditions. At a similar solution pH of 7.0–
8.0, lag times of 6–9 h have been reported in studies that have employed higher insulin 
concentrations [61] or higher temperatures with more vigorous agitation [62], which have both 
been reported to enhance amyloid protein aggregation [5,57,63–65]. Furthermore, changes in the 
lag time to ThT fluorescence have been observed to depend upon the change in solution ionic 
strength when insulin is aggregated under continuous agitation. Nielsen et al. observed that an 
increase in the NaCl concentration from 50 to 500 mM led to an initial decrease in the lag time 
from 1.6 to 1.3 h, whereas at the highest salt concentration of 500 mM, the lag time increased to 
1.5 h [5]. Although much shorter lag times were observed is this study, likely due to the higher 
incubation temperature (37 °C) and acidic solution pH (1.6), the latter result parallels the effect 




where an increase in the NaCl concentration to 250 mM resulted in an increase in the lag time 
























Figure 3. Effect of solution ionic strength on the formation of insulin aggregates 
detected by ThT binding. Insulin was diluted to 0.2 mg/mL in 40 mM Tris (pH 8.0) 
containing 100 mM (), 150 mM (), or 250 mM () NaCl. Aggregation was 
induced at 25 °C by continuous agitation (185 rpm) and monitored via ThT 
fluorescence by periodic dilution into 10 µM ThT. Error bars represent SE. Results are 
representative of two independent experiments. 
 
Figure 14 Effect of solution ionic strength on the formation of insulin aggregates detected 












When results from UV-CE (Figure 2) and ThT binding detection (Figure 3) of the initial 
aggregation state are compared (Figure 4, Table 1), it is clear that UV-CE is able to detect the 
aggregation process significantly earlier than ThT binding. In the presence of 100 and 150 mM 
NaCl, oligomers were detected using UV-CE 10 h prior to the observed increase in ThT 
fluorescence, and in the presence of 250 mM NaCl, UV-CE was able to resolve oligomers more 
than 11 h prior to the detection of aggregates using ThT. These differences most likely result 
from the inability of ThT to recognize early oligomeric species due to their lack of β-sheet 
structure.  In contrast, UV-CE does not rely on the binding of a dye to this specific conformation 
but can instead detect oligomers regardless of their conformation.  These results show that CE is 
capable of detecting early insulin oligomeric species while ThT binding can be used to verify the 
appearance of larger aggregates present in higher quantities. Therefore, CE and ThT binding can 
be used in a complimentary manner to detect species formed during all stages of aggregation. 
Differences in detection capabilities of UV-CE and ThT binding lead to a more 
comprehensive understanding of the effect of NaCl on insulin aggregation. Results from UV-CE 
suggest that NaCl has little effect on the appearance of early aggregated states, shown by 
filtration studies to be oligomeric in nature. In contrast, results from ThT binding conversely 
suggest that increasing the NaCl concentration extends the lag time to formation of aggregated 
states with β-sheet conformations (Table 1). This comparison underscores the differences in 
amyloid protein aggregation that can be observed between oligomer and β-sheet aggregate 
behavior and emphasizes the need for a complimentary detection method, like CE, that can 
follow early stages in the aggregation process. A higher solution ionic strength could alter the 
structure of oligomers, leading to a slower conversion to the β-sheet structure detectable by ThT 




solution ionic strength, thus precluding their detection by ThT binding, which exhibits high 
nanomolar to low micromolar limit of detection, for longer periods of time. An increase in the 
lag time detected by ThT binding at higher NaCl concentrations has also been observed in 
studies of other proteins that form amyloid aggregates [66]. The conclusion drawn by Lin et al. 
in these studies was that short and thick fibrils are formed at higher NaCl concentrations, and 
these fibrils are characterized by low intensity ThT binding signals. Thus, the ability of CE to 
detect insulin species independent of their conformation and at very low concentrations provides 


















Figure 4. Comparison of lag times observed by UV-CE () and ThT binding (). 
Insulin was diluted to 0.2 mg/mL in 40 mM Tris (pH 8.0) containing 150 mM NaCl. 
Aggregation was induced at 25 °C by continuous agitation (185 rpm) and monitored 
via UV-CE or ThT fluorescence as described in Figure 2 and Figure 3, respectively. 
 















2.3. Determination of Insulin Limit of Detection  
The ability to detect proteins at low concentrations will be necessary for the study of 
insulin aggregation at biological concentrations (300 pM) [67]. CE typically uses either UV 
absorbance or LIF to detect proteins. UV can detect proteins without any additional labeling, but 
typically has a lower sensitivity than LIF. LIF usually requires fluorescent labeling of the 
molecule to be detected, but is highly sensitive with previous reports of LIF-CE detection of 
double-stranded DNA down to the pg/μL range [68,69]. To determine the insulin detection limit 
using UV-CE, insulin monomer prepared at concentrations ranging from 0.005 mg/mL to 0.2 
mg/mL was analyzed. The S/N ratio of the insulin peak was >3 at concentrations of 0.01 mg/mL 
and higher, defining 0.01 mg/mL (1.72 µM) as the limit of detection for insulin using UV-CE 
(Figure 5A). The definition of the detection limit as the analyte concentration with a S/N ratio >3 
has been used previously in studies utilizing CE detection [70,71]. In addition, a similar limit of 
detection for insulin of 0.02 mg/mL (3.44 µM) has been obtained by Kunkel et al. using UV-CE 
[52].  
A parallel limit of detection study was performed for fluorescein isothiocyanate (FITC)-
labeled insulin monomer using LIF-CE. First, injection conditions were optimized by studying a 
range of sample injection voltages and injection times. As both the injection voltage and 
injection time were increased, observed insulin peaks increased in intensity. However, when the 
injection voltage and injection time were increased beyond 12 kV and 12 s, respectively, 
significant carryover of insulin between runs was observed due to the large amount of insulin 
injected into the capillary. Therefore, an injection voltage of 12 kV and an injection time of 12 s 
were selected as optimal. To determine the insulin detection limit using LIF-CE, FITC-labeled 




S/N ratio of the insulin peak was >3 at concentrations of 0.3 ng/mL and higher, thus establishing 
0.3 ng/mL (48.4 pM) as the limit of detection for FITC-labeled using LIF-CE (Figure 5B) and 
illustrating the superior limit of insulin detection for LIF-CE compared with UV-CE. In fact, the 
LIF detection limit of 48.4 pM is lower than the physiological insulin concentration of 300 pM 
[67] and to the authors’ knowledge, is the lowest LIF detection limit of insulin for an 
electrophoresis based method. Thus, LIF-CE is a promising technique for the detection of 
physiologically relevant insulin concentrations. Figure 5B also demonstrates the detection of four 
peaks in addition to the peak corresponding to monomeric protein. These additional peaks are 
most likely the presence of dimers and hexamers that have been reported to exist in vitro in 
freshly dissolved insulin solutions [72,73]. These species may be present at concentrations below 
the limit of insulin detection by UV-CE. The lower limit of detection offered by LIF-CE should 














Figure 5. Limit of detection for monomeric insulin. (A) UV-CE detection of insulin 
with a 0.5 psi pressure injection for 8 s at 15 kV separation voltage using 0.1% 
PHEA separation matrix in a PHEA coated capillary; (B) LIF-CE detection of insulin 
with a 12 kV electrokinetic injection for 12 s at 15 kV separation voltage using 0.1% 
PHEA separation matrix in a PHEA coated capillary. 
 




2.4. Analysis of FITC Tracer Incorporation into Unlabeled Insulin  
The ability of LIF-CE to detect insulin at sub-physiological concentrations suggests that 
this technique holds promise for the study of insulin aggregation at physiological insulin 
concentrations. Such studies will require the presence of a fluorescent label within insulin 
oligomers that appear during early stages of aggregation. Therefore, the ability of FITC-labeled 
insulin and unlabeled insulin to co-aggregate was explored. FITC-labeled insulin was selected 
because it has been previously shown to be an effective insulin label for LIF-CE applications 
[74,75]. FITC is covalently bound to the ε-amino groups of internal lysine residues and the α-
amino group of the N-terminal residue. Unlike fluorescent amyloid-binding dyes, the covalent 
incorporation of this FITC label ensures its presence within both monomeric protein and 
aggregates that incorporate the labeled protein, including those that precede the appearance of β-
sheet structure. 
A sample consisting of 75% unlabeled insulin and 25% FITC-labeled insulin was 
prepared in 40 mM Tris (pH 8.0) containing 150 mM NaCl and agitated at 185 rpm to promote 
amyloid assembly. The reaction was analyzed using LIF-CE to assess the appearance of insulin 
oligomers. As shown in Figure 6, no change in the normalized migration time was observed over 
a 36 h period. Because oligomers of unlabeled insulin were observed using UV-CE beginning 
after 5 h following the onset of aggregation (Figure 2), this result suggested that the presence of 
the FITC label was preventing the aggregation of FITC-labeled insulin. To explore this 
possibility, LIF-CE was used to monitor the aggregation of 100% FITC-labeled insulin 
solubilized in Tris (pH 8.0), subjected to 150 mM NaCl, and agitated at 185 rpm (data not 




initiation of agitation, confirming that the presence of the FITC label prevents aggregation within 
























Figure 6. Coaggregation of FITC-labeled insulin and unlabeled insulin. Insulin 
solutions consisting of 25% FITC-labeled insulin and 75% unlabeled insulin with 
LIF detection (, n = 6) and UV detection (, n = 3) were prepared at a 
concentration of 0.2 mg/mL in 40 mM Tris (pH 8.0) containing 150 mM NaCl. 
Solutions were subjected to agitation (185 rpm), and the formation of aggregates was 
monitored. LIF-CE was performed with a sample injection at 12 kV for 12 s with 15 
kV separation and UV-CE was performed with a sample injection at 10 kV for 12 s 
with 15 kV separation. Both separations were performed using 1% PHEA separation 
matrix in PHEA coated capillary. Migration times were normalized as described in 
Figure 2. Error bars represent SE, n = 3–6. Some error bars lie within symbols. For 
all time points >0 h, UV data was statistically different from the LIF data with a p < 
0.015. 
 
Figure 17 Effect of aggregation time on the normalized migration time for the 






To further determine whether the FITC-labeled insulin was inhibiting the formation of 
unlabeled insulin aggregates or failing to incorporate into aggregates formed from the unlabeled 
protein, UV-CE was performed in parallel with LIF-CE to monitor the aggregation of 75% 
unlabeled insulin and 25% FITC-labeled insulin solubilized in 40 mM Tris (pH 8.0) containing 
150 mM NaCl and subjected to agitation at 185 rpm. As shown in Figure 6, the normalized 
migration time for UV-CE increased significantly over a period of 36 h, beginning by 10 h 
following the onset of agitation, while the normalized migration time for LIF-CE remained 
unchanged. These results indicate that insulin oligomers and larger aggregates were formed from 
the unlabeled protein and that the FITC-labeled insulin did not incorporate into these aggregates. 
Since some small compounds have been previously reported as inhibitors of β-sheet formation, it 
is possible that the FITC label is acting as an inhibitor to insulin aggregation. Another possibility 
is that the FITC attachment site is critical for proper β-sheet folding. A similar extension of the 
lag time to aggregation has been observed following the methylation of amino groups within the 
amyloid-β protein [76] and the introduction of a mutant that mimics phosphorlyation of serine 
residues within Huntington protein [77]. In addition, the quantity of amyloid aggregates formed 
is reduced following the citraconylation of lysine residues within lysozyme [78] or stilbine 
modification of ε-amino groups within transthyretin [79]. Therefore, dyes with alternative 
properties or attachment sites need to be explored. In particular, less bulky fluorescent probes, 
such as BODIPY, or attachment of dyes exclusively at the N- or C- terminus would be less likely 




3. Materials and Methods 
3.1. Materials 
Previous studies have shown no differences between the three-dimensional structures of 
bovine and synthetic human insulin [80] and the binding affinity of bovine and synthetic insulin 
to insulin receptors at three major sites of insulin action are similar [81]. Similar to human 
insulin, bovine insulin contains 51 amino acids but differs from human insulin in residues A8 
(Thr→Ala), A10 (Iso→Val), and B30 (Thr→Ala) [82]. Therefore, bovine insulin was used for 
all studies. Insulin and fluorescein isothiocyanate (FITC)-labeled insulin from bovine pancreas, 
poly-N-hydroxyethyl acrylamide (PHEA) and thioflavin T (ThT) were obtained from Sigma-
Aldrich (St. Louis, MO). Polymerization initiation compound 2,2′-azobis(2-amidinopropane) 
dihydrochloride (V-50) was purchased from Wako Chemical (Richmond, CA). Amicon 
centrifugal filter units were purchased from Millipore (Billerica, MA).  
3.2. Insulin Preparation 
Lyophilized insulin and FITC-labeled insulin were stored at −20 °C. Unlabeled insulin 
was reconstituted to a final concentration of 0.005–0.2 mg/mL in 40 mM Tris (pH 8.0) containing 
0–250 mM NaCl. FITC-labeled insulin was reconstituted to a final concentration of 0.03 ng/mL–
0.2 mg/mL in 40 mM Tris (pH 8.0) containing 0–150 mM NaCl. Samples consisting of 75% 
unlabeled insulin and 25% FITC-labeled insulin were prepared by mixing the necessary 
proportions of insulin and FITC-labeled insulin from individual stock concentrations of 0.3 and 
0.2 mg/mL, respectively. 
3.3. Electrophoresis Conditions for UV and LIF Studies 
All studies were carried out in 0.1% w/v PHEA coated capillaries with a 0.1–1% PHEA 




were Lt = 31 cm, Ld = 10 cm and for LIF-CE studies were Lt = 36 cm, Ld = 10 cm. The first UV-
CE study was conducted using a 0.5% PHEA separation matrix. For the study on the effect of 
salt concentration on insulin oligomer formation, the capillary was filled with 1% PHEA and 
rinsed with 40 mM Tris (pH 8.0) for 5 min prior to each run. This rinse was utilized to dilute the 
PHEA on-column and overcome the long run times associated with the 0.5% PHEA separation 
matrix. Polymers of HEA were synthesized as described previously [83] with the following 
changes: 4% w/w initial monomer concentration and polymerization for 5 h. CE separations 
using UV detection were carried out using a P/ACE MDQ Glycoprotein System from Beckman 
Coulter, Inc. (Fullerton, CA) (214 nm filter) interfaced with an IBM computer utilizing 32 Karat 
software (V. 5.0, Beckman Coulter, Inc.) for data collection. Samples were pressure injected at 
0.5 psi for 8 s and separated at 15 kV. Between each run, the capillary was rinsed with deionized 
water for 10 min to ensure that the insulin was not retained on the capillary wall. CE separations 
using LIF detection were carried out using an Applied Biosystems (Foster City, CA) 3130 
Genetic Analyzer (excitation = 494 nm, emission = 522 nm) interfaced with a Dell computer 
utilizing Foundation Data Collection V 3.0 software. Samples were electrokinetically injected at 
10 or 12 kV for 12 s and separated at 15 kV.  
3.4. Limit of Detection Studies 
Unlabeled insulin was prepared at concentrations of 0.05–0.2 mg/mL in 40 mM Tris (pH 
8.0), and FITC-labeled insulin was prepared at concentrations of 0.03–3 ng/mL. Immediately 
following preparation, 100 μL samples of unlabeled insulin and 10 µL samples of FITC-labeled 
insulin were analyzed by UV-CE or LIF-CE, respectively, to determine the intensity of the first 




deionized water for 20–120 min, and elution of 40 mM Tris (pH 8.0) was analyzed to ensure that 
insulin was not retained on the capillary wall.  
3.5. Oligomer Formation Assay 
To observe the time course for insulin oligomer formation, insulin was solubilized in 5 
mM NaOH for 30 min and diluted into 40 mM Tris (pH 8.0) to make a 1 mg/mL stock. The 
stock was then diluted to 0.2 mg/mL in 40 mM Tris (pH 8.0) containing 150 mM NaCl and 
incubated at 25 °C under continuous agitation (185 rpm). At times of 0, 4, 8, 12, and 24 h, a 50 µL 
sample was removed and analyzed by UV-CE, with 0.5% PHEA separation matrix, to determine 
the migration time and intensity of all peaks. Separate experiments were conducted using the same 
sample preparation and CE conditions in order to determine the size range of insulin oligomers 
observed. At 0, 4, 8, and 12 h, a 50 µL sample was taken and ultrafiltrated (20 min, 14,000 × g) 
through Amicon filters with cut-off values of 30 kDa, 50 kDa and 100 kDa. The filtrate was 
removed and analyzed via UV-CE to determine the relative size of oligomers.  
To examine the effect of solution ionic strength on insulin oligomer formation, insulin 
was prepared at a concentration of 0.2 mg/mL in 40 mM Tris (pH 8.0) containing 100, 150, or 
250 mM NaCl. Samples were incubated at 25 °C under continuous agitation (185 rpm). Both 
prior to the onset of agitation and at times between 5 and 24 h following the onset of agitation, a 
50 µL sample was removed and analyzed by UV-CE to determine the migration time of the first 
and last peaks. In parallel experiments, aggregation was monitored using ThT binding as 
described previously [84] by diluting an aliquot into ThT (10 µM) and evaluating fluorescence 
using a Perkin-Elmer LS-45 luminescence spectrometer (Waltham, MA) (excitation = 450 nm, 
emission = 470–500 nm) with baseline (ThT) subtraction. Lag times to aggregate formation were 




CE, this increase was an extension of the migration time for the last peak greater than 2-fold that 
of the monomer migration time. For ThT binding, this increase was 5% of the fluorescence 
observed at equilibrium. 
The co-incorporation of unlabeled insulin and FITC-labeled insulin into oligomers was 
examined using LIF-CE and UV-CE in parallel. FITC-labeled insulin was prepared alone at a 
concentration of 0.2 mg/mL or combined with unlabeled insulin for final concentrations of 0.2 
mg/mL unlabeled insulin and 0.067 mg/mL FITC-labeled insulin (75% unlabeled, 25% FITC-
labeled). Both samples were prepared in 40 mM Tris (pH 8.0) containing 150 mM NaCl and 
incubated at 25 °C under continuous agitation (185 rpm). Both prior to the onset of agitation and 
at times between 5 and 24 h following the onset of agitation, the migration times of the first and 
last peak were determined by both UV-CE and LIF-CE. Here, a 50 µL sample was removed for 
analysis by UV-CE and a 20 µL sample was removed and diluted to 0.013 mg/mL for analysis 
by LIF-CE. 
3.6. Statistical Analysis 
The migration time and intensity of peaks were analyzed using Chromagna (VO 9.8) 
software (provided by Mark Miller, NIH) and Origin (V. 8.0) software from OriginLab 
Corporation (Northampton, MA). Chromagna software was used to convert the fsa file format of 
the ABI 3130 Genetic Analyzer to excel files, which are compatible with Origin. A Gaussian fit 
was used to calculate the peak area and migration time in Origin. The migration times of peaks 
observed in the insulin oligomer time course and salt concentration studies were normalized in 
order to draw qualitative conclusions about the sizes of insulin species present at various times 
throughout aggregation. Peak migration times were determined by normalizing the migration 




the onset of aggregation. In addition, the peak height for the monomeric peaks detected in the 
UV and LIF limit of detection studies was determined and the S/N ratio was calculated. Peaks 
with a S/N ratio >3 were considered significant. Statistical analysis for comparison of lag times 
was performed using Prism 5 software (GraphPad Software Inc., San Diego, CA). The effect of 
detection method upon lag time was assessed using a one-way ANOVA with Bonferroni post-
test. Unpaired t-tests were performed using GraphPad QuickCalcs (GraphPad Software Inc., San 
Diego, CA) to compare CE normalized migration times. 
4. Conclusion 
Insulin aggregation poses problems both in vivo and in vitro. These problems include 
injection site bleeding and bruising which can occur during the treatment of Type II diabetes in 
addition to problems with the pharmaceutical quality control of insulin. Elucidating the 
molecular mechanism by which insulin aggregation occurs, in particular the early stages of 
aggregation during which oligomeric species are formed, will facilitate the prevention of these 
problems. However, most techniques utilized for studies of insulin aggregation are not sensitive 
enough to detect physiologically relevant concentrations or oligomeric species present transiently 
throughout aggregation under physiologically relevant solution conditions. These limitations 
highlight the importance of employing a complementary technique to explore the evolution of 
insulin oligomer appearance at physiologically relevant concentrations. The current study 
illustrates that CE is a promising technique for monitoring the appearance of oligomeric species 
during the early events of insulin aggregation and is the first report of the use of UV-CE to 
monitor insulin oligomer formation at pH 8.0 and physiological salt concentration. UV-CE was 
employed to demonstrate that a change in salt concentration from 100 mM NaCl to 250 mM 




use of UV-CE and ThT binding for monitoring insulin aggregation revealed that CE was able to 
detect the appearance of aggregated species at significantly earlier times than ThT binding, 
demonstrating that CE and ThT binding may be used as complementary techniques to identify 
insulin species present at all times throughout aggregation. The lowest concentration of 
monomeric insulin that can be detected was determined using both UV and LIF detection modes. 
Physiologically relevant insulin concentrations in the picomolar range were detectable using LIF 
detection while concentrations in the micromolar range were required for UV detection. Using 
UV-CE and LIF-CE to simultaneously monitor the aggregation of a mixture of FITC-labeled 
insulin and unlabeled insulin, this study was the first to show that FITC-labeled insulin was 
unable to incorporate into oligomers formed by the unlabeled protein. These results demonstrate 
that while CE is a promising technique for the detection of physiologically relevant insulin 
concentrations, caution must be taken when choosing a dye for detection of oligomeric and 
aggregate insulin species. This necessitates further investigation to identify optimum fluorescent 
labels for the study of insulin oligomer formation at physiological insulin concentrations.  
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CHAPTER 4:  MONITORING AΒ AGGREGATION VIA CAPILLARY 
ELECTROPHORESIS 
1. Introduction 
 Alzheimer’s Disease (AD) is a devastating neurodegenerative disorder which currently 
affects 5.4 million Americans and is the 6th leading cause of death [1]. The amyloid β protein 
(Aβ) is a partially folded protein that contributes to the neurodegenerative effects of AD. In its 
monomer form, this protein is harmless [2]. This monomer can self-assemble into Aβ oligomers 
and eventually fibrillar aggregates which deposit as amyloid plaques in the brain [3]. 
Controversy currently exists over the direct effect Aβ has on neurodegeneration, but it appears 
likely that soluble aggregates of Aβ (protofibrils or oligomers), rather than monomers or 
insoluble fibrils, may be responsible for the toxic effects of AD [4-7]. This hypothesis is 
supported by experimental observations in vitro which showed that soluble aggregates formed by 
synthetic Aβ1-40 and Aβ1-42 induced toxicity in cultured cells [8,9] and in vivo where soluble Aβ 
aggregates generated in cell cultures drastically inhibited hippocampal long-term potentiation in 
rats [10]. Furthermore, the direct neuron-to-neuron transfer and corresponding toxicity of soluble 
oligomers formed by synthetic Aβ1-42 has been demonstrated [11]. 
 The detection of soluble Aβ oligomeric species, specifically Aβ1-40, is challenging due to 
the fact that these intermediate sized species are difficult to isolate because they are transient 
[12,13], and present at low concentrations [14]. Many different techniques have been examined 
for their ability to detect the smaller oligomeric Aβ species. These include SDS-PAGE and/or 
Western blotting [8,15-27], mass spectrometry [20,28-33], and size exclusion chromatography 
(SEC) [15]. SDS-PAGE with Western blotting is one of the most common electrophoretic 




molecular weight Aβ1-40 oligomers ranging from 8-24 kDa is difficult due to gel smearing [15]. 
This study also compared SDS-PAGE to SEC and found that Aβ1-40 was aggregating into higher 
molecular weight species (>24 kDa) which were not detectable using SDS-PAGE. SEC is further 
complicated by the dissociation of reversible aggregates that occurs upon sample dilution [34]. 
Western blotting also has been shown to be a promising technique for the detection of oligomeric 
Aβ species, but it requires the use of expensive antibodies and gel smearing often limits the 
ability to distinguish molecular weights. Mass spectrometry has also been used alone and in 
combination with SDS-PAGE to evaluate the sizes formed during the early stages of Aβ 
aggregation [20,28-31,33]. Studies by Iurascu et al. and Maji et al. have utilized MS in 
combination with SDS-PAGE to detect Aβ1-40 species ranging from monomer to hexamer 
[28,29]. Since aggregated species have highly similar mass-to-charge ratios, ion-mobility 
coupled with MS (IM-MS) has been the most effective method for the separation of small 
oligomers of Aβ by both size and charge. An aggregation mechanism for Aβ1-40 has been 
proposed which involves the formation of dimers and tetramers followed by the slow formation 
of fibrils containing a β-sheet structure [20,31].  IM-MS is expensive and the addition of a step 
such as ion-mobility also increases the time needed for analysis and therefore decrease the 
chances of detecting transient species. In addition, these techniques are not capable of detecting 
the Aβ oligomerization process under physiological concentrations.   
Capillary electrophoresis (CE) as a technique for the detection of Aβ species formed 
throughout aggregation is still in its early stages. Therefore, studies on the use of CE for the 
detection of Aβ aggregates, especially, Aβ1-40, are limited. The detection of proteins via CE can 
be conducted using either ultraviolet (UV) absorbance or laser induced fluorescence (LIF) 




lower sensitivity than LIF. LIF usually requires labeling of the molecules, but is highly sensitive, 
with previous reports of LIF-CE detection of synthetic Aβ down to 35 nM [35]. The process of 
fluorescence occurs when a photon is emitted by an electronically excited molecule as it relaxes 
to its ground electronic state [36]. For LIF-CE, the fluorescence excitation source is typically a 
He-Cd, Ar-ion, or He-Ne laser [36]. In general, the fluorescent compound used to label proteins 
for analysis via LIF-CE can be 1) covalently bound to the protein or 2) specific for a certain 
protein conformation. Furthermore, these fluorescent probes are typically bulky, aromatic 
compounds. 
The ability of UV-CE to detect Aβ aggregates has been demonstrated in the literature. A 
study by Sabella et al. utilized UV-CE to detect small Aβ1-40 species ranging from 3 - 30 kDa 
and Aβ1-42 species ranging from 3 - 50 kDa and > 50 kDa [37]. However, this study looked at a 
small size range (3 – 50 kDa) and did not use a sieving matrix within the capillary to enhance 
resolution. The separation of larger fibrillar species from monomer has been achieved for both 
Aβ1-40 and Aβ1-42 using UV-CE [38]. The detection of intermediate sizes larger than monomer 
which are formed prior to fibrils was not accomplished. These studies demonstrate the ability of 
UV-CE to detect sizes from monomers to fibrils but highlight the need for more studies on the 
use of UV-CE to monitor the Aβ aggregation process over time.  
The ability of LIF-CE to detect Aβ aggregates using dyes which are specific for the β-
sheet conformation has been demonstrated in the literature [3,38,39]. These dyes bind structures 
containing β-sheets and therefore cannot be used for the detection of small oligomers which 
precede β-sheet formation. Carboxy-fluorescein (FAM) and fluorescein isothiocyanate (FITC) 




insulin and Aβ via LIF-CE [35,40]. Less attention has been paid to the use of LIF-CE to detect 
oligomeric and aggregated species formed by FAM or FITC-labeled insulin and Aβ. 
These previous studies highlight the potential for CE using a buffer solution to analyze 
early stages of the Aβ1-40 oligomerization process. In this chapter, we report the first study on the 
use of UV-CE with a polymer separation matrix to detect smaller oligomeric native Aβ1-40 
species (10 – 30 kDa) and larger oligomeric and aggregate species (100– 300 kDa and > 300 
kDa). To our knowledge this is the first study to investigate the use of a polymer matrix to 
increase the effect of hydrodynamic radius of the oligomer species on CE separation to study the 
early oligomerization process of Aβ1-40. In addition, we have compared the oligomeric species 
sizes detected utilizing a traditional Aβ1-40 oligomer sample preparation with initial dilution into 
NaOH compared to a sample thought to contain SEC-purified Aβ1-40 monomer as the initial 
species present in solution. Dot blots were utilized to verify the presence of Aβ oligomeric 
species detected via UV-CE. Furthermore, we have probed the ability of CE to detect 
physiological concentrations of Aβ1-40. The potential for LIF-CE to monitor the aggregation of 
FAM-labeled Aβ1-42 is explored and the limitations of LIF-CE as a tool to monitor amyloid 
aggregation will be given. We believe that these are the first CE studies to use a polymer matrix 
to enhance the separation of native Aβ1-40 oligomers and to determine and compare UV versus 
LIF detection limits.  
2. Materials and Methods 
2.1. Aβ preparation 
 Aβ1-40 and FAM-Aβ1-40 were stored dessicated at -20°C. 4.33 mg/mL Aβ1-40 and 0.47 mg/ 
mL FAM-Aβ1-40 peptide stocks were prepared in hexafluoroisopropanol (HFIP) in order to break 




Aβ1-40 and 0.01563 mg for FAM-Aβ1-40 and the HFIP was allowed to evaporate overnight. Vials 
were stored at -80°C.  
 SEC-purified Aβ1-40 monomer samples were prepared in the laboratory of Dr. Melissa 
Moss as described previously [41]. Briefly, Aβ1-40 peptide was reconstituted to a final 
concentration of 2 mg/mL in 50 mM NaOH. Preexisting aggregates were removed by size 
exclusion chromatography (SEC) on a Superdex 75 HR10/30 column (GE Healthcare, 
Piscataway, NJ, USA). Purified Aβ1-40 monomer was flash frozen and shipped overnight on dry 
ice to the laboratory of Dr. Christa Hestekin. The purified Aβ1-40 monomer was used fresh or 
stored at -80°C. 
Aβ1-42 and FAM-Aβ1-42 were stored dessicated at -20°C. 4.51 mg/mL Aβ1-42 and 0.49 mg/ 
mL FAM-Aβ1-42 peptide stocks were prepared in hexafluoroisopropanol (HFIP) in order to 
ensure the samples were monomeric. These stock solutions were split into vials containing 
0.0271 mg for Aβ1-42 and 0.006775 mg for FAM-Aβ1-42 and the HFIP was allowed to evaporate 
overnight. Vials were stored at -80°C. 5 mM stock solutions of FAM-labeled Aβ1-42 and 
unlabeled Aβ1-42 were prepared separately in 100% DMSO and diluted to 0.14 mg/mL in 40 mM 
Tris (pH 8.0) containing 10 mM NaCl. These samples were then combined to yield a total final 
concentration of 0.14 mg/mL containing 50 – 80% unlabeled Aβ1-42 and 20 – 50% FAM-labeled 
Aβ1-42. 
2.2. Poly(ethylene oxide) coating and separation matrix synthesis  
 The utility of poly(ethylene oxide) as a capillary coating and separation matrix was 
investigated due to the commercial availability of this polymer. All UV-CE studies were 
conducted using PEO as a coating and separation matrix in the capillary. One sample of long-




(MW = 100,000 g/mol) were obtained from Sigma-Adrich (St. Louis, MO). The EO polymer with 
MW = 2,000,000 g/mol was diluted to 0.5% w/v in de-ionized water and used for the capillary 
coating and the EO polymer with MW = 100,000 g/mol was diluted to 0.5% w/v in 100 mM Tris-
HCl and used as the protein separation matrix. 
2.3. Poly-N-hydroxyethyl acrylamide coating and separation matrix synthesis and 
characterization 
 All LIF-CE studies were conducted using PHEA as a coating and separation matrix in the 
capillary. Two samples of long-chained HEA polymers (MW = 6,230,000 g/mol and 5,100,000 
g/mol) were synthesized as described previously [42] with the following changes: 4% w/w initial 
monomer concentration and polymerization for 5 hours. One sample of short-chained HEA 
polymer (MW = 2,700,000 g/mol) was synthesized as described previously [43] with the 
following changes: 3.5 mL isopropanol added to 200 mL of 4% w/w initial monomer solution. 
Solution deoxygenated by bubbling nitrogen through mixture at 47°C for 2 h followed by 
polymerization for 4 hours. Once the polymerization was complete, the polymer was dialyzed, 
lyophilized, and characterized to confirm its molecular weight by multi-angle laser light 
scattering (Wyatt Technology, Santa Barbara, CA). The HEA polymer with MW = 6,230,000 
g/mol was diluted to 0.1% w/v in de-ionized water and used for the capillary coating and the 
HEA polymers with MW = 5,100,000 and 2,700,000 g/mol were diluted to 1% (UV and LIF 
insulin studies) and 0.5% (LIF Aβ studies), respectively, in 40 mM Tris (pH 8.0) and used as 
protein separation matrices.  
2.4. Electrophoresis conditions for UV and LIF studies 
 Aβ1-40 oligomer formation studies with analysis via UV-CE were carried out in 0.5% w/v 




Aβ limit of detection and oligomer formation studies with analysis via LIF-CE were carried out 
in 0.1% w/v PHEA coated capillaries with a 0.1–1% PHEA separation matrix and a capillary 
temperature of 25 °C.  Capillary dimensions for UV-CE studies were Lt = 31 cm, Ld = 10 cm and 
for LIF-CE studies were Lt = 36 cm, Ld = 10 cm. CE separations using UV detection were carried 
out using a P/ACE MDQ Glycoprotein System from Beckman Coulter, Inc. (Fullerton, CA) (214 
nm filter) interfaced with an IBM computer utilizing 32 Karat software (V. 5.0, Beckman 
Coulter, Inc.) for data collection. Samples were pressure injected at 0.5 psi for 8 s and separated 
at 7 kV. Between each run, the capillary was rinsed with deionized water for 10 minutes to 
ensure that the Aβ1-40 was not retained on the capillary wall. CE separations using LIF detection 
were carried out using an Applied Biosystems (Foster City, CA) 3130 Genetic Analyzer 
(excitation = 494 nm, emission = 522 nm) interfaced with a Dell computer utilizing Foundation 
Data Collection V 3.0 software from Applied Biosystems (Foster City, CA). For limit of 
detection studies, Aβ1-40 and Aβ1-42 samples were electrokinetically injected at 12 kV for 12 s 
and separated at 15 kV. For oligomer formation studies, Aβ1-42 samples were electrokinetically 
injected at 7 kV for 7 s and separated at 7 kV. 
2.5. Aβ oligomer formation assay 
To observe the time course for Aβ1-40 oligomer formation, Aβ1-40 was dissolved in 5 mM 
NaOH and diluted into 40 mM Tris-HCl (pH 8.0) supplemented with 5 mM NaCl to a final 
concentration of 0.22 mg/mL and incubated at 25°C under continuous agitation (800 rpm). Both 
prior to the onset of aggregation and at times between 5 and 48 hours following the onset of 
aggregation, a 15 µL sample was removed and analyzed by UV-CE to determine the elution time 
and intensity of all peaks. Separate experiments were conducted using the same sample 




At 0 and 28 hours, a 50 µL sample was taken and ultrafiltrated (20 minutes, 14,100 x g) through 
Amicon filters with cut-off values of 10, 30, 50, and 300 kDa. The filtrate and retentate were 
removed and analyzed via UV-CE to determine the relative size of oligomers.  
To observe the effect of model inhibitory compounds on the formation of Aβ1-40 
oligomeric species, Aβ1-40 was dissolved in 5 mM NaOH and diluted into 40 mM Tris-HCl (pH 
8.0) supplemented with 5 mM NaCl to a final concentration of 0.22 mg/mL. Congo Red and 
Orange G were dissolved in DMSO and added to Aβ1-40 to obtain a mixture containing 2% 
DMSO, 0.15 mg/mL Orange G or 0.23 mg/mL Congo Red and incubated at 25°C under 
continuous agitation (800 rpm). Both prior to the onset of aggregation and at times of 24 and 28 
hours following the onset of aggregation, a 15 µL sample was removed and analyzed by UV-CE 
to determine the elution time and intensity of all peaks. 
To compare the effect of sample preparation on the Aβ1-40 sizes formed, SEC-purified 
Aβ1-40 was diluted into 40 mM Tris-HCl (pH 8.0) supplemented with 5 mM NaCl to a final 
concentration of 0.22 mg/mL and incubated at 25°C under continuous agitation (800 rpm). 
Identical time points and aliquot volumes as those given in the previous paragraph were taken 
and analyzed via UV-CE. Separate experiments were conducted using the same sample 
preparation and CE conditions in order to determine the size range of Aβ1-40 oligomers observed. 
At 0 and 5 hours, a 50 µL sample was taken and ultrafiltrated (20 minutes, 14,100 x g) through 
Amicon filters with cut-off values of 10 and 30 kDa (0 hours) and 30, 50, and 300 kDa (5 hours). 
The filtrate and retentate were removed and analyzed via UV-CE to determine the relative size of 
oligomers. 
The co-incorporation of unlabeled Aβ1-42 and FAM-labeled Aβ1-42 into oligomers was 




prepared separately in 100% DMSO and diluted to 0.14 mg/mL in 40 mM Tris (pH 8.0) 
containing 10 mM NaCl. These samples were then combined to yield a total final concentration 
of 0.14 mg/mL containing 50 – 80% unlabeled Aβ1-42 and 20 – 50% FAM-labeled Aβ1-42. This 
oligomer preparation was then incubated at 25°C and both prior to the onset of oligomer 
formation and at times between 3 and 24 hours following the onset of oligomer formation, a 27 
µL sample was removed and combined with 3 µL of 1% tween to obtain a final volume 
containing 0.1% tween for analysis by LIF-CE. Tween was added in order to stop oligomer 
formation.   
2.6. Dot blot analyses of Aβ aggregation 
 To validate Aβ1-40 oligomer detection via CE with a more commonly used technique for 
oligomer detection, Aβ1-40 aggregates were analyzed via dot blotting. Aβ1-40 aggregation 
reactions were prepared and incubated as described above for CE measurements on Aβ1-40 
oligomer formation. Both prior to the onset of aggregation and at times between 5 and 48 hours 
following the onset of aggregation, 3 µL aliquots were spotted on nitrocellulose membranes 
(VWR) and allowed to dry for at least 1 hour. Membranes were blocked in 5% skim milk in tris 
buffered saline containing 0.01% Tween 20 (TBS-T) for 1 hour. After washing 3 times with 
TBS-T, membranes were incubated with either Aβ1-16 specific 6E10 antibody (1:2000 dilution), 
Aβ oligomer specific A11 antibody (1:2000 dilution), or Aβ fibril specific OC antibody (1:4000 
dilution) for 1 hour at 4°C with gentle shaking. Membranes were again washed with TBS-T and 
bound 6E10, A11, and OC antibodies were detected by incubation for 1 hour at 4°C with 
alkaline phosphatase-conjugated anti-mouse IgG (1:2000 dilution) or alkaline phosphatase-
conjugated anti-rabbit IgG (1:3000 dilution). All antibodies were diluted in 5% skim milk in 




+ 50 µL of 50 mg/mL 5-bromo-4-chloro-3-indolyl phosphate (BCIP) + 50 µL of 50 mg/mL 
nitroblue tetrazolium chloride (NBT) was used to develop the membranes. 
2.7. Limit of detection studies 
 A 0.22 mg/mL unlabeled Aβ1-40 stock solution was prepared in 5 mM NaOH and 40 mM 
Tris-HCl (pH 8.0) supplemented with 5 mM NaCl and diluted to concentrations of 0.0087 - 
0.043 mg/mL in 40 mM Tris-HCl (pH 8.0). A 0.47 mg/mL stock solution of FAM-Aβ1-40 and 
FAM-Aβ1-42 were prepared separately and diluted in 40 mM Tris-HCl (pH 8.0) to concentrations 
of 0.0047 - 4140 ng/mL for FAM-Aβ1-40 and 0.0049 - 4870 ng/mL for FAM-Aβ1-42.  
Immediately following preparation, 25 and 10 µL samples were analyzed by UV and LIF-CE, 
respectively, to determine the intensity of the first peak. Between runs for determining the limit 
of detection, the capillary was rinsed with deionized water for 10 minutes, and elution of de-
ionized water was analyzed to ensure that Aβ1-40, FAM-Aβ1-40 and FAM-Aβ1-42 were not retained 
on the capillary wall. 
2.8. Statistical analysis 
 The elution time and intensity of peaks were analyzed using Chromagna (VO 9.8) 
software (provided by Mark Miller, NIH) and Origin (V. 8.0) software from OriginLab 
Corporation (Northampton, MA). Chromagna software was used to convert the fsa file format of 
the ABI 3130 Genetic Analyzer to excel files, which are compatible with Origin software. For 
UV-CE studies, a Gaussian fit was used to calculate the peak area and migration time in Origin. 
The peak height for the peaks detected in the UV and LIF limit of detection studies was 
determined and the signal-to-noise ratio was calculated. Peaks with a signal-to-noise ratio > 3 
were considered significant. Unpaired t-tests were performed using GraphPad QuickCalcs 




migration times of peaks observed in the Aβ1-42 oligomer time course studies were normalized in 
order to draw qualitative conclusions about the sizes of Aβ1-42 species present at various times 
throughout aggregation. Peak migration times were determined by normalizing the migration 
time for the last peak observed relative to the migration time of the first peak observed prior to 
the onset of aggregation. Unpaired t-tests were performed using GraphPad QuickCalcs 
(GraphPad Software Inc., San Diego, CA) to compare CE normalized migration times. 
3. Results and Discussion 
3.1. Detection of Aβ1-40 oligomers using CE with UV detection 
 Although insoluble Aβ fibrils are a post mortem signature, recent studies suggest that 
soluble Aβ oligomers impair cognitive function and in addition to synapse loss, correlate most 
accurately with the stage of neurological impairment [44-46]. Therefore, it is important to have a 
technique which is capable of detecting these soluble oligomeric Aβ species. To explore the 
utility of CE for the detection of Aβ1-40 oligomers that appear during early stages of Aβ1-40 
aggregation, Aβ1-40 was solubilized in 5 mM NaOH, diluted into 40 mM Tris (pH 8.0), subjected 
to 5 mM NaCl, and agitated at 800 rpm to promote amyloid assembly. The reaction was analyzed 
using UV-CE at early and late time points to assess the appearance of oligomers and progression 
into larger aggregate species. At 0 hours, UV-CE demonstrated the presence of an early, sharp 
peak at ~9 min (Figure 1B) in addition to a broader peak migrating at 220 minutes (Figure 1A). 
The size of these species was estimated using a filtration analysis similar to that performed by 
Sabella et al. who used molecular weight cutoff membranes to size early amyloid-β aggregation 
species detected via UV-CE [37]. For our experiments, we used membranes with molecular 
weight cutoffs of 10, 30, 50, 100, and 300 kDa to analyze the filtrate obtained after 0 and 28 




molecular weight between 10 – 30 kDa, or oligomers of 2 - 6 monomer units. Furthermore, a 
broad peak at 220 min was obtained and indicates the presence of larger species. A similar 
monomer peak pattern was obtained after 5, 10, and 24 hours (Figure 1B) while the later peak 
became more broad and exhibited a progressively shorter migration time (Figure 1A). This later 
broad peak was estimated to have a molecular weight of 100 – 300 kDa.  At 28 hours, a set of 
sharp peaks with migration times between 8 – 8.5 minutes appeared (Figure 1B). The size of 
these species was estimated by filtration analysis to be > 300 kDa, or larger than 70 monomer 
units. Furthermore, we have confirmed that this sharp peak corresponds to an oligomeric 
structure, and not a fibril structure by looking at the affect of model inhibitory compounds 
(Figure 2). These compounds include Orange G, which is known to inhibit the formation of Aβ 
fibrils and Congo Red, which is known to inhibit the formation of Aβ oligomers [47]. By 36 and 
48 hours, the intensity for the sharp peak at ~8.5 minutes increased and appeared to resolve into 
a single species.  
 In order to better understand the growth process, the peak area for the initially present 
species (10 – 30 kDa peak at ~9 minutes) was compared to the peak area for the > 300 kDa 
oligomer peak at ~8.5 minutes, which appeared after 28 hours of aggregation (Figure 3). As 









Figure 1. Detection of smaller, intermediate, and larger molecular weight Aβ1-40 
aggregation states using UV-CE. Aβ1-40 was aggregated under agitation (800 rpm) at  
0.22 mg/mL in 40 mM Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0 – 48  
hours, CE was performed in conjunction with UV detection with a 0.5 psi pressure 
injection for 8 s with separation at 7 kV using 0.5% PEO separation matrix in a PEO 
coated capillary. Panel A) shows all peaks while panel B) is zoomed in on the 
smaller peaks. Results are representative of three independent experiments. 
 
Figure 18 Detection of smaller, intermediate, and larger molecular weight Aβ1-40 aggregation states using UV-CE 




Figure 2. Comparison of Aβ1-40 peak pattern obtained with and without the presence 
of inhibitory compounds. Aβ1-40 was aggregated under agitation (800 rpm, 25 °C) at 
0.22 mg/mL in 40 mM Tris (pH 8.0) containing 5 mM NaCl in the absence of 
inhibitor, or in the presence of 0.23 mg/mL Congo Red or 0.15 mg/mL Orange G. At 
0 – 28  hours, CE was performed in conjunction with UV detection with a 0.5 psi 
pressure injection for 8 s with separation at 7 kV using 0.5% PEO separation matrix 
in a PEO coated capillary.  
 









Figure 3. Effect of aggregation time on the peak areas obtained for 10 – 30 kDa (, 
n = 3) and > 300 kDa (, n = 3) Aβ1-40 species. Aβ1-40 was aggregated under 
agitation (800 rpm) at 0.22 mg/mL in 40 mM Tris (pH 8.0) containing 5 mM NaCl 
and at 25 °C. At 0 – 48  hours, CE was performed in conjunction with UV detection 
with a 0.5 psi pressure injection for 8 s with separation at 7 kV using 0.5% PEO 
separation matrix in a PEO coated capillary. A * represents the first time point in 
which peak areas are statistically different with p < 0.05. 
 
Figure 20 Effect of aggregation time on the peak areas obtained for 10 – 30 kDa (, n = 3) and > 











aggregation time of 24 hours. This initial increase in peak area could be due to the breakdown of 
the larger species present at 0 hours into 10 – 30 kDa species. After 28 hours, the 10 – 30 kDa 
peak area decreases and a new peak (> 300 kDa) with a faster migration time than the 10 – 30 
kDa peak appears. Finally, between 28 – 48 hours of aggregation, both the 10 – 30 kDa and        
> 300 kDa peak areas further decrease. We hypothesize that sharp peak (> 300 kDa) with a faster 
migration time which appears after 28 hours of aggregation represents a species with an 
increased negative surface charge due to conformational changes which occur during oligomer 
formation. An increase in negative surface charge of Aβ1-42 fibrils has been observed by Wang et 
al [48]. This study utilized surface plasmon resonance to monitor the absorption of Aβ1-42 at 
various times throughout aggregation to four model self-assembled monolayers: hydrophobic 
CH3-terminated SAM, hydrophilic OH-terminated SAM, negatively charged COOH-terminated 
SAMs, and positively charged NH2-terminated SAM. They found that as Aβ grew into larger 
aggregates, the amount absorbed onto positively charged NH2-SAM increased while the amount 
absorbed onto negatively charged COOH-SAM decreased. This increase in electrostatic 
interactions with the positively charged NH2-SAM suggests an increase in negative surface 
charge of Aβ1-42 aggregates. Furthermore, a structural model for Aβ1-40 fibrils has been suggested 
by Petkova et al. in which the negatively charged N-terminus residues are exposed to solution on 
the outside of the fibril [49].  
 A previous study by Sabella et al. utilized UV-CE with an SDS rinse for the detection of 
Aβ1-40 oligomers formed in PBS (pH 7.4) at room temperature [37]. A decrease in the intensity of 
the 10 to 30 kDa peak was observed over an incubation period of 24 hours with the 
disappearance of all peaks after 48 hours. In contrast to our results, no new peaks were observed 




separations have been utilized to characterize SDS-stable Aβ1-40 assemblies [22,24,27,32]. A 
smear for Aβ1-40 species ranging from ~60 - 80 kDa was obtained after incubation at 4°C for 6 
weeks of an Aβ1-40 oligomer preparation employing DMSO and F12 culture media at pH 7.4, 150 
mM NaCl [24,27].  This smear obtained with Western blotting could represent the broad peaks 
with longer migration times seen in our UV-CE studies (Figure 1A). Our studies are the first to 
utilize UV-CE to detect the formation of native Aβ1-40 species ranging from 100 – 300 kDa and  
> 300 kDa at near physiological pH.      
3.2. Effect of sample preparation on Aβ1-40 aggregate sizes formed 
 The type of solvent used to dissolve lyophilized Aβ1-40 has been shown to have an effect 
on the initial conformation and subsequent aggregation kinetics of this peptide [50]. However, 
this study employed organic solvents, which have been known to accelerate Aβ aggregation and 
misrepresent the true “native” aggregation of the protein [51]. Furthermore, larger aggregates 
which are initially present in solution can serve as “seeds” that promote the formation oligomeric 
species [52,53]. Therefore, since a range of Aβ1-40 sizes were detected at the onset of aggregation 
(Figure 1A) using a sample preparation thought to produce smaller Aβ sizes, we explored the 
aggregation of a sample containing SEC-purified Aβ1-40 as the starting material. Furthermore, we 
utilized a non-organic solvent, sodium hydroxide, for initial dissolution of Aβ1-40 peptide. 
Preexisting Aβ1-40 aggregates were removed by SEC and samples thought to contain purified 
Aβ1-40 monomer were diluted into 40 mM Tris (pH 8.0), subjected to 5 mM NaCl, and agitated at 
800 rpm to promote amyloid assembly. The reaction was analyzed using UV-CE at various 
points throughout the aggregation process to assess the appearance of oligomers and progression 
into larger aggregate species. Similar to the filtration analyses conducted with non-purified Aβ1-




filtrate obtained after 0 and 5 hours of aggregation (Appendix). At 0 hours, a peak migrating at 
~9.5 min was observed, which was estimated to range in size from 10 – 30 kDa (Figure 4A). 
After 5 hours of aggregation, a new peak with a faster migration time of ~8 min appeared. The 
size of these species was estimated by filtration analysis to be > 300 kDa, or larger than 70 
monomer units. A similar peak pattern for the 10 – 30 kDa species and faster eluting oligomer 
species was obtained after 10 – 48 hours (Figure 4B) while a later peak appeared which became 
more broad and exhibited a progressively shorter migration time (Figure 4A). The size of this 
peak was estimated by filtration analyses to be 100 - 300 kDa. 
 In order to better visualize the differences between SEC-purified Aβ1-40 and non-purified 
Aβ1-40 samples, the peak pattern obtained at 0 hours for SEC-purified samples and non-purified 
samples is compared (Figure 5A and B). Compared to the non-SEC purified Aβ1-40 sample, no 
peak was observed at 220 min for the SEC-purified Aβ1-40 sample, indicating the presence of 
predominantly 10 – 30 kDa Aβ1-40 at 0 hours (Figure 5). Furthermore, the area for the 10 – 30 
kDa peak at ~9 minutes is compared to the peak area for the > 300 kDa oligomer peak at ~8.5 
minutes. Figure 6A shows peak areas for the non-purified Aβ1-40 sample while Figure 6B shows 
the peak areas for the SEC-purified Aβ1-40 sample. Compared to the non-purified Aβ1-40 sample, 
the SEC-purified Aβ1-40 sample showed a decrease in the 10 – 30 kDa peak area and appearance 
of > 300 kDa oligomer peak after 5 hours, which is ~23 hours earlier than non-purified Aβ1-40 
sample. Figure 7 shows changes in the 10 – 30 kDa peak area for the SEC-purified Aβ1-40 
sample compared to the non-purified Aβ1-40 sample. Initially, an increase in the 10 – 30 kDa peak 
area is observed for the non-purified Aβ1-40 sample. Furthermore, the 10 – 30 kDa peak for the 
non-purified Aβ1-40 sample decreased after 28 hours while the 10 – 30 kDa peak for the SEC-




Figure 4. Detection of smaller, intermediate, and larger SEC-purified Aβ1-40 
molecular weight aggregation states using UV-CE. SEC-purified Aβ1-40 was 
aggregated under agitation (800 rpm) at 0.22 mg/mL in 40 mM Tris (pH 8.0) 
containing 5 mM NaCl and at 25 °C. At 0 – 48  hours, CE was performed in 
conjunction with UV detection with a 0.5 psi pressure injection for 8 s with 
separation at 7 kV using 0.5% PEO separation matrix in a PEO coated capillary. 
Panel A) shows all peaks while panel B) is zoomed in on the smaller peaks. Results 
are representative of three independent experiments. 
 
Figure 21 Detection of smaller, intermediate, and larger SEC-purified Aβ1-40 molecular weight 




Figure 5. Comparison of peak pattern obtained at the onset of aggregation for SEC-
purified Aβ1-40 and non-purified Aβ1-40 using UV-CE. SEC-purified Aβ1-40 and non-
purified Aβ1-40 were aggregated under agitation (800 rpm) at 0.22 mg/mL in 40 mM 
Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0  hours, CE was performed in 
conjunction with UV detection with a 0.5 psi pressure injection for 8 s with 
separation at 7 kV using 0.5% PEO separation matrix in a PEO coated capillary. 
Panel A) shows all peaks while panel B) is zoomed in on the smaller peaks.  
 
Figure 22 Comparison of peak pattern obtained at the onset of aggregation for SEC-purified Aβ1-







– 30 kDa (, n = 3) and > 300 kDa (, n = 3) non-purified Aβ1-40 species and B) 10 – 30 
kDa (, n = 3) and > 300 kDa (, n = 3) SEC-purified Aβ1-40 species. 
Figure 6. Effect of aggregation time on the peak areas obtained for A) 10 – 30 kDa 
(, n = 3) and > 300 kDa (, n = 3) non-purified Aβ1-40 species and B) 10 – 30 kDa 
(, n = 3) and > 300  kDa (, n = 3) SEC-purified Aβ1-40 species. SEC-purified and 
non-purified Aβ1-40 were aggregated under agitation (800 rpm) at 0.22 mg/mL in 40 
mM Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0 – 48  hours, CE was 
performed in conjunction with UV detection with a 0.5 psi pressure injection for 8 s 
with separation at 7 kV using 0.5% PEO separation matrix in a PEO coated capillary. 
A * represents the first time point in which peak areas are statistically different with 
p < 0.05 for non-purified Aβ1-40 samples and p < 0.02 for SEC-purified Aβ1-40 
samples. 
 
Figure 23Effect of aggregation time on the peak areas obtained for A) 10 – 30 kDa (, n = 3) and 
> 300 kDa (, n = 3) non-purified Aβ1-40 species and B) 10 – 30 kDa (, n = 3) and > 300  kDa 








Figure 7. Effect of aggregation time on the 10 – 30 kDa peak areas obtained for non-
purified (, n = 3) and SEC-purified (, n = 3) Aβ1-40 species. SEC-purified and 
non-purified Aβ1-40 were aggregated under agitation (800 rpm) at 0.22 mg/mL in 40 
mM Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0 – 48  hours, CE was 
performed in conjunction with UV detection with a 0.5 psi pressure injection for 8 s 
with separation at 7 kV using 0.5% PEO separation matrix in a PEO coated capillary. 
A * represents the first time point in which peak areas are statistically different with 
p < 0.05 for non-purified Aβ1-40 samples and p < 0.0002 for SEC-purified Aβ1-40 
samples. 
  
Figure 24 Effect of aggregation time on the 10 – 30 kDa peak areas obtained for non-purified 






peak area is accompanied by the appearance of a > 300 kDa oligomer peak for both non-purified 
and SEC-purified Aβ1-40 samples. Figure 8 compares the area for the > 300 kDa peak for non-
purified and SEC-purified Aβ1-40 samples. This peak appears ~23 hours earlier compared to non-
purified Aβ1-40 samples.  
 Our findings that a very short lag time to aggregate formation exists when SEC-purified 
monomer is the predominant Aβ1-40 species at the onset of aggregation are similar to those 
observed by Taylor et al [54]. This study prepared a solution of Aβ1-40 which consisted of 
predominantly monomer, as confirmed by HPLC, and monitored aggregate formation by dilution 
to 50 µM in PBS and agitation at 800 rpm. Turbidity measurements showed that aggregate 
formation occurred after 60 min. They propose a three-step kinetic model for Aβ1-40 in which; 1) 
an unactivated monomer is slowly converted to an activated monomer, 2) an oligomeric nucleus 
is formed by the cooperative interaction between four activated monomers that serves as the 
growing site for the fibril, 3) fibril growth proceeds by the successive addition of unactivated 
monomer to elongate the aggregates. As shown in Figure 3.7, SEC-purified Aβ1-40 has a much 
larger initial population of 10 – 30 kDa species compared to the non-purified Aβ1-40. In addition, 
the population of 10 – 30 kDa species for the non-purified Aβ1-40 increases initially and then 
begins to decrease before forming larger oligomeric species > 300 kDa. This suggests that a 
criticial concentration of 10 – 30 kDa species is necessary in order to progress to the next 
aggregation state. Furthermore, as shown in Figure 3.8, the > 300 kDa species formed by non-
purified Aβ1-40 samples increases after 28 hours and begins to decrease after 36 hours while the 
peak area for the > 300 kDa species formed by SEC-purified Aβ1-40 increases after 5 hours but 
does not begin to decrease until 48 hours. We hypothesize that a key size is needed, which is 




Figure 8. Effect of aggregation time on the > 300 kDa peak area obtained for non-
purified (, n = 3) and SEC-purified (, n = 3) Aβ1-40 species. SEC-purified and 
non-purified Aβ1-40 were aggregated under agitation (800 rpm) at 0.22 mg/mL in 40 
mM Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0 – 48  hours, CE was 
performed in conjunction with UV detection with a 0.5 psi pressure injection for 8 s 
with separation at 7 kV using 0.5% PEO separation matrix in a PEO coated capillary. 
A * represents the first time point in which peak areas are statistically different with 
p < 0.04 for non-purified Aβ1-40 samples and p < 0.02 for SEC-purified Aβ1-40 
samples. 
 
Figure 25 Effect of aggregation time on the > 300 kDa peak area obtained for non-purified (, n 








aggregation growth. Whatever the cause, the differences between lag times in addition to peak 
areas for samples containing larger aggregates at the onset of aggregation and samples 
containing predominantly smaller species at the onset of aggregation highlights the importance 
of sample preparation on Aβ1-40 aggregation.  
3.3 Validation of CE detection with traditional measures of Aβ aggregation states 
 The recent development of antibodies specific for Aβ oligomers has led to an increase in 
the application of dot blotting to study Aβ aggregation [55-57]. Furthermore, antibodies which 
are specific for a certain part of the Aβ sequence or a particular conformation can be used to 
detect Aβ1-16 and Aβ fibrillar species, respectively. In these studies, we utilized the conformation 
specific antibodies A11 and OC, which are known to recognize Aβ prefibrillar oligomers [55,56] 
and Aβ fibrils [55], respectively, and the sequence specific antibody 6E10, which is known to 
recognize Aβ1-16 [55,56]. Non-purified and SEC-purified Aβ1-40 samples were agitated using the 
same sample and aggregation conditions as were used in the UV-CE studies. Figure 9 shows the 
dot blot analysis of Aβ1-40 monomer (Panel A, 6E10 antibody), oligomer (Panel B, A11 
antibody), and fibril (Panel C, OC antibody). The top row in each panel is for non-purified 
Aβ1-40 samples while the bottom row is for SEC-purified Aβ1-40 samples. At all times during 
aggregation, both non-purified and SEC-purified Aβ1-40 samples contain 6E10 positive stains 
(Figure 9A). This is expected as both Aβ oligomer and fibril samples have been shown to react 
with 6E10 in the literature [55]. A11 and OC positive dots are detected in non-purified Aβ1-40 
samples after 24 hours and in SEC-purified Aβ1-40 samples after 5 hours (Figure 9B, C). This 




form after 24 hours of aggregation while for SEC-purified Aβ1-40 samples oligomeric and 
























Figure 9. Monitoring Aβ1-40 aggregation by dot blotting. Non-purified Aβ1-40 and 
SEC-purified Aβ1-40 samples were aggregated under agitation (800 rpm) at 0.22 
mg/mL in 40 mM Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0 – 48 
hours, samples were taken and spotted onto a nitrocellulose membrane. Membranes 
were stained with Aβ1-16 specific antibody 6E10 (Panel A), oligomer specific 
antibody A11 (Panel B) and fibril specific antibody OC (Panel C).  
 





 These results are in agreement with previous studies which utilized dot blots to monitor 
Aβ1-40 aggregation. A study by Wong et al. utilized dot blotting to monitor the aggregation of a 
50 µM Aβ1-40 sample containing 10 mM NaH2PO4 and 150 mM NaCl at pH 7.4 incubated at 
37°C [56]. They observed positive stains for the 6E10 antibody at times ranging from 0 – 3 days 
with the highest signal intensity at 1 and 2 days followed by a decrease in intensity at 3 days. A 
similar trend to the 6E10 antibody was observed for the A11 antibody but with a much lower 
signal intensity at day 0. This study did not look at the binding of OC to Aβ1-40. A comparison 
between the binding of A11 and OC to Aβ1-42 has been investigated by Kayed et al [55]. This 
study incubated Aβ1-42 under two sets of conditions, one known to promote the formation of 
fibrillar oligomers and fibrils while the other set of conditions is known to promote the formation 
of prefibrillar oligomers. A mechanism for aggregation was suggested (Figure 10) whereby; 1) 
misfolded monomer aggregates to form prefibrillar oligomers (recognized by A11), 2) 
prefibrillar oligomers align to form protofibrils followed by a conformational change to form 
fibrils (recognized by OC). An alternative mechanism of aggregation was also suggested where; 
1) misfolded monomer aggregates to form fibrillar oligomers (recognized by OC), 2) fibrillar 
oligomers elongate by the addition of monomer onto the ends of fibrillar oligomers, thus 
resulting in fibril formation. A comparison of our dot blot results with the results obtained from 
UV-CE suggests that both of these mechanisms of aggregation may be occurring under our 
incubation conditions. This is supported by examination of the non-purified Aβ1-40 time course. 
After 24 hours of aggregation, dot blots reveal positive stains for A11 and OC (Figure 9B and 
C) while the UV-CE peak pattern for the 10 – 30 kDa peak at ~9 min (Figure 1B) remains 
virtually the same as earlier time points. After 28 hours, UV-CE shows that the area for the 10 – 




Figure 10. Representation of distinct types of Aβ1-42 oligomers and their relationship 
to Aβ1-42 fibrils. Monomeric Aβ1-42 misfolds and aggregates to form two different 
conformations. One conformation formed is a prefibrillar oligomer, recognized by 
A11 (left pathway), which aligns to form protofibrils and undergoes another 
conformational change “en bloc” to form fibrils. Alternatively, a fibrillar oligomeric 
conformation can be formed which is recognized by OC (right pathway). The fibrillar 
oligomers may represent the fibril nuclei which are capable of elongating by 
recruiting additional monomers. Addition of monomers to the ends of fibrillar 
oligomers and fibrils results in fibril growth. Reprinted from [55] with permission 
from Charles Glabe, cglabe@uci.edu, corresponding author for this publication. 
Copyright 2007 by the authors; licensee BioMed Central, an open access journal.  
 





decreases while a new peak with a faster migration time of ~8 – 8.5 min (> 300 kDa) appears. 
Therefore, this fast peak could correspond to the conformational change that the prefibrillar 
oligomer undergoes.  
3.4 Determination of Aβ1-40 limit of detection 
 The physiological concentration of Aβ in CSF is 100 – 2000 pM [58]. Therefore, the 
ability of a technique to detect Aβ at these low concentrations is necessary to analyze patient 
samples. In Chapter 2, we determined the limit of detection for insulin protein to be 1.72 µM and 
48.4 pM using UV- and LIF-CE, respectively. To determine the Aβ1-40 limit of detection using 
UV-CE, Aβ1-40 was prepared at concentrations ranging from 0.0087 mg/mL to 0.043 mg/mL and 
analyzed. The S/N ratio of the Aβ1-40 peak was > 3 at concentrations of 0.02 mg/mL and higher, 
defining 0.02 mg/mL (5 µM) as the limit of detection for Aβ1-40 using UV-CE. The definition of 
the detection limit as the analyte concentration with a S/N ratio > 3 has been used previously in 
studies utilizing CE detection [59,60]. The Aβ detection limit obtained is in agreement with the 
detection limit obtained in our previous studies on insulin protein of 1.72 µM [61]. A study by 
Verpillot et al. obtained a lower detection limit for Aβ using UV-CE of 0.002 mg/mL (0.5 µM) 
[62]. This study utilized a 20 s injection time at 0.5 psi where our studies were conducted using a 
8 s injection at 0.5 psi. Therefore, the amount of Aβ injected into the capillary was most likely 
higher in the Verpillot et al. study, which would lead to a lower detection limit. Furthermore, the 
Aβ detection limit achieved by Verpillot et al. is higher than the physiological Aβ concentration 
in CSF of 100 – 2000 pM [58]. 
 A parallel limit of detection study was performed for carboxy-fluorescein (FAM)-labeled 
Aβ1-40 and Aβ1-42 using LIF-CE. The optimized injection conditions used previously for the 




detection limits using LIF-CE, FAM-labeled Aβ1-40 and Aβ1-42 were prepared at concentrations 
ranging from 0.0047 - 4140 ng/mL for FAM-Aβ1-40 and 0.0049 – 4870 ng/mL for FAM-Aβ1-42. 
The S/N ratio of the FAM-Aβ1-40 peak was > 3 at concentrations of 0.09 ng/mL and higher, thus 
establishing 0.09 ng/mL (20 pM) as the limit of detection for FAM-Aβ1-40 using LIF-CE. 
Furthermore, the S/N ratio of the FAM-Aβ1-42 peak was > 3 at concentrations of 0.0049 ng/mL 
and higher, thus establishing 0.0049 ng/mL (1 pM) as the limit of detection for FAM-Aβ1-42 
using LIF-CE and illustrating the superior limit of FAM-Aβ1-42 detection for LIF-CE compared 
with FAM-Aβ1-40. In fact, the LIF detection limits of 1 and 20 pM are lower than the 
physiological Aβ concentration in CSF of 100 – 2000 pM [58] and to the authors’ knowledge, is 
the lowest LIF detection limit of Aβ for an electrophoresis based method. A study by Verpillot et 
al. obtained a LIF-CE detection limit for FAM-Aβ of 35 nM [35], thus exhibiting the superior 
LIF-CE detection limit for Aβ (1 – 20 pM) obtained in our studies. Thus, LIF-CE is a promising 
technique for the detection of physiologically relevant Aβ concentrations.  
3.5 Analysis of FAM tracer incorporation into unlabeled Aβ 
 Similar to FITC, FAM is a fluorescein derivative which contains a carboxylic acid 
reactive group where FITC contains an isothiocyanate reactive group (Table 1). These reactive 
groups react with primary amines present on internal lysine residues and N-terminal residues via 
an SN2 reaction. Insulin contains two N-terminal residues and one lysine residue whereas Aβ 
contains one N-terminal residue and two lysine residues. Therefore, the number of possible 
attachment sites between the two proteins is similar. Since Aβ1-42 is highly prone to aggregation, 






Table 1: Structure and spectral properties of FAM and FITC. 
































The potential for LIF-CE to monitor the ability of FAM-labeled Aβ1-42 to incorporate into 
unlabeled Aβ1-42 was investigated using a sample preparation method which has been previously 
shown to promote Aβ1-42 oligomer formation [65]. Figure 11 shows the LIF-CE peak pattern 
obtained where Panel A is a zoom in of the data shown in Panel B. At 0 hours, LIF-CE 
demonstrated the presence of three peaks with migration times < 30 min (Figure 11A) in 
addition to larger, more broad peaks with migration times ranging from 50 – 70 min (Figure 
11B). After 3 hours, a similar peak pattern was obtained with the appearance of two more peaks 
with migration times of ~31 and 36 min, respectively (Figure 11A). In addition, a peak with a 
faster migration time of ~6 min appeared. The area for the peak with a faster migration time of 
~6 min increased over an aggregation time of 9 hours then decreased after 24 hours (Figure 12A, 
yellow squares). The area for the larger peak at 70 min decreased over a time period of 24 hours 
(Figure 12A, green triangles). Figure 12B shows changes in the normalized migration time for 
the last peaks in Figure 11A (~36 min) and Figure 11 B (~70 min) relative to the first peak at 
~15 min, thus representing growth for faster and slower migrating species, respectively. The 
normalized migration time for later peaks did not change over time while the normalized 
migration time for earlier peaks increased. These results suggest that FAM-labeled Aβ1-42 was 
incorporating into smaller unlabeled Aβ1-42 species but was interfering with the formation of 
larger Aβ1-42 species. Based on the peak pattern obtained in Chapter 3 for Aβ1-40 after 28 hours of 
aggregation with analysis via UV-CE, we estimate that the peak formed after 3 hours of 
aggregation at ~6 min corresponds to a larger species. Furthermore, the peaks with migration 
times > 40 min were estimated to be due to larger aggregates. Filtration or dot blot analyses were 




Figure 11. Coaggregation of FAM-labeled Aβ1-42 and unlabeled Aβ1-42. Aβ1-42 
solutions consisting of 30% FAM-labeled Aβ1-42 and 70% unlabeled Aβ1-42 with LIF 
detection (n = 2) were prepared at a concentration of 0.14 mg/mL in 40 mM Tris (pH 
8.0) containing 10 mM NaCl. Solutions were allowed to sit at room temperature and 
the formation of aggregates was monitored. Panel A is zoomed in on the early peaks 
while panel B shows all peaks. LIF-CE was performed with a sample injection at 7 
kV for 7 s with 7 kV separation using 0.5% PHEA separation matrix in PHEA coated 
capillary.  
 




Figure 12. Change in peak areas and normalized migration times for the 
coaggregation of FAM-labeled Aβ1-42 and unlabeled Aβ1-42. Aβ1-42 solutions 
consisting of 30% FAM-labeled Aβ1-42 and 70% unlabeled Aβ1-42 with LIF detection 
were prepared at a concentration of 0.14 mg/mL in 40 mM Tris (pH 8.0) containing 
10 mM NaCl. Solutions were allowed to sit at room temperature and the formation of 
small and large species was monitored. Panel A shows the change in peak area for 
peaks at ~6 min (, n = 2), and 70 min (, n = 2). Panel B shows the changes in 
normalized migration time for the peak at 36 min (, n = 2) and 70 min (, n = 2). 
LIF-CE was performed with a sample injection at 7 kV for 7 s with 7 kV separation 
using 0.5% PHEA separation matrix in PHEA coated capillary. Peak migration times 
were determined by normalizing the migration time for the last peak observed 
relative to the migration time of the first peak observed for each incubation time 
point. A * represents the first time point in which peak normalized migration times 
are statistically different with p < 0.004. 
 





 Other researchers have examined the effect of the FAM label on aggregation. Similar 
results were obtained by Jungbauer et al. using SDS-PAGE with Western blotting to analyze a 
100 µM FAM-labeled Aβ1-42 sample incubated in phenol-red free Hams F12 media, pH 7.4 at 
4°C for 24 hours [66]. This study observed bands for monomer, dimer, trimer, and tetramer (~4.5 
– 13.5 kDa) with a smear for larger molecular weight species ranging from 35 – 60 kDa for 
FAM-Aβ1-42. Compared to oligomers formed by labeled Aβ1-42, the unlabeled Aβ1-42 trimer and 
tetramer bands were less intense and the high molecular weight smear ranged from 40 – 100 
kDa. These results suggest that the FAM label could be interfering with the formation of high 
molecular weight species ranging from 60 – 100 kDa. Alternatively, the FAM label could be 
affecting the kinetics for the formation of Aβ1-40 aggregates as a study by Edwin et al. found that 
in some cases it took longer than 3 weeks to observe FAM-Aβ1-40 aggregates using fluorescence 
photobleaching recovery [67].  
 Although it appears that FAM-labeled Aβ1-42 was capable of incorporating into smaller 
Aβ1-42 species, we found this behavior to be highly dependent upon the lot obtained from the 
manufacturer. Aggregation studies were conducted using identical sample and LIF-CE 
conditions as those used to obtain the data shown in Figures 11 and 12 but using different FAM-
labeled Aβ1-42 and unlabeled Aβ1-42 lots. Furthermore, these lots were obtained from the same 
manufacturer (Anaspec). Figures 13A and B show the peak pattern obtained for the old lot while 
Figures 13C and D show the peak pattern obtained for the new lot. Panels A and C are a zoom 
in of the early peaks in Panels B and D. Peaks at ~31 and 36 min appear after 3 hours of 
aggregation with the old lot (Figure 13A) but not with the new lot (Figure 13C). In both lots, 
the peak with a faster migration time of ~5 min appears after 3 hours of  




Figure 13. Effect of peptide lot on the coaggregation of FAM-labeled Aβ1-42 and 
unlabeled Aβ1-42. Aβ1-42 solutions consisting of 30% FAM-labeled Aβ1-42 and 70% 
unlabeled Aβ1-42 with LIF detection (n = 2) were prepared at a concentration of 0.14 
mg/mL in 40 mM Tris (pH 8.0) containing 10 mM NaCl. Solutions were allowed to 
sit at room temperature and the formation of aggregates was monitored. Panels A 
and B show the peak pattern obtained for the old lot. Panels C and D show the peak 
pattern obtained for the new lot. Panels A and C are zoomed in on the early peaks 
shown in Panels B and D. LIF-CE was performed with a sample injection at 7 kV for 
7 s with 7 kV separation using 0.5% PHEA separation matrix in PHEA coated 
capillary.  
 




aggregation (Figures 13A and C). Figure 14 compares the change in area for the peak with a 
faster migration time obtained with the old lot (yellow squares) and the new lot (green circles). 
The overlap in error bars between the two sets of data makes it difficult to draw conclusions 
about differences in peak area for the two lots. A similar trend of an increase in peak area after 3 
hours followed by a decrease in area after 24 hours is exhibited with both lots.  
Lot-to-lot variability in synthetic preparations of Aβ peptides has been observed in the 
literature [68,69]. A study by Wogulis et al. observed varying amounts of fibrillar Aβ1-40 for 
three lots upon solubilization in water and dilution to 30 µM in tissue culture medium [68]. 
Furthermore, they found that neuronal cell death required the presence of both soluble and 
fibrillar forms of Aβ. Similar to Wogulis et al., we have observed significant lot-to-lot variations 
that have the potential to impact the aggregation processs. This indicates the complexity of the 
Aβ aggregation process and further highlights the need for a screening technique which more 















Figure 14. Change in early peak area for the coaggregation of FAM-labeled Aβ1-42 
and unlabeled Aβ1-42 using two different lots. Aβ1-42 solutions consisting of 30% 
FAM-labeled Aβ1-42 and 70% unlabeled Aβ1-42 with LIF detection were prepared at a 
concentration of 0.14 mg/mL in 40 mM Tris (pH 8.0) containing 10 mM NaCl. 
Solutions were allowed to sit at room temperature and the formation of oligomers 
and aggregates was monitored. The change in area for the peak with a faster 
migration time of ~6 min is shown for the old lot (, n = 2) and the new lot (, n = 
2). LIF-CE was performed with a sample injection at 7 kV for 7 s with 7 kV 
separation using 0.5% PHEA separation matrix in PHEA coated capillary. A * 
represents the first time point in which peak areas are statistically different with p < 
0.0008. 
 






 Although the exact nature of Alzheimer’s Disease is not well understood, there are 
significant indications that it involves the aggregation of the Aβ protein, in particular the ~40 
residue hydrophobic proteins Aβ1-40 and Aβ1-42 [70]. This highlights the importance of the 
development of a technique which is capable of detecting Aβ sizes produced throughout 
aggregation, in particular during the earliest stages of aggregation. Although there are certain 
advantages to using techniques such as SDS-PAGE, Western blotting, mass spectrometry, and 
SEC for Aβ detection, there are disadvantages as well. These limitations highlight the importance 
of employing a complementary technique to explore the evolution of Aβ oligomer appearance. 
Therefore, in these studies, we explored the potential of UV-CE to monitor the Aβ1-40 
aggregation process. In particular, we utilized a PEO separation matrix to enhance the resolution 
of Aβ1-40 oligomers and aggregates. Strikingly, we found that the lag time to oligomer formation 
for SEC-purified Aβ1-40 samples was ~23 hours shorter compared to non-purified Aβ1-40 samples. 
This indicates that the initial sample sizes present have a drastic effect on the lag time to 
oligomer formation. The size of smaller, intermediate, and larger species was estimated using 
membrane filtration units. It should be noted that a spherical shape is assumed in order to 
generate the molecular weight cutoff for these membranes, thus providing a range of sizes. 
Therefore, we confirmed that these species were oligomeric in nature by utilizing dot blots and 
two compounds known to inhibit fibrils and oligomers, respectively. Furthermore, we utilized 
the sequence specific antibody 6E10 and conformation specific antibodies A11 and OC to 
confirm the presence of Aβ1-16, Aβ prefibrillar oligomers, and Aβ fibrils, respectively. The 
presence of 6E10 positive spots was observed at all times throughout aggregation for both non-




obtained after 24 hours of aggregation for non-purified Aβ1-40 samples and after 5 hours of 
aggregation for SEC-purified Aβ1-40 samples. A comparison of the dot blot and UV-CE results 
suggests that non-purified Aβ1-40 samples begin to form both prefibrillar oligomers (A11 
positive) and fibrillar oligomers or fibrils (OC positive) after 24 hours of aggregation. These 
prefibrillar oligomers could then undergo a conformational change after 28 hours, which is 
represented by a sharp UV-CE peak with a faster mobility that corresponds to Aβ1-40 species > 
300 kDa. Similar results were obtained for SEC-purified Aβ1-40 samples but with much faster lag 
times (~5 hours). Furthermore, we have determined the lowest concentration of Aβ that can be 
detected using both UV and LIF detection modes. Physiologically relevant Aβ concentrations in 
the picomolar range were detectable using LIF detection while concentrations in the micromolar 
range were required for UV detection.  
 Using UV-CE and LIF-CE to simultaneously monitor the aggregation of a mixture of 
FAM-labeled Aβ1-42 and unlabeled Aβ1-42, this study was the first to show that FAM-labeled Aβ1-
42 was capable of incorporating into smaller species formed by unlabeled Aβ1-42 but this ability 
was highly dependent on the lot employed. This further illustrates the complexity of the Aβ1-42 
aggregation process and necessitates further investigation to identify optimum fluorescent labels 
for the study of insulin and Aβ oligomer formation at physiological concentrations. In particular, 
less bulky fluorescent probes, such as BODIPY, or attachment of dyes exclusively at the N- or C- 
terminus would be less likely to impact aggregate formation. Furthermore, since dyes often 
change the net protein charge, alternative dyes such as CE503 which do not alter the net charge 
may be explored. A more detailed discussion of alternative dyes will be given in the future work 




The studies in Chapter 4 were conducted in order to explore the ability of UV-CE to 
monitor the aggregation of Aβ1-40 in a native state and highlight certain advantages and 
disadvantages of UV-CE compared to other traditional Aβ detection techniques. In theory, CE is 
a fast and highly efficient technique for the detection of charged molecules. Due to the small 
charge and/or large size of certain Aβ species present throughout aggregation, the UV-CE 
analysis time exceeds 4 hours. Furthermore, there are no commercially available size standards 
for the detection of native protein states with CE, thereby making the estimation of Aβ size 
difficult. In addition, we found that larger Aβ species can exhibit a shorter migration time, which 
is contrary to the general theory of CE which predicts an increase in migration time with size. 
Our studies are the first to utilize a polymer separation matrix to enhance the resolution of Aβ 
species. CE is also a powerful tool to monitor the disappearance of 10 – 30 kDa Aβ species and 
appearance of new peaks throughout aggregation, thereby providing a complementary technique 
in which to validate the general trends observed for Aβ aggregation.  
 In addition, the studies in Chapter 4 were conducted in order to determine the ability of 
LIF-CE to monitor FAM-labeled Aβ1-42 aggregation. The limitations of LIF-CE for amyloid 
aggregate detection are; 1) the requirement of a fluorescent probe which can interfere with 
aggregation and thereby misrepresent the “true” native aggregation of the protein and 2) the 
dependence of LIF-CE to monitor aggregation on the particular protein lot employed. The focus 
of this thesis is on the detection of amyloid aggregates formed under conditions which mimic 
native protein aggregation rather than the detection of physiologically relevant concentrations. 
Since it was shown that FITC and FAM could misrepresent native aggregation states, alternative 
techniques for the detection of native Aβ were proposed such as dot blots. Therefore, dot blots 
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CHAPTER 5:  MICROCHIP ELECTROPHORESIS FOR DETECTION OF Β-SHEET 
FORMATION BY AΒ AGGREGATES 
1. Introduction 
 Electrophoresis in flat planar microchips, or microchip electrophoresis (ME), was 
implemented by Harrison, Manz and Widmer in 1992 [1,2]. This miniaturization allowed 
electrophoretic processes to be performed in seconds as opposed to minutes with capillary 
instrumentation. ME possesses other advantages over conventional electrophoretic methods 
including low sample consumption and a strong potential for automation and integration [3,4]. 
As a result, the application of ME for the analysis and separation of proteins has advanced 
enormously in recent years [5]. 
 When considering the translation of protein separations from a capillary format to a 
microchip format, several parameters must be taken into account. One of the major challenges 
for the application of ME to peptide and protein analyses is the adsorption of protein onto the 
silanoate groups present in glass microchannel walls [6,7]. This can lead to peak “tailing” and 
decrease the analytical efficiency. Therefore, two main strategies have been devised to suppress 
electroosmotic flow (EOF) in glass capillaries and microchannels; 1) covalent modification of 
the microchannel surface and 2) dynamic coating of the microchannel surface. Previous studies 
in our lab have demonstrated the ability of the dynamic coatings poly(ethylene oxide) (PEO) and 
poly-N-hydroxyethyl acrylamide (PHEA) to effectively suppress EOF and enhance the 
separation of insulin and Aβ proteins in capillaries [8,9]. In addition, the microchannel separation 
length is much shorter than the capillary separation length (8 cm versus 33 cm). Since the peak 
resolution increases as the square root of the separation length, the analytical selectivity of ME is 




increase the effect of protein hydrodynamic radius on ME separation, thereby leading to 
enhanced resolution. However, higher polymer concentrations or molecular weights must be 
utilized with ME compared to CE separations. 
 Although ME has been applied for analyses of monomeric proteins, less attention has 
been paid to the use of ME for the detection of Aβ oligomers and aggregates in the literature. A 
study by Mohamadi et al. used a microchannel coating consisting of poly(dimethylacrylamide-
co-allyl glycidyl ether) and with methylcellulose-Tween 20 in the electrophoresis buffer to 
achieve the separation of five synthetic Fluoroprobe-488 labeled Aβ peptides (Aβ1-37, Aβ1-38, 
Aβ1-39, Aβ1-40, and Aβ1-42) [6]. The detection of Aβ species larger than monomer was not 
achieved. One particularly interesting aspect of Aβ aggregation is the formation of a β-sheet 
containing fibrillar structure. Traditionally, the detection of β-sheet aggregates is conducted by 
monitoring the emission of Thioflavin T (ThT) using a fluorometer. ThT is an intercalating 
fluorescent dye that binds to the β-sheet structure within amyloid fibrils, giving rise to a shifted 
excitation maximum at 450 nm and a shifted and enhanced emission at 482 nm [10,11]. A study 
by Lee et al. utilized a microfluidic platform and ThT to detect Aβ1-42 aggregates [12]. Aβ1-42 
monomers were immobilized on the microchannel surface via N-hydroxysuccinimide ester 
activation of the internal surfaces. A fresh solution of Aβ1-42 was continuously fed into the 
microchannels and Aβ1-42 aggregation was monitored using ThT fluorescence microscopy, but 
electrophoresis was not used to separate Aβ aggregates in this study. In addition to ThT, other β-
sheet binding dyes such as BTA-1 exist for the detection of Aβ aggregates. BTA-1 is an 
uncharged benzothiazole ThT analogue which has been shown to bind Aβ aggregates with a 
higher affinity (11.5 nM – 20 nM [13,14] versus 240 – 890 nM [14-16] for ThT) and is 3000 




plaques and neurofibrillary tangles in post-mortem AD brains, with a preference for plaque 
staining [16,17]. Furthermore, the ability of BTA-1 to cross the blood-brain barrier makes it an 
attractive candidate for in vivo detection of Aβ fibrils [13]. Unlike ThT, there is no shift in the 
excitation and emission maxima of BTA-1 upon binding to β-sheet containing aggregates. 
Therefore, the aggregates must be separated prior to analysis with a fluorometer, thus 
highlighting the need for a technique which is capable of both separating and detecting β-sheet 
containing aggregates.   
 ME offers the potential to monitor the binding of BTA-1 to Aβ aggregates. Previous 
studies in our lab have demonstrated that covalently bound dyes can interfere with the formation 
of insulin and Aβ aggregates and thereby misrepresent the “true” native aggregation of the 
protein [8]. The use of dyes which bind to the β-sheet structure offer a way to monitor the native 
aggregation of Aβ. However, the analysis time for the detection of native unlabeled Aβ 
aggregates via UV-CE is very long (~4 hours). ME provides a way to overcome these problems 
by; 1) offering the capability to detect the excitation and emission wavelengths of β-sheet 
binding dyes and 2) achieving the separation of Aβ aggregates in a much shorter time (minutes 
versus hours). Therefore, in these studies, we have explored the utility of ME to detect both 
monomeric FAM-labeled Aβ1-42 and the binding of BTA-1 to β-sheet containing Aβ1-40 
aggregates. The ME results obtained with BTA-1 are compared to results obtained using a 
fluorometer to detect ThT fluorescence.  
2. Materials and Methods 
2.1. Aβ preparation 
 Aβ1-40 and FAM-Aβ1-42 were stored dessicated at -20°C. 4.33 mg/mL Aβ1-40 and 0.49 mg/ 




ensure the samples were monomeric. These stock solutions were split into vials containing 
0.0625 mg Aβ1-40 and 0.006775 mg FAM-Aβ1-42 and the HFIP was allowed to evaporate 
overnight. Vials were stored at -80°C.  For studies on the detection of FAM-Aβ1-42 via LIF-ME, 
FAM-Aβ1-42 was dissolved in 5 mM NaOH and diluted into 40 mM Tris-HCl (pH 8.0) to a final 
concentration of 0.15 mg/mL. 
2.2. Poly-N-hydroxyethyl acrylamide coating and separation matrix synthesis and 
characterization 
 One sample of long-chained HEA polymer (MW = 12,500,000 g/mol) was synthesized as 
described previously [18] with the following changes: 4% w/w initial monomer concentration 
and polymerization for 5 hours. One sample of short-chained HEA polymer (MW = 1,380,000 
g/mol) was synthesized as described previously [19] with the following changes: 3.5 mL 
isopropanol added to 200 mL of 4% w/w initial monomer solution. Solution deoxygenated by 
bubbling nitrogen through mixture at 47°C for 2 h followed by polymerization for 4 hours. Once 
the polymerization was complete, the polymer was dialyzed, lyophilized, and characterized to 
confirm its molecular weight by multi-angle laser light scattering (Wyatt Technology, Santa 
Barbara, CA). The HEA polymer with MW = 12,500,000 g/mol was diluted to 0.1% w/v in de-
ionized water and used for the capillary coating and the HEA polymer with MW = 1,380,000 
g/mol was diluted to 1% in 40 mM Tris (pH 8.0) for FAM-Aβ1-42 studies and 1.5% in 40 mM 
Tris (pH 8.0) for Aβ1-40 oligomer studies with BTA-1 and used as protein separation matrices.  
2.3. Aβ1-40 aggregation assay with BTA-1 and ThT 
 To observe the time course for Aβ1-40 aggregate formation, Aβ1-40 was dissolved in 5 mM 
NaOH and diluted into 40 mM Tris-HCl (pH 8.0) supplemented with 5 mM NaCl to a final 




rpm). A 1 mg/mL BTA-1 stock solution was prepared in 100% DMSO and diluted to 0.0064 
mg/mL (4160 µM) in 40 mM Tris-HCl (pH 8.0). Both prior to the onset of aggregation and at 
times between 8 and 28 hours following the onset of aggregation, an aliquot of Aβ1-40 was 
removed and combined with BTA-1 for final Aβ1-40 and BTA-1 concentrations of 0.021 mg/mL 
(4.8 µM) and 0.0058 mg/mL (24.2 µM), respectively. A final BTA-1 concentration in solution 
(24.2 µM) was chosen, which was 5 times the final Aβ1-40 concentration (4.84 µM). This sample 
was analyzed by LIF-ME to determine the elution time and intensity of all peaks. 
 In parallel experiments, aggregation was monitored using ThT binding as described 
previously [20,21] with the following changes: dilution of Aβ1-40 into ThT for final Aβ1-40 and 
ThT concentrations of 0.021 mg/mL (4.8 µM) and 0.0077 mg/mL (24.2 µM), respectively. 
Fluorescence was monitored at the onset of aggregation and at times between 5 and 28 hours 
following the onset of aggregation using a Shimadzu RF-Mini-150 fluorometer (Columbia, MD) 
(excitation = 460 nm, emission = 480–500 nm). 
2.4. Microfluidic chips and polymer matrix loading into microfluidic chips 
 Glass borosilicate microfluidic chips (Micralyne, Edmonton, Alberta, Canada) with the 
following properties were used in the experiments: double T injector with an offset of 100 µm, 
channel width of 50 µm, channel depth of 20 µm, and separation length of 79 mm. Prior to being 
used for ME runs, the uncoated glass microchips were conditioned and dynamically coated by 
rinsing them via vacuum with the following: water for 15 min, HCl (aq., 1M) for 15 min, poly-
N-hydroxyethylacrylamide (coating reagent, aq., 0.1%,) for 15 min, followed by a water rinse. 
The chip was filled with the separation matrix polymer (1 – 1.5% PHEA) via vacuum prior to 




2.5. Microchip Electrophoresis 
FAM-Aβ1-42 samples were injected at 194-500 V/cm for 20 s and electrophoresed at 214-
380 V/cm with 24 V/cm pullback at ambient temperature (17-20 °C). Aβ1-40 samples with BTA-1 
were injected at 200-600 V/cm for 10-20 s and electrophoresed at 380 V/cm with 12-24 V/cm 
pullback at ambient temperature (17-20 °C). The microchip electrophoresis system was custom-
built in the laboratory of Dr. Christa Hestekin. The system consisted of a high voltage power 
supply (LabSmith Inc., Livermore, CA) with the ability to independently control 4 electrodes, a 
488 nm argon ion laser (JDS Uniphase, San Jose, CA) and a 355 nm semi-conductor laser 
(Coherent Inc., Santa Clara, CA), and a high-quantum-efficiency, 1024 x 128 pixel charge-
coupled device (CCD) cooled to -50 °C (Andor, South Windsor, CT). 
3. Results and Discussion 
3.1. Detection of FAM-Aβ1-40 using LIF-ME 
 The utility of LIF-ME for the detection of FAM-labeled Aβ1-42 was explored. In order to 
compare the peak pattern obtained using LIF-ME with that obtained previously with LIF-CE, the 
LIF-CE sample injection voltage and time (194 V/cm for 7 s) as well as separation voltage (214 
V/cm) were used. Figure 1A shows the LIF-ME peak pattern obtained under these conditions. In 
order to enhance the signal intensity, the LIF-ME injection voltage and time were increased 
to500 V/cm for 20 s (Figure 1B). The FAM-labeled Aβ1-42 peak pattern obtained utilizing LIF-
ME (Figure 1B) is similar to that obtained using LIF-CE (Figure 1C). In addition, the run time 







Figure 32 Detection of FAM-labeled Aβ1-42 using LIF-ME and LIF-CE. 
Figure 1 Detection of FAM-labeled Aβ1-42 using LIF-ME and LIF-CE. FAM-labeled 
Aβ1-42 was prepared at 0.15 mg/mL in 40 mM Tris-HCl (pH 8.0) and analyzed via A) 
LIF-ME with 194 V/cm injection for 7 s with 214 V/cm separation with 24 V/cm 
pullback, B) LIF-ME with 500 V/cm injection for 20 s with 214 V/cm separation and 
C) LIF-CE with 194 V/cm injection for 7 s with 214 V/cm separation. All runs were 






analysis time, the separation voltage was increased to 380 V/cm (Figure 2). This led to a 
separation ~5 times faster compared to LIF-CE.  
 A previous study by Mohamadi et al. utilized LIF-ME to separate five synthetic 
Fluoroprobe-488 labeled Aβ peptides (Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-40, and Aβ1-42) dissolved in 
borate buffer (pH 10.5) [6]. The migration time obtained for Aβ1-42 was ~1.5 min, which is 
similar to the migration time obtained in our studies for FAM-Aβ1-42 (Figure 2). The separation 
channel length used in our studies was about twice as long as what was utilized in the Mohamadi 
et al. study (7.9 cm versus 3.5 cm). This suggests that a faster FAM-Aβ1-42 migration time could 
be obtained in our studies if a shorter separation channel distance is used. Furthermore, the 
Mohamadi et al. study observed extraneous peaks before and after the peak for Aβ1-42, which 
they suggest are due to unbound dye and peptide containing variations in the label number, 
respectively. Our study demonstrates the ability of the LIF-ME system built in our laboratory to 
detect FAM-Aβ1-42 with a similar peak pattern to LIF-CE, but with a greatly reduced analysis 
time.  
3.2. Detection of β-sheet formation by Aβ1-40 using LIF-ME and comparison to ThT binding 
 Insoluble Aβ fibrils containing a β-sheet structure are important for the clinical 
determination of Alzheimer’s Disease [22,23]. Various fluorescent dyes exist which are capable 
of binding to the β-sheet structure present in Aβ aggregates such as ThT and BTA-1. BTA-1 is 
an uncharged benzothiazole ThT analogue which has been shown to bind Aβ aggregates with a 
higher affinity than ThT (11.5 nM [13] versus 240 – 890 nM [15,16] for ThT) and is 3000 times 







Figure 33 Effect of increased LIF-ME separation voltage on the detection of FAM-labeled 
Aβ1-42. 
Figure 2 Effect of increased LIF-ME separation voltage on the detection of FAM-
labeled Aβ1-42. FAM-labeled Aβ1-42 was prepared at 0.15 mg/mL in 40 mM Tris-HCl 
(pH 8.0) and analyzed via LIF-ME with 500 V/cm injection for 20 s and 214 V/cm or 
380 V/cm separation with 24 V/cm pullback. All runs were performed in 0.1% 














Table 1 Structure and spectral properties of ThT and BTA-1. 
Table 6 Structure and spectral properties of ThT and BTA-1. 





































The purpose of our studies is twofold; 1) investigate the ability of LIF-ME to detect the binding 
of BTA-1 to Aβ1-40 aggregates and 2) validate β-sheet formation using a fluorometer to detect 
ThT binding. In Chapter 3, we have previously demonstrated the detection of Aβ1-40 oligomers   
> 300 kDa via UV-CE after ~28 hours of agitation at 800 rpm. To explore the utility of ME for 
the detection of β-sheet containing Aβ1-40 aggregates, the same sample preparation utilized in 
Chapter 3 was used to promote amyloid assembly. The reaction was analyzed using ME at early 
and late time points to assess the appearance of β-sheet containing Aβ1-40 aggregates. At 0 hours, 
no peaks with S/N > 3 were observed using ME (Figure 3). After 8 and 24 hours of aggregation, 
two small peaks were detected with migration times of ~3 and 6 min. A similar peak pattern was 
obtained after 28 hours with the appearance of two sharper, more intense peaks at ~4.5 min with 
S/N > 3. Furthermore, the S/N ratio for the peak at ~3 min was > 3.  
 A study by Levine et al. explored the binding of BTA-1 to Aβ1-40 fibrils using 
fluorometry [14]. Since there is no change in BTA-1 fluorescence upon binding to Aβ1-40 fibrils 
[14], centrifugation was necessary in order to determine the amount of bound BTA-1 in the 
resuspended fibril pellet. This pre-separation step is unnecessary for ME analyses due to the 
ability of ME to separate and detect aggregates in one step.  
 In order to validate the results obtained via ME to a more traditional method of detecting 
amyloid aggregates containing a β-sheet structure, ThT with analysis via fluorometry was used to 
follow Aβ aggregation. Aβ1-40 aggregate detection using ThT with fluorometry was conducted 
simultaneously on the same sample as the studies utilizing BTA-1 with ME. Aβ1-40 was 




NaCl. The general trend for the growth of aggregates analyzed via ThT fluorescence (Figure 4) 
was similar to that observed using ME, thus validating the formation of β-sheet aggregates.   
 























Figure 3 Detection of BTA-1 binding to Aβ1-40 using LIF-ME. Aβ1-40 was aggregated 
under agitation (800 rpm) at 0.22 mg/mL in 40 mM Tris (pH 8.0) containing 5 mM 
NaCl and at 25 °C. At 0 – 28 hours, Aβ1-40 was diluted into BTA-1 for final Aβ1-40 
and BTA-1 concentrations of 0.021 mg/mL (4.8 µM) and 0.0058 mg/mL (24.2 µM), 
respectively. Fluorescence was monitored via ME with LIF detection with a 200-600 
V/cm injection for 10-20 s with a 380 V/cm separation with 12-24 V/cm pullback. 










Figure 4 Detection of ThT binding to Aβ1-40 using fluorometry. Aβ1-40 was 
aggregated under agitation (800 rpm) at 0.22 mg/mL in 40 mM Tris (pH 8.0) 
containing 5 mM NaCl and at 25 °C. At 0 – 36 hours, Aβ1-40 was diluted into ThT for 
final Aβ1-40 and ThT concentrations of 0.021 mg/mL (4.8 µM) and 0.0077 mg/mL 
(24.2 µM), respectively. Fluorescence was monitored via fluorometry (excitation = 












 In these studies, we have demonstrated the capability of ME to detect both monomeric 
FAM-Aβ1-42 and Aβ1-40 aggregates. The detection of FAM-Aβ1-42 was achieved in ~1.5 minutes, 
which is ~5 times faster than analyses via LIF-CE. Furthermore, ME was utilized to detect β-
sheet formation using the conformationally specific dye BTA-1. A fluorometer was also 
employed in order to validate β-sheet formation using ThT binding. We found that similar trends 
were observed for BTA-1 binding detection via ME compared to ThT binding detection via 
fluorometry. Although BTA-1 is an attractive alternative to ThT for the detection of Aβ1-40 
aggregates, Aβ1-40 aggregates must be separated in order for the use of BTA-1 to be effective and 
this separation is typically achieved via centrifugation for ~15 min. We have demonstrated the 
utility of ME to both separate and detect Aβ1-40 aggregates using BTA-1 in < 7 min, which is 2 – 
3 times faster than traditional measures of BTA-1 fluorescence (ie. centrifugation with 
fluorometry). Further studies must be conducted which optimize the BTA-1 and Aβ1-40 
concentrations for analysis via ME. In particular, a saturation binding curve must be generated 
for BTA-1 by varying the BTA-1 concentration with a constant concentration of Aβ1-40 and 
analyzing the peak pattern obtained via ME. This will give the maximum BTA-1 fluorescence 
which can be obtained at a given Aβ1-40 concentration. In order to explore the utility of ME to 
detect physiologically relevant concentrations of β-sheet aggregates formed by Aβ1-40, the 
saturation binding curve will be repeated for different Aβ1-40 concentrations down to 
physiologically relevant concentrations (ie. varying the BTA-1 concentration with 5 µM Aβ1-40, 
varying the BTA-1 concentration with 0.5 µM Aβ1-40, etc). This will give the optimal BTA-1 
concentration necessary for a range of Aβ1-40 concentrations and further indicate whether ME is 




voltage and time as well as the separation polymer concentration and chip separation length must 
be optimized in order to achieve the best detection of Aβ1-40. 
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 CHAPTER 6:  CONCLUSIONS AND FUTURE DIRECTIONS 
1. Impact of the presented work 
 The detection of oligomers and aggregates formed by two amyloid proteins, insulin and 
Aβ, is of particular importance due to the role which these species play in Diabetes and 
Alzheimer’s disease, respectively. However, existing techniques are limited in the ability to 
detect insulin and Aβ oligomers due to the fact that these early aggregates are transient, present 
at low concentrations, and difficult to isolate. Improvements must be made to existing techniques 
or alternative techniques must be explored in order to identify and quantify the size of these 
oligomeric and aggregate species without disrupting their structure and develop treatments that 
target these pivotal aggregation events. 
 In Chapters 1 and 2, the advantages and disadvantages of traditional methods for the 
detection of insulin and Aβ oligomers and aggregates were outlined. We also introduced the 
potential of microchannel electrophoresis (CE and ME) as a complimentary technique for the 
existing analyses. This thesis focuses on addressing previously unexplored areas for the 
development of CE and ME as early amyloid aggregation detection techniques. 
  In Chapter 3, we reported the first studies on the use of UV-CE with a polymer 
separation matrix to detect native insulin aggregates ranging in size from 30 – 100 kDa. In 
particular, we looked at the ability of UV-CE to detect insulin aggregates formed using a 
relatively low sample concentration (0.2 mg/mL), near neutral pH (8.0), and physiological salt 
concentration (150 mM). Thioflavin T binding was utilized to compare the lag times observed 
with UV-CE and and it was found that UV-CE displayed a lag time ~3 times faster than ThT 
binding. This suggests that UV-CE is detecting oligomers which are present prior to β-sheet 




and it was found that the time to insulin oligomer appearance was unaffected by salt 
concentrations ranging from 100 – 250 mM. In order to draw conclusions on the ability of CE to 
detect physiologically relevant insulin and Aβ concentrations, the detection limit for UV-CE was 
compared to LIF-CE and it is shown that LIF-CE can detect physiologically relevant FITC-
insulin concentrations. Furthermore, the detection sensitivity of LIF-CE was ~35,000 fold higher 
than UV-CE for the detection of FITC-insulin. In addition, we explored the potential for LIF-CE 
to monitor the formation of oligomers and aggregates of FITC-labeled insulin. It is shown that 
FITC-labeled insulin is unable to incorporate into unlabeled insulin oligomers. This demonstrates 
that LIF-CE is a promising technique for the detection of low concentrations of monomeric 
FITC-insulin but caution must be taken when choosing a fluorescent dye for the detection of 
FITC-insulin oligomers and aggregates. 
 In Chapter 4, we demonstrated ability of UV-CE with a polymer separation matrix to 
detect native small oligomeric Aβ1-40 species (10 – 30 kDa) and larger oligomeric species (100– 
300 kDa and > 300 kDa). Specifically, we looked at the ability of UV-CE to detect Aβ1-40 
aggregates formed using a relatively low sample concentration (0.2 mg/mL), near neutral pH 
(8.0), and low salt concentration (5 mM). In addition, the effect of sample preparation on the 
formation of Aβ aggregates was determined. Dot blots were utilized to verify the presence of Aβ 
oligomeric and fibril species detected via UV-CE and compare lag times. It was found that the 
lag times for oligomers and aggregates obtained using UV-CE were nearly identical to those 
obtained via dot blotting. Furthermore, we found that the lag time to oligomer formation for 
SEC-isolated Aβ1-40 samples was ~23 hours shorter compared to non-purified Aβ1-40 samples. 
This indicates that the initial sample sizes present have a drastic effect on the lag time to 




relevant Aβ concentrations, the detection limit for UV-CE was compared to LIF-CE and it was 
shown that LIF-CE can detect physiologically relevant FAM-Aβ1-40 and FAM-Aβ1-42 
concentrations. Furthermore, the detection sensitivity of LIF-CE was 250,000 – 5,000,000 fold 
higher than UV-CE for the detection of FAM-Aβ. This demonstrates that LIF-CE is a promising 
technique for the detection of low concentrations of monomeric FAM-Aβ. We also explored the 
potential for LIF-CE to monitor the formation of oligomers and aggregates of FAM-Aβ1-42 and 
found that FAM-labeled Aβ1-42 is capable of incorporating into unlabeled Aβ1-42 oligomers but 
not aggregates. Furthermore, the ability to detect FAM- Aβ1-42 is highly dependent on the protein 
lot utilized. These results demonstrate that while LIF-CE is a promising technique for the 
detection of physiologically relevant FAM-Aβ concentrations, caution must be taken when 
choosing a dye for detection of oligomeric and aggregate species. In particular, dye properties 
including size, effect of dye on the net protein charge, or dye attachment site may interfere with 
the native aggregation of insulin and Aβ and thereby misrepresent the species detected via LIF-
CE. 
 Since the studies in Chapters 3 and 4 demonstrated that covalently bound dyes can 
interfere with the formation of insulin and Aβ aggregates and thereby misrepresent the “true” 
native aggregation of the protein [1], we investigated the use of dyes which bind to the β-sheet 
structure and offer a way to monitor the native aggregation of Aβ in Chapter 5. Due to the fact 
that the UV- and LIF-CE instruments in our lab are not capable of detecting the excitation and 
emission wavelengths associated with β-sheet binding amyloid dyes (ie. BTA-1), we explored 
the utility of ME to detect β-sheet formation. In particular, we determined that ME could detect 
monomeric FAM-labeled Aβ1-42 in ~1.5 min and the binding of BTA-1 to β-sheet containing 




to results obtained using a fluorometer to detect ThT fluorescence. We found that BTA-1 was 
capable of detecting low levels of Aβ1-40 aggregates ~7 hours earlier compared to ThT binding. 
Further studies must be conducted which optimize the BTA-1 and Aβ1-40 concentrations for 
analysis via ME. 
 In this work, we have demonstrated that UV-CE is capable of detecting insulin and Aβ 
oligomers in a native state. The drawbacks of current techniques include the requirement of 
conditions that induce non-native behavior (SDS-PAGE) or destabilize oligomers (SEC), limited 
resolution of individual sizes of oligomers and aggregates (Native-PAGE, DLS, FCS, and TEM), 
limited ability to detect a wide range of populations (oligomers - fibrils) within a sample 
(MALS), inability to provide size information about oligomers or fibrils (dot blotting, ELISA), 
and reliance on assumptions in the model to predict size (centrifugation, FCS). The main 
advantages of UV-CE over alternative techniques are the ability to detect the native formation of 
oligomers and aggregates and the ability to detect a wide range of sizes (oligomers - fibrils) 
within a sample. The advantages of LIF-CE and ME compared to UV-CE are the capability to 
detect physiologically relevant concentrations and enhanced resolution. Further improvements 
must be made in order to model and determine limitations on the ability of CE and ME to resolve 
different species. A major disadvantage of LIF-CE is the interference of fluorescent dyes 
necessary for detection with native protein aggregation. Compared to fluorometry, ME is capable 
of monitoring the binding of conformationally dependent dyes which do not exhibit a shift in 
fluorescence upon binding without the use of another separation method. Further improvements 
to LIF-CE and ME must be made in order to overcome the disadvantages associated with these 
techniques. These include the exploration of alternative dyes which do not interfere with 




whether physiologically relevant concentrations of β-sheet aggregates can be detected via ME. 
The specifics for these improvements are given in the next section. 
2. Future directions 
2.1. Testing of alternative dyes with LIF-CE 
The use of a fluorescent dye which is covalently bound to amyloid proteins is necessary 
in order to achieve detection via LIF-CE of smaller oligomeric species formed prior to species 
containing a β-sheet structure. In Chapter 3, we demonstrated the ability to detect physiologically 
relevant concentrations of monomeric FITC-insulin and FAM-Aβ using LIF-CE. In order to 
determine whether physiologically relevant concentrations of oligomeric insulin and Aβ could be 
detected via LIF-CE, we explored the ability of FITC-insulin and FAM-Aβ to incorporate into 
oligomers formed by unlabeled insulin and Aβ in Chapter 4. We found that FITC-labeled insulin 
was unable to incorporate into oligomers formed by the unlabeled protein while FAM-labeled 
Aβ1-42 was capable of incorporating into oligomers formed by unlabeled Aβ1-42 but not aggregate 
species. However, the ability of FAM-labeled Aβ1-42 to incorporate into oligomers formed by 
unlabeled Aβ1-42 was highly dependent on the lot employed. These findings necessitate the 
exploration of alternative covalently bound fluorescent dyes. Since some small compounds have 
been previously reported as inhibitors of β-sheet formation, it is possible that the FITC and FAM 
labels are acting as inhibitors to aggregation. Another possibility is that the FITC and FAM 
attachment sites are critical for proper β-sheet folding. A similar extension of the lag time to 
aggregation has been observed following the methylation of amino groups within the Aβ protein 
[2] and the introduction of a mutant that mimics phosphorlyation of serine residues within the 
Huntington protein [3]. In addition, the quantity of amyloid aggregates formed is reduced 




amino groups within transthyretin [5]. Therefore, dyes with alternative properties or attachment 
sites may need to be explored. In particular, dyes with a wider linker region, such as BODIPY, 
dyes which do not alter the net protein charge, or attachment of dyes exclusively at the N- or C- 
terminus would be less likely to impact aggregate formation. Table 1 gives the structures for 
FITC and FAM as well as three alternative dyes which we are interested in exploring. Since 
FITC and FAM are bulky dyes, alter the net protein charge upon attachment, and are attached to 
the N-terminus and Lysine residues, we have chosen the alternative dyes BODIPY, CE503, and 
AMCA-Hydrazide in order to explore the three properties given above, respectively.  
Preliminary studies in our lab have indicated the potential for BODIPY to be used to 
monitor the formation of oligomers and larger aggregates formed by unlabeled Aβ1-40. Since we 
already had data for the behavior of 100% unlabeled Aβ1-40 (Chapter 3), we used this data as a 
control to determine the effect of the wider linker region of BODIPY on the aggregation of 
unlabeled Aβ1-40. Therefore, we used identical Aβ1-40 sample and aggregation conditions to 
determine whether BODIPY-Aβ1-40 interfered with the formation of oligomers and aggregates. 
Aβ1-40 was labeled with BODIPY according to the manufacturers’ protocol. Separate stock 
solutions of unlabeled Aβ1-40 and BODIPY-labeled Aβ1-40 were prepared in 5 mM NaOH and 
diluted into 40 mM Tris (pH 8.0) containing 5 mM NaCl. These solutions were combined to 
yield a sample consisting of 80% unlabeled Aβ1-40 and 20% BODIPY-Aβ1-40 with a total Aβ1-40 
concentration of 0.22 mg/mL (50 µM) and incubated at 25°C under continuous agitation (800 
rpm). Both prior to the onset of aggregation and at times between 5 and 72 hours following the 
onset of aggregation, a 20 µL sample was removed and analyzed by LIF-CE to determine the 




Table 1 Structure and spectral properties of FITC, FAM, BODIPY, CE503, and 
AMCA-Hydrazide  





































































points where Panel A shows all peaks and Panel B is zoomed in on the early peaks with 
migration times < 40 min. At 0 hours, a sharp peak at ~20 min (Peak 3, Figure 1A and B) was 
observed in addition to several smaller intensity peaks with migration times ranging from10 – 40 
min (Peaks 1, 2, and 4 – 8, Figure 1A and B). A possible explanation for the observance of 
several smaller intensity peaks is that these peaks are due to variations in the BODIPY label 
number since BODIPY labels the N-terminus and Lysine residues, thus creating 7 different 
possible variations of label number per Aβ1-40 peptide. A similar peak pattern was observed after 
5 and 10 hours with an initial increase in the intensity of peaks 1 – 8 followed by a decrease after 
10 hours. After 24 hours, two new peaks with an S/N > 3 were observed; a sharp peak with a 
faster migration time at ~8 min (Peak 9, Figure 1A and B) and a small peak with a longer 
migration time at ~53 min (Peak 10, Figure 1A). Furthermore, the intensity of peaks 1 - 8 was 
drastically reduced. The same peak pattern as was obtained after 24 hours was obtained after 28 
– 72 hours with an increase in intensity of peak 9 at ~8 min and peak 10 at ~53 min. In addition, 
dot blots showed a positive A11 (oligomer) stain at 28 hours (data not shown). 
 In order to better understand the growth process, the area for peaks 1 – 8 with migration 
times ranging from 10 – 40 min was compared to the area for peak 9 with a migration time of ~8 
min which appeared after 24 hours of aggregation. As shown in Figure 2, the area for peaks 1 – 
8 initially increases and then starts to decrease after 10 hours (blue diamonds). This initial 
increase in peak area is similar to the results obtained in Chapter 3 using UV-CE to detect 
oligomers formed by 0.22 mg/mL unlabeled Aβ1-40. After 24 hours, the area for peaks 1 - 8 
decreases further (blue diamonds) while peak 9 with a faster migration time of ~8 min appears 





Figure 36 Coaggregation of BODIPY-labeled Aβ1-40 and unlabeled Aβ1-40 with analysis via 
LIF-CE. 
Figure 1 Coaggregation of BODIPY-labeled Aβ1-40 and unlabeled Aβ1-40 with 
analysis via LIF-CE. Aβ1-40 solutions consisting of 20% BODIPY-labeled Aβ1-40 and 
80% unlabeled Aβ1-40 were prepared at a concentration of 0.22 mg/mL in 40 mM Tris 
(pH 8.0) containing 5 mM NaCl and aggregated under agitation (800 rpm, 25°C). At 
0 – 72 hours, CE was performed in conjunction with LIF detection (n = 1 - 2) with a 
7 kV injection for 7 s with separation at 7 kV using 1.5% PHEA separation matrix in 
a PHEA coated capillary. Panel A shows all peaks while panel B is zoomed in on the 





Figure 37 Effect of aggregation time on the area for peaks 1 - 8 (, n = 1 - 2) and peak 9 
(, n = 1 - 2) obtained for BODIPY-Aβ1-40. 
Figure 2 Effect of aggregation time on the area for peaks 1 - 8 (, n = 1 - 2) and 
peak 9 (, n = 1 - 2) obtained for BODIPY-Aβ1-40. Aβ1-40 was aggregated under 
agitation (800 rpm) at 0.22 mg/mL in 40 mM Tris (pH 8.0) containing 5 mM NaCl 
and at 25 °C. At 0 – 72 hours, CE was performed in conjunction with LIF detection 
with a 7 kV injection for 7 s with separation at 7 kV using 1.5% PHEA separation 












observed after 28 hours using UV-CE to detect oligomers formed by 0.22 mg/mL unlabeled Aβ1-
40 in Chapter 3. Furthermore, the overall trend for the changes in peak areas are similar for 
aggregates formed by 100% unlabeled Aβ1-40 with analysis via UV-CE (Figure 3A) and 
aggregates formed by a mixture of 80% unlabeled Aβ1-40 and 20% BODIPY-Aβ1-40 with analysis 
via LIF-CE (Figure 3B) Since a similar peak pattern is obtained for UV-CE and LIF-CE after 28 
hours, this suggests that BODIPY-Aβ1-40 has the potential to be used to detect oligomers formed 
by unlabeled Aβ1-40. In addition, since 20% of BODIPY-Aβ1-40 is mixed with unlabeled Aβ1-40, 
only 20% of oligomers formed will be labeled with BODIPY-Aβ1-40 and detected via LIF-CE. 
Figure 4 shows the UV-CE data obtained for 100% unlabeled Aβ1-40 multiplied by 20% and the 
LIF-CE data obtained for a mixture of 80% unlabeled Aβ1-40 and 20% BODIPY-Aβ1-40. Overall, 
the peak areas obtained after 0, 5, 10, 24, 36, and 48 hours are similar while the peak areas 
obtained after 28 hours are somewhat different. This further demonstrates that BODIPY-Aβ1-40 
has the potential to be used to detect oligomers formed by unlabeled Aβ1-40.  
 The appearance of a peak with a faster migration time was obtained using both BODIPY 
and FAM (Chapter 4) for the analysis of Aβ1-40 and Aβ1-42, respectively. In contrast, BODIPY 
was able to detect the appearance of peaks with migration times > 40 min. This indicates that dye 
size may play a role in the ability of LIF-CE to detect Aβ1-40 oligomers and aggregates. In 
addition, we have successfully labeled Aβ1-40 with CE503 and AMCA-Hydrazide in our lab. 
CE503 is a dye which does not alter the net protein charge upon attachment while AMCA-
Hydrazide is attached exclusively to the C-terminus. Future studies will be conducted to explore 
the effects of net protein charge (CE503) and attachment site (AMCA-Hydrazide) on the ability 





 38 Effect of aggregation time on the peak areas obtained for A) 10 – 30 kDa (, n = 3) and > 300 kDa (, n = 3) Aβ1-40 
species analyzed via UV-CE and B) peak 1 - 8 (, n =d peak 9 (, n = 1 - 2) BODIPY-Aβ1-40 species analed 
via LIF-CE. 
Figure 3 Effect of aggregation time on the peak areas obtained for A) 10 – 30 kDa 
(, n = 3) and > 300 kDa (, n = 3) Aβ1-40 species analyzed via UV-CE and B) peak 
1 - 8 (, n = 1 - 2) and peak 9 (, n = 1 - 2) BODIPY-Aβ1-40 species analyzed via 
LIF-CE. Samples containing 100% Aβ1-40 and samples containing 20% BODIPY-
labeled Aβ1-40 and 80% unlabeled Aβ1-40 were aggregated under agitation (800 rpm) 
at 0.22 mg/mL in 40 mM Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0 – 
48  hours, CE was performed in conjunction with A) UV detection with a 0.5 psi 
pressure injection for 8 s with separation at 7 kV using 0.5% PEO separation matrix 
in a PEO coated capillary or B) LIF detection with a 7 kV injection for 7 s with 









Figure 39 Effect of aggregation time on the peak areas obtained for > 300 kDa (, n = 3) Aβ1-40 species 
detected via UV-CE and peak 9 (, n = 1 - 2) BODIPY-Aβ1-40 species detected via LIF-CE. 
Figure 4 Effect of aggregation time on the peak areas obtained for > 300 kDa (, n 
= 3) Aβ1-40 species detected via UV-CE and peak 9 (, n = 1 - 2) BODIPY-Aβ1-40 
species detected via LIF-CE. The peak areas for the UV-CE data were multiplied by 
20% in order to facilitate comparisons between UV-CE and LIF-CE. Samples 
containing 100% Aβ1-40 and samples containing 20% BODIPY-labeled Aβ1-40 and 
80% unlabeled Aβ1-40 were aggregated under agitation (800 rpm) at 0.22 mg/mL in 
40 mM Tris (pH 8.0) containing 5 mM NaCl and at 25 °C. At 0 – 48  hours, CE was 
performed in conjunction with UV detection with a 0.5 psi pressure injection for 8 s 
with separation at 7 kV using 0.5% PEO separation matrix in a PEO coated capillary 
or LIF detection with a 7 kV injection for 7 s with separation at 7 kV using 1.5% 






detect oligomers and aggregates formed by unlabeled Aβ1-40. Future work will need to be done to 
determine if these dyes can be used to label the aggregation process in a way that does not affect 
the natural aggregation. Once the optimal dye is identified, the potential for LIF-CE to detect 
physiologically relevant concentrations of Aβ1-40 oligomers and aggregates can be determined. 
3. Conclusions 
 The detection of oligomers and aggregates formed by two amyloid proteins, insulin and 
Aβ, is of particular importance due to the role which these species play in Diabetes and 
Alzheimer’s disease, respectively. However, existing techniques are limited in the ability to 
detect insulin and Aβ oligomers due to the fact that these early aggregates are transient, present 
at low concentrations, and difficult to isolate. The present work has demonstrated the potential 
for CE and ME to detect the native aggregation of insulin and Aβ proteins, in particular the 
formation of oligomers and aggregates. Specifically, we have demonstrated that UV-CE is 
capable of monitoring native aggregation and provides a size range for the oligomeric and 
aggregate species produced. LIF-CE is capable of detecting physiologically relevant 
concentrations of FITC-insulin and FAM-Aβ but the fluorescent dye necessary for these analyses 
interferes with native aggregation and thus could give inexact information about the amount of 
oligomers and aggregates formed. ME is capable of detecting physiological concentrations of 
FAM-Aβ but detection of the binding of BTA-1 to physiological concentrations of unlabeled Aβ 
was not demonstrated. Therefore, significant work lies ahead to investigate alternative 
fluorescent dyes and optimization of dye concentration in order to achieve the detection of 
physiologically relevant concentrations of insulin and Aβ. This work has laid the foundation for 
future studies by establishing UV-CE, LIF-CE, and LIF-ME protocols for the detection of 




ME to detect physiological concentrations although a significant amount of work is needed in the 
future in order for these techniques to be applied in a clinical setting.  
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Doctoral committee comments addressed 
Shear and temperature sensitivity of the various constructs 
 The effect of shear stress on Aβ1-40 fibrils has been previously investigated [11,12]. The 
Young’s Moduli for Aβ1-40 fibrils ranges from 12 – 30 GPa where longer fibrils are generally 
more stable [11,12]. For Aβ1-40 fibrils < 50 nm in length, Xu et al. found that shear effects 
dominate lateral deformation.[12] However, the amount of total stress necessary to break apart 
hydrogen bonds in Aβ1-40 fibrils is ~0.14 GPa (20,300 psi) [11]. Since our studies are conducted 
at atmospheric pressure (14.7 psi), it is unlikely that shear effects would produce a significant 
change in the structure of the Aβ constructs produced in our experiments. Furthermore, the 
radius of the pores within the polymer network of the capillary is in the µm range which results 
in a relatively open network for the Aβ constructs to travel through. 
 It is widely accepted that an increase in temperature leads to an increase in the rate of 
fibrillation for amyloid proteins [13]. Thus, larger aggregate sizes will be obtained at elevated 
temperatures. During CE experiments, an increase in capillary temperature may occur as a result 
of Joule heating. In order to determine what run voltages will produce a significant amount of 
Joule heating, an Ohm’s law plot was generated for the Aβ1-40 conditions utilized in these 
studies. It was found that above a separation voltage of 9 kV, Joule heating began to occur. 
Therefore, all Aβ1-40 experiments were carried out at a separation voltage of 7 kV in order to 
minimize the production of heat. Furthermore, the capillary is surrounded by coolant which pulls 
heat away and maintains a constant capillary temperature during the experiments. A study by 




the peak pattern obtained for Aβ1-40 [14]. It is unlikely that the change in temperature occurring 
during these CE experiments has an affect on the stability of the amyloid constructs. 
Mass balances in electropherograms 
 In order to determine whether a mass balance could be performed using the CE 
electropherograms, the peak areas obtained for experiments in Chapter 3 were summed. The 
values obtained were not constant over time. When the 10 – 30 kDa and > 300 kDa peak areas 
were summed, the total peak area decreased over an aggregation time of 48 hours for both HFIP-
treated and SEC-isolated Aβ1-40 samples (Figure A). Since we did not account for the peaks with 
longer migration times in these calculations, this decrease in area could be due to the 
incorporation of the 10 – 30 kDa peak into larger aggregate sizes which would elute at longer 
migration times. When all peaks with S/N > 3 were summed, the total peak area increased over 
an aggregation time of 48 hours for both HFIP-treated and SEC-isolated Aβ1-40 samples (Figure 
B). Since the β-sheet structure absorbs light at around 214 nm, this increase in area over time 
could be due to the presence of this structure. Alternatively, Aβ could be retained on the capillary 
wall between runs which would lead to an increase in area over time. These observations 










Figure: Effect of aggregation time on the peak areas obtained for A) 10 – 30 kDa + > 
300 kDa (HFIP-treated,, n = 3 and SEC-isolated,, n = 3) Aβ1-40 species and B) 
All Peaks (HFIP-treated,, n = 3 and SEC-isolated,, n = 3) Aβ1-40 species. Aβ1-40 
was aggregated under agitation (800 rpm) at 0.22 mg/mL in 40 mM Tris (pH 8.0) 
containing 5 mM NaCl and at 25 °C. At 0 – 48  hours, CE was performed in 
conjunction with UV detection with a 0.5 psi pressure injection for 8 s with 












Results of reinjection of capillary effluent 
 The volume injected into the capillary using a pressure injection can be calculated 
according to the following equation: 




Where volume = volume introduced (nL), ΔP = pressure difference (psi), r = inner radius of 
capillary (µm), tint = introduction time (s), η = viscosity of sample (mPa*s), Lt = total length of 
capillary (cm). For the experimental conditions used in Chapter 3, the volume introduced is ~14 
nL. The recovery of such a small volume of sample makes the reinjection of the capillary 
effluent quite difficult, since the sample would be highly diluted in buffer solution at the outlet. 
Number of theoretical plates calculations 
 The number of theoretical plates (N) was calculated for the 10 – 30 kDa and > 300 kDa 





Where N = number of theoretical plates, Lt = total capillary length (cm), and HETP = height 










Where Ld = effective capillary length to detector (cm), W1/2 = peak width at half maximum 
(min), and tm = migration time (min). The number of theoretical plates obtained for the 10 – 30 
kDa peak at various points throughout aggregation is shown in Figure A. For both HFIP-treated 
Aβ1-40 and SEC-isolated Aβ1-40, N for the 10 – 30 kDa peak decreases over an aggregation time 
of 48 hours. The number of theoretical plates obtained for the > 300 kDa peak at various points 




significantly larger (~70 times greater) compared to the values obtained for the 10 – 30 kDa 
peak. Similar values as those obtained for the number of theoretical plates for the > 300 kDa 
peak have been obtained in the literature for cytochrome C [17]. The HETP for capillary 
electrophoresis can be thought of as the fraction of the capillary occupied by the analyte. Since 
higher values of N are obtained for the > 300 kDa peak versus the 10 – 30 kDa peak, this 




















Figure: Effect of aggregation time on the theoretical plate number obtained for A) 10 
– 30 kDa (HFIP-treated,, n = 3 and SEC-isolated,, n = 3) Aβ1-40 species and B) > 
300 kDa (HFIP-treated,, n = 3 and SEC-isolated,, n = 3) Aβ1-40 species. Aβ1-40 
was aggregated under agitation (800 rpm) at 0.22 mg/mL in 40 mM Tris (pH 8.0) 
containing 5 mM NaCl and at 25 °C. At 0 – 48  hours, CE was performed in 
conjunction with UV detection with a 0.5 psi pressure injection for 8 s with 













Long Chain Poly-N-Hydroxyethyl Acrylamide Polymerization Protocol (Coating Polymer) 
NOTE:  Wear gloves and a lab coat at all times as HEA monomer is very toxic.  
4% Initial Monomer Solution: 
Add 16.5 mL of N-hydroxyethyl acrylamide to 383.5 mL of dH2O 
Note:  The N-hydroxyethylacrylamide solution is 97% w/w aqueous solution so calculate 
amounts by 
         M1V1 = M2V2 
            (97)*(x) = (4)*(400) 
 x = 16.5 mL N-hydroxyethyl acrylamide (PHEA) so 400-16.5 = 383.5 mL of dH2O 
-Run 400 mL PHEA solution through MEHQ inhibitor remover column at speed 6 (~1.8 
mL/min). The solution will take ~ 4 hours to run through the column. 
Solution de-oxygenation: 
-Deoxygenate solution in 47°C water bath by bubbling nitrogen through the mixture for 2 hours. 
0.02% V-50 Solution: 
0.04 mL (40 μL) of V-50 for every 200 mL of polymer solution.  
-Add 40 µL of V-50 to 200 mL PHEA solution and then blow nitrogen over the solution for 4-5 
hours. 
-Transfer final solution to dialysis tubing bags (MWCO = 100,000 Da). 
-Place dialysis tubes with polymer in them in the fish bowls (4 tubes per fish bowl) and fill fish 







-Change the de-ionized water in the fish bowls 10 times total. Each water change should be at 
least 4 hours apart. 
Freezing and lyophilizing polymer: 
-After 10 water changes have been completed, transfer the polymer to 45 mL falcon tubes (~35 
mL polymer solution in each tube). 
-Place falcon tubes in freezer box and store in -80°C freezer for 2 days. 
-After polymer has been stored in -80°C freezer for 2 days, lyophilize polymer for 2 days, 


















Short Chain Poly-N-Hydroxyethyl Acrylamide Polymerization Protocol (Separation Polymer) 
NOTE:  Wear gloves and a lab coat at all times as HEA monomer is very toxic.  
4% Initial Monomer Solution: 
Add 16.5 mL of N-hydroxyethyl acrylamide to 383.5 mL of dH2O 
Note:  The N-hydroxyethylacrylamide solution is 97% w/w aqueous solution so calculate 
amounts by 
    M1V1 = M2V2 
         (97)*(x) = (4)*(400) 
       x = 16.5 mL N-hydroxyethyl acrylamide (PHEA) so 400-16.5 = 383.5 mL of dH2O 
-Run 400 mL PHEA solution through MEHQ inhibitor remover column at speed 6 (~1.8 
mL/min). The solution will take ~ 4 hours to run through the column. 
Isopropanol (chain transfer agent): 
-For ~770 kDa polymer, 2 mL isopropanol (IPA) added to 100 mL of 5% initial monomer 
solution (Hert et al.) Therefore, add 3.2 mL IPA to 200 mL of 4% initial monomer solution. 
Swirl IPA into solution. 
 2 mL IPA/100 mL of 5% initial monomer  = x mL/200 mL of 4% initial monomer 
    2 mL IPA/5 mL initial monomer = x mL/8 mL initial monomer 
x = 3.2 mL IPA 
-Deoxygenate solution in 47°C water bath by bubbling nitrogen through the mixture for 2 hours. 
0.02% V-50 Solution: 
0.04 mL (40 μL) of V-50 for every 200 mL of polymer solution.  





-Transfer final solution to dialysis tubing bags (MWCO = 100,000 Da). 
-Place dialysis tubes with polymer in them in the fish bowls (4 tubes per fish bowl) and fill fish 
bowls with 18 MΩ de-ionized water so the water covers tubing. 
Water changes: 
-Change the de-ionized water in the fish bowls 10 times total. Each water change should be at 
least 4 hours apart. 
Freezing and lyophilizing polymer: 
-After 10 water changes have been completed, transfer the polymer to 45 mL falcon tubes (~35 
mL polymer solution in each tube). 
-Place falcon tubes in freezer box and store in -80°C freezer for 2 days. 
-After polymer has been stored in -80°C freezer for 2 days, lyophilize polymer for 2 days, 















Polymer Molecular Weight determination using Multi-Angle Light Scattering (MALS) 
NOTE: Wear gloves and safety glasses when handling polymer solutions! 
Sample preparation: 
-Prepare 6 mL of a 5 mg/mL stock solution of your polymer in de-ionized water. For example, 
if analyzing PDMA polymer, dissolve 30 mg of dry PDMA in 6 mL of de-ionized water. If 
sample limited, adjust calculations accordingly. 
-Prepare 10 mL of the following concentrations by diluting 5 mg/mL stock PDMA solution: 
 1 mg/mL 
 0.75 mg/mL 
 0.5 mg/mL 
 0.25 mg/mL 
0.1 mg/mL 
For example, to prepare 1 mg/mL dilution: 
 M1V1 = M2V2 
 (5 mg/mL)*(V1) = (1 mg/mL)*(10 mL) 
 V1 = 2 mL of 5 mg/mL stock PDMA solution 
 So add 2 mL of 5 mg/mL stock PDMA solution to 8 mL of de-ionized water 
Fill five 10 mL plastic syringes (without rubber tips) with PDMA dilutions. 
Fill one 10 mL plastic syringe with de-ionized water. 








Double click the Astra 5.3.4.14 icon. 
Click the green circle to start experiment. 
Once experiment has started, use the syringe pump to flush water through system until ~5 
minutes of a stable baseline is obtained. 
Using syringe pump, flush 1 mg/mL polymer solution through system until ~3 minutes of a 
stable line is obtained. 
Using syringe pump, flush 0.75 mg/mL polymer solution through system until ~3 minutes of a 
stable line is obtained. 
Using syringe pump, flush 0.5 mg/mL polymer solution through system until ~3 minutes of a 
stable line is obtained. 
Using syringe pump, flush 0.25 mg/mL polymer solution through system until ~3 minutes of a 
stable line is obtained. 
Using syringe pump, flush 0.1 mg/mL polymer solution through system until ~3 minutes of a 
stable line is obtained. 
Using syringe pump, flush water through system until ~5 minutes of a stable baseline is 
obtained. 
NOTE: Water must be flushed through the system before and after sample data collection in 
order to obtain a proper baseline for data analysis. 
Once water and all 5 sample dilutions have been flushed through system, press the red stop 
button at the top of the page. 
The software will ask you to draw your baseline and define peaks. You must do this before the 




Under the Procedures tab, click “Peaks” and enter in the concentrations for each peak you have 
defined and a dn/dc value of 0.175 for each peak. You must enter in these values to generate the 
Zimm Plot! 
View the Zimm Plot by clicking “A2, Mass & Radius from LS”. The mass and rms radius are 






















Cleaning MALS Flowcell with 0.1 M Nitric Acid 
NOTE: Nitric Acid (HNO3) is extremely toxic. Work with in hood and do not inhale fumes.  
0.1 M HNO3 is in fume hood in BEC 2238. 
1) Flow ~6 mL of 0.1 M HNO3 through the MALS instrument. 
2) Let solution sit in MALS instrument for 3 hours. 
3) After 3 hours, rinse with filtered de-ionized water for 15 min (or flow ~5 mL through) 
4) Rinse with 100% ethanol for 15 min (or flow ~5 mL through) 
5) Rinse with 100% toluene for 15 min (or flow ~5 mL through) 
6) Rinse with 100% ethanol for 15 min (or flow ~5 mL through) 
7) Rinse with filter de-ionized water for 15 min (or flow ~5 mL through) 
Compare the light scattering voltages for the toluene to the voltages given in the certificate of 















Polymer Solution Preparation for use on CE 
NOTE: All solution percents are calculated as weight/volume (w/v). 
Preparation of coating polymer: 
Coating polymers should have a higher  molecular weight (ie. > 1,500,000 g/mol) 
To prepare a 1% PHEA solution, use the following calculation: 
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑤𝑎𝑡𝑒𝑟 𝑛𝑒𝑒𝑑𝑒𝑑 (𝑚𝐿)
=  
(𝑝𝑜𝑙𝑦𝑚𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑚𝑔)) − ( 1%100 × 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑚𝑔))
�1%100�
 
Always add water to coating polymer solutions! 
Preparation of separation matrix polymer: 
Separation matrix polymers should have a lower molecular weight (ie. < 1,500,000 g/mol) 
Same protocol as above except dissolve separation polymer solutions in CE separation buffer (ie. 














0.1% Polyhydroxyethyl acrylamide (PHEA) Capillary Coating Protocol 
-Capillary should be 31 cm total length, 10 cm effective length, and 50 μm ID. 
-All steps done using reverse rinses (outlet to inlet) 
15 minute de-ionized water rinse at 20 psi 
15 minute 1 M HCl rinse at 20 psi 
20 minute 0.1% w/v PHEA polymer solution rinse at 20 psi  
15 minute de-ionized water rinse at 20 psi 



















0.5% Polyethylene oxide (PEO) Capillary Coating Protocol 
-Capillary should be 31 cm total length, 10 cm effective length, and 50 μm ID. 
-Protocol adapted from Fung et al. 1995-“High-Speed DNA Sequencing by Using Mixed 
Poly(ethylene oxide) Solutions in Uncoated Capillary Columns” 
-All steps done using reverse rinses (outlet to inlet) 
 10 min rinse with water at 20 psi 
 15 min rinse with 0.1 M HCl at 20 psi 
 30 min rinse with 0.5% PEO at 50 psi  
  (PEO from Sigma Cat # 372803, Mv ~2,000,000 prepared in de-ionized water) 
 15 min rinse with water at 20 psi 
















Microchip Coating Procedure 
 15 min de-ionized water 
 15 min 1 M HCl 
 20 min 0.1% PHEA (dissolved in de-ionized water) 
 15 min de-ionized water 
-Pull solution through channels with the vacuum pump. 
-Let each solution sit in chip for given amount of time. Watch for evaporation. If evaporation 
occurs, pull more solution through channel. 
-After given amount of time, pull solution out of channels. 
-Repeat procedure for each solution. 
















40 mM Tris-HCl Protocol 
Buffer recipe, generated by Buffer Calculator (c) Rob Beynon 1996-2006 
http://www.liv.ac.uk/buffers  
BUFFER: 
To make 1000 ml of 0.04 M Tris (pKa = 8.06) Buffer, pH =  8,  
Ionic strength = 0.022 M,  
(Ionic strength due to the buffer = 0.022M ) 
Thermodynamic pKa = 8.06, Apparent pKa' = 8.12 
Temperature coefficient = -0.028 per oC 
Prepared at 25oC, used at 25 oC 
RECIPE:  
Weigh out 3.594 g Tris-HCl crystals (0.0228 mol of acid component) 
Weigh out 2.071 g Tris base crystals (0.0171 mol of basic component) 
(No added neutral salts, I due to buffer alone.) 
Make up to 1000 ml with pure water 
Check to make sure pH = 8.0. If pH does not equal 8, add 0.04 g more Tris-HCl crystals and 0.04 
g more Tris base crystals. 









Monomerization by HFIP and storage of Aβ1-40 peptide 
Objective:  Aβ1-40 storage 
Stock Solutions: 
A. Assay Buffer:   
        HFIP (1,1,1,3,3,3-hexafluoro-2-propanol) 
B. Aβ1-40:  1mg/vial    Anaspec 
Procedure: 
1. Solid Aβ1-40 is stored as a solid at -80C. Remove and place on ice when ready to prepare stock 
peptide films. 
2. Place 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) on ice in the hood and allow to cool. HFIP is 
highly corrosive and very volatile. Add enough HFIP to Aβ1-40 such that the final peptide 
concentration is 1mM (e.g. 231 ul cold HFIP to 1 mg Aβ1–40). Rinse vial thoroughly. 
3. Incubate at room temperature for 60 min, keeping vial closed. Solution should be clear and 
colorless. Any traces of yellow color or cloudy suspension indicate poor peptide quality and 
should not be used. 
4. Place peptide—HFIP solution back on ice for 5–10 min. 
5. Separate the HFIP into vials with 0.0625 mg/vial. That means each vial has 14.4 µL stock. 
6. Aliquot solution into non-siliconized microcentrifuge tubes. Do not close tubes. 
7. Allow HFIP to evaporate overnight in the hood at room temperature. 
8. All traces of HFIP must be removed. The resulting peptide should be a thin clear film at the 
bottom of the tubes. The peptide should not be white or chunky. 





Monomerization by HFIP and storage of FAM-Aβ1-40 peptide 
Objective:  FAM-Aβ1-40 storage 
Stock Solutions: 
A.  Assay Buffer:   
        HFIP (1,1,1,3,3,3-hexafluoro-2-propanol) 
B.  FAM-Aβ1-40:  0.1mg/vial    Anaspec 
Procedure: 
1. Solid FAM-Aβ1-40 is stored as a solid at -80C. Remove and place on ice when ready to prepare 
stock peptide films. 
2. Place 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) on ice in the hood and allow to cool. HFIP is 
highly corrosive and very volatile. Add enough HFIP to FAM-Aβ1-40 such that the final peptide 
concentration is 0.1 mM (e.g. 213.3 ul cold HFIP to 0.1 mg FAM-Aβ1–40). Rinse vial thoroughly. 
3. Incubate at room temperature for 60 min, keeping vial closed. Solution should be clear and 
colorless. A cloudy suspension indicates poor peptide quality and should not be used. 
4. Place peptide—HFIP solution back on ice for 5–10 min. 
5. Separate the HFIP into vials with 0.01563 mg/vial. That means each vial has 33.3 µL stock. 
6. Aliquot solution into non-siliconized microcentrifuge tubes. Do not close tubes. 
7. Allow HFIP to evaporate overnight in the hood at room temperature. Cover with foil! 
8. All traces of HFIP must be removed. The resulting peptide should be a thin clear film at the 
bottom of the tubes. The peptide should not be white or chunky. 






Monomerization by HFIP and storage of Aβ1-42 peptide 
Objective:  Aβ1-42 storage 
Stock Solutions: 
A. Assay Buffer:   
        HFIP (1,1,1,3,3,3-hexafluoro-2-propanol) 
B. Aβ1-42:  1mg/vial    Anaspec 
Procedure: 
1. Solid Aβ1-42 is stored as a solid at -80C. Remove and place on ice when ready to prepare stock 
peptide films. 
2. Place 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) on ice in the hood and allow to cool. HFIP is 
highly corrosive and very volatile. Add enough HFIP to Aβ1-42 such that the final peptide 
concentration is 1mM (e.g. 222 ul cold HFIP to 1 mg Aβ1–42). Rinse vial thoroughly. 
3. Incubate at room temperature for 60 min, keeping vial closed. Solution should be clear and 
colorless. Any traces of yellow color or cloudy suspension indicate poor peptide quality and 
should not be used. 
4. Place peptide—HFIP solution back on ice for 5–10 min. 
5. Separate the HFIP into vials with 0.0271 mg/vial. That means each vial has 6.02 µL stock. 
6. Aliquot solution into non-siliconized microcentrifuge tubes. Do not close tubes. 
7. Allow HFIP to evaporate overnight in the hood at room temperature. 
8. All traces of HFIP must be removed. The resulting peptide should be a thin clear film at the 
bottom of the tubes. The peptide should not be white or chunky. 





Monomerization by HFIP and storage of FAM-Aβ1-42 peptide 
Objective:  FAM-Aβ1-42 storage 
Stock Solutions: 
A. Assay Buffer:   
        HFIP (1,1,1,3,3,3-hexafluoro-2-propanol) 
B. FAM-Aβ1-42:  0.1mg/vial    Anaspec 
Procedure: 
1. Solid FAM-Aβ1-42 is stored as a solid at -80C. Remove and place on ice when ready to prepare 
stock peptide films. 
2. Place 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) on ice in the hood and allow to cool. HFIP is 
highly corrosive and very volatile. Add enough HFIP to FAM-Aβ1-42 such that the final peptide 
concentration is 0.1mM (e.g. 205.2 ul cold HFIP to 0.1 mg FAM-Aβ1–42). Rinse vial thoroughly. 
3. Incubate at room temperature for 60 min, keeping vial closed. Solution should be clear and 
colorless. A cloudy suspension indicates poor peptide quality and should not be used. 
4. Place peptide—HFIP solution back on ice for 5–10 min. 
5. Separate the HFIP into vials with 0.006775 mg/vial. That means each vial has 13.9 µL stock. 
6. Aliquot solution into non-siliconized microcentrifuge tubes. Do not close tubes. 
7. Allow HFIP to evaporate overnight in the hood at room temperature. Cover tubes with foil! 
8. All traces of HFIP must be removed. The resulting peptide should be a thin clear film at the 
bottom of the tubes. The peptide should not be white or chunky. 






Insulin Oligomer Time Course Protocol for Analysis Via UV-CE 
1 mg/mL insulin stock sample preparation: 
1) Weigh out ~1 mg insulin and add 5 mM NaOH such that the ratio of NaOH:40 mM Tris-HCl 
is 500:10000, assuming a 1 mg/mL final concentration. For example, if 1 mg insulin weighed 
out, amount of NaOH added is as follows: 
( 500
10000
× 1000 µ𝐿) = 50 µ𝐿 5 𝑚𝑀 𝑁𝑎𝑂𝐻 
2) Let insulin solution sit in 5 mM NaOH for 30 min. 
3) Bring up to 1 mg/mL with 40 mM Tris-HCl (pH = 8.0) 
4) Dilute the 1 mg/mL solution to 0.2 mg/mL in 40 mM Tris-HCl supplemented with 0 - 250 
mM NaCl by adding the appropriate amount of 4.4 M NaCl to the tube. The final total volume 
should be 800 µL. For example, the amount of 40 mM Tris-HCl and 4.4 M NaCl to add for a 
sample supplemented with 150 mM NaCl is as follows: 
𝑀1𝑉1 = 𝑀2𝑉2 
(4,400 𝑚𝑀 𝑁𝑎𝐶𝑙) × (𝑥) = (150 𝑚𝑀 𝑁𝑎𝐶𝑙) × (800 µ𝐿) 




𝑖𝑛𝑠𝑢𝑙𝑖𝑛� × (𝑥) = �0.2
𝑚𝑔
𝑚𝐿
𝑖𝑛𝑠𝑢𝑙𝑖𝑛� × (800 µ𝐿) 




𝑆𝑜,𝑓𝑜𝑟 𝑎 𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 800 µ𝐿,𝑎𝑑𝑑 160 µ𝐿 1
𝑚𝑔
𝑚𝐿
𝑖𝑛𝑠𝑢𝑙𝑖𝑛 + 27.3 µ𝐿 4,400 𝑚𝑀 𝑁𝑎𝐶𝑙
+ (800 µ𝐿 − 27.3 µ𝐿 − 160 µ𝐿) = 612.7 µ𝐿 40 𝑚𝑀 𝑇𝑟𝑖𝑠 − 𝐻𝐶𝑙 (𝑝𝐻 8.0) 







NOTE: For studies in this thesis, 0.1% poly-N-hydroxyethyl acrylamide (PHEA) was used to 
coat the capillary and 0.5% PHEA was used for separation. However, PHEA interferes with the 
detection of insulin at 214 nm so 0.5% poly-ethylene oxide (PEO) coated capillaries should be 
utilized with 0.5% PEO separation matrix. A new capillary should be coated before each time 
course. 
Capillary dimensions: Lt = 31 cm, Ld = 10 cm 
Before each time point run, perform the following steps on the Beckman P/ACE instrument: 
Reverse rinse (ie. outlet = inlet) with de-ionized water for 10 min at 50 psi 
Reverse rinse with 0.5% PEO for 10 min at 50 psi 
0.5 psi injection for 8 s  















Aβ1-40 Oligomer Time Course Protocol for Analysis Via UV-CE 
50 µM (0.22 mg/mL) Aβ1-40 Sample Concentration: 
1) Take vial containing 0.0625 mg Aβ1-40 out of -80°C freezer. Add 5 mM NaOH such that the 
ratio of NaOH:40 mM Tris-HCl is 500:10000, assuming a 0.22 mg/mL final concentration (ie. 
add 14.2 µL 5 mM NaOH). 
2) Let Aβ1-40 solution sit in 5 mM NaOH for 5 min. 
3) Bring up to 0.22 mg/mL in 40 mM Tris-HCl supplemented with 5 mM NaCl by adding the 
appropriate amount of 4.4 M NaCl to the tube. The final total volume should be 284 µL. For 
example, the amount of 40 mM Tris-HCl and 4.4 M NaCl to add for a sample supplemented with 
5 mM NaCl is as follows: 
𝑀1𝑉1 = 𝑀2𝑉2 
(4,400 𝑚𝑀 𝑁𝑎𝐶𝑙) × (𝑥) = (5 𝑚𝑀 𝑁𝑎𝐶𝑙) × (284 µ𝐿) 
𝑥 = 0.33 µ𝐿 4,400 𝑚𝑀 𝑁𝑎𝐶𝑙 
𝑆𝑜, 𝑓𝑜𝑟 𝑎 𝑡𝑜𝑡𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 284 µ𝐿,𝑎𝑑𝑑 (284 µ𝐿 − 0.33 µ𝐿 − 14.2 µ𝐿)
= 269.5 µ𝐿 40 𝑚𝑀 𝑇𝑟𝑖𝑠 − 𝐻𝐶𝑙 (𝑝𝐻 8.0) 
 5) Agitate sample at 25°C and 800 rpm. At various time points, take 20 µL sample and analyze 
via UV-CE. 
CE conditions: 
NOTE: 0.5% poly-ethylene oxide (PEO) coated capillaries should be utilized with 0.5% PEO 
separation matrix. A new capillary should be coated before each time course. 
Capillary dimensions: Lt = 31 cm, Ld = 10 cm 
Before each time point run, perform the following steps on the Beckman P/ACE instrument: 




Reverse rinse with 0.5% PEO for 10 min at 50 psi 
0.5 psi injection for 8 s  
























Size Estimation Analysis Via Centrifugal Filter Units 
1) Perform protocols for either “Insulin Oligomer Time Course” or “Aβ1-40 Oligomer Time 
Course”. 
2) When taking time points throughout aggregation, take a 50 µL sample and centrifuge at 
14,000 x g for 20 minutes. 





















Protocol for Aggregation of Aβ1-40 in Presence of Congo Red 
Congo Red stock solution: 
1) Prepare a 16.7 µM (0.23 mg/mL) stock solution of congo red in DMSO by adding ~18.9 mg 
congo red + 1.6 mL 100% DMSO.  
NOTE: Amounts may be adjusted according to how much congo red is weighed out.  
Aβ1-40 Aggregation Assay with Congo Red: 
1) Take vial containing 0.0625 mg Aβ1-40 out of -80°C freezer. Add 5 mM NaOH such that the 
ratio of NaOH:40 mM Tris-HCl is 500:10000, assuming a 0.221 mg/mL (51.02 µM) final 
concentration (ie. add 14.15 µL 5 mM NaOH). 
2) Let Aβ1-40 solution sit in 5 mM NaOH for 5 min. 
3) Bring up to 0.221 mg/mL in 40 mM Tris-HCl supplemented with 5 mM NaCl by adding the 
appropriate amount of 4.4 M NaCl to the tube. The final total volume should be 282.93 µL. For 
example, the amount of 40 mM Tris-HCl and 4.4 M NaCl to add for a sample supplemented with 
5 mM NaCl is 268.5 µL 40 mM Tris-HCl (pH 8.0) and 0.32 µL 4.4 M NaCl. 
4) Add 5.77 µL of 16.7 µM congo red stock solution to sample in Step 3. The final percent 
DMSO in solution should be 2% and the final Aβ1-40 concentration should be 50 µM. 
5) Agitate sample at 25°C and 800 rpm. At various time points, take 20 µL sample and analyze 
via UV-CE. 
CE conditions: 
NOTE: 0.5% poly-ethylene oxide (PEO) coated capillaries should be utilized with 0.5% PEO 
separation matrix. A new capillary should be coated before each time course. 
Capillary dimensions: Lt = 31 cm, Ld = 10 cm 




Reverse rinse (ie. outlet = inlet) with de-ionized water for 10 min at 50 psi 
Reverse rinse with 0.5% PEO for 10 min at 50 psi 
0.5 psi injection for 8 s  























Protocol for Aggregation of Aβ1-40 in Presence of Orange G 
Orange G stock solution: 
1) Prepare a 16.7 µM (0.23 mg/mL) stock solution of orange G in DMSO by adding ~12.1 mg 
congo red + 1.6 mL 100% DMSO.  
NOTE: Amounts may be adjusted according to how much orange G is weighed out.  
Aβ1-40 Aggregation Assay with Orange G: 
1) Take vial containing 0.0625 mg Aβ1-40 out of -80°C freezer. Add 5 mM NaOH such that the 
ratio of NaOH:40 mM Tris-HCl is 500:10000, assuming a 0.221 mg/mL (51.02 µM) final 
concentration (ie. add 14.15 µL 5 mM NaOH). 
2) Let Aβ1-40 solution sit in 5 mM NaOH for 5 min. 
3) Bring up to 0.221 mg/mL in 40 mM Tris-HCl supplemented with 5 mM NaCl by adding the 
appropriate amount of 4.4 M NaCl to the tube. The final total volume should be 282.93 µL. For 
example, the amount of 40 mM Tris-HCl and 4.4 M NaCl to add for a sample supplemented with 
5 mM NaCl is 268.5 µL 40 mM Tris-HCl (pH 8.0) and 0.32 µL 4.4 M NaCl. 
4) Add 5.77 µL of 16.7 µM orange G stock solution to sample in Step 3. The final percent 
DMSO in solution should be 2% and the final Aβ1-40 concentration should be 50 µM. 
5) Agitate sample at 25°C and 800 rpm. At various time points, take 20 µL sample and analyze 
via UV-CE. 
CE conditions: 
NOTE: 0.5% poly-ethylene oxide (PEO) coated capillaries should be utilized with 0.5% PEO 
separation matrix. A new capillary should be coated before each time course. 
Capillary dimensions: Lt = 31 cm, Ld = 10 cm 




Reverse rinse (ie. outlet = inlet) with de-ionized water for 10 min at 50 psi 
Reverse rinse with 0.5% PEO for 10 min at 50 psi 
0.5 psi injection for 8 s  























Aβ1-40 Dot Blot Protocol 
NOTE: Wear gloves and safety glasses when dealing with antibodies.  
Chemicals Needed: 
5% milk/TBS-T 
 Dissolve 2 g dry milk in 40 mL 1X TBST 
A11 primary antibody (anti-Aβ oligomer, 1 mg/mL) 
Anti-rabbit secondary antibody (use with A11 and OC primary, 2 mg/mL) 
6E10 primary antibody (anti-Aβ monomer, 1 mg/mL) 
Anti-mouse secondary antibody (use with 6E10 primary, 0.6 mg/mL) 
OC primary antibody (anti-Aβ fibril) 
Procedure: 
1) Cut single nitrocellulose membrane into 0.5” wide pieces. At each aggregation time point, 
spot 3 µL of sample onto each membrane. 
2) After all spots have been applied to membrane, allow last applied spot to dry for 1 hour. 
3) Block membranes in 5% milk/TBS-T solution at 4°C for 1 hour with gentle shaking. 
4) Wash membranes 3 times in 1X TBS-T. 
5) Cover each membrane with the following amounts of primary antibody: 
 Membrane 1: 5 mL 5% milk/TBS-T + 2.5 µL A11 primary antibody (1:2000 dilution) 
 Membrane 2: 5 mL 5% milk/TBS-T + 2.5 µL 6E10 primary antibody (1:2000 dilution) 
 Membrane 3: 5 mL 5% milk/TBS-T + 1.25 µL OC primary antibody (1:4000 dilution) 
6) Incubate with gentle shaking at 4°C for 1 hour. 
7) Wash membranes 3 times in 1X TBS-T. 




 Membrane 1: 5 mL 5% milk/TBS-T + 0.83 µL anti-rabbit secondary antibody (1:3000  
   dilution) 
 Membrane 2: 5 mL 5% milk/TBS-T + 4.17 µL anti-mouse secondary antibody (1:2000  
   dilution) 
 Membrane 3: 5 mL 5% milk/TBS-T + 0.83 µL anti-rabbit secondary antibody (1:3000  
   dilution) 
9) Incubate with gentle shaking at 4°C for 1 hour. 
7) Wash membranes 3 times in TBS-T/MgCl2. NOTE the use of TBS-T/MgCl2 for this step. 
8) Develop membranes by adding the following amounts of developing solution to each 
membrane: 
 Membrane 1: 15 mL TBS-T/MgCl2 + 50 µL BCIP (50 mg/mL) + 100 µL NBT (50  
   mg/mL) 
 Membrane 2: 15 mL TBS-T/MgCl2 + 50 µL BCIP (50 mg/mL) + 100 µL NBT (50  
   mg/mL) 
 Membrane 3: 15 mL TBS-T/MgCl2 + 50 µL BCIP (50 mg/mL) + 100 µL NBT (50  
   mg/mL) 
NOTE: Stock BCIP (50 mg/mL) prepared in 100% DMF and stock NBT (50 mg/mL) prepared 
in 70% DMSO. 
9) Allow membranes to develop and when begin to see spots, rinse membrane with 10% acetic 







25% FITC-labeled Insulin/75% Unlabeled Insulin Oligomer Time Course Protocol for Analysis 
Via LIF-CE 
-Prepare unlabeled insulin and FITC-labeled insulin separately: 
Unlabeled Insulin (0.3 mg/mL) supplemented with 150 mM NaCl: 
0.3 mg unlabeled insulin + 966 µL of 40 mM Tris-HCl + 34.1 µL of 4.4 M NaCl  
Note: If exact amounts are not weighed out, adjust volumes using excel spreadsheet but do not 
weigh out more than 0.3 mg unlabeled insulin! 
FITC-labeled Insulin (0.2 mg/mL) supplemented with 150 mM NaCl: 
0.1 mg FITC-labeled insulin + 483 µL of 40 mM Tris-HCl + 17 µL of 4.4 M NaCl 
Note: If exact amounts are not weighed out, adjust volumes using excel spreadsheet but do not 
weight out more than 0.1 mg FITC-labeled insulin! 
-Combine unlabeled insulin with FITC-labeled insulin so that final unlabeled insulin 
concentration is 0.2 mg/mL and final FITC-labeled insulin concentration is 0.067 mg/mL and 
place on shaking incubator at 185 rpm. 
-After 0, 4, 8, 10, 24, and 36 hours, take 20 µL of sample and dilute to 0.013 mg/mL in 40  mM 
Tris-HCl (pH 8.0). Run sample on LIF-CE. 
CE conditions: 
Rinse capillary with de-ionized water in between each run using syringe pump. 
12 kV injection for 12 s 







Aβ1-42/FAM-Aβ1-42 Oligomer Formation Assay with DMSO and Tween for Analysis Via LIF-CE 
1) When ready to start experiment, take vial containing 0.0271 mg Aβ1-42 and 0.006775 mg 
FAM-Aβ1-42 out of the -80°C freezer. Make a 5 mM Aβ1-42 stock and a 1.16 mM FAM-Aβ1-42 
stock in 100% DMSO. Pipette thoroughly, washing down the sides of the tube to ensure 
complete re-suspension of peptide film.  
2) Dilute Aβ1-42 and FAM-Aβ1-42 peptide stocks to 30 µM (0.14 mg/mL) with 40 mM Tris-HCl 
(pH 8.0) supplemented with 10 mM NaCl. 
3) Combine Aβ1-42 and FAM-Aβ1-42 samples to yield a total final concentration of 30 µM (0.14 
mg/mL) containing 50 – 80% unlabeled Aβ1-42 and 20 – 50% FAM-labeled Aβ1-42. 
NOTE: Look at excel spreadsheet for exact volume amounts. 
4) Allow oligomer prep to sit in microcentrifuge tube at room temperature (25°C) with cap on. 
5) At 0, 3, 6, 9, and 24 hours, add tween to obtain a final volume containing 0.1% tween. (ie. 
Prepare 1% tween stock solution by adding 10 µL pure tween to 990 µL de-ionized water. Take 
27 µL aliquot and add 3 µL of 1% tween. 
6) Analyze sample via LIF-CE. 
CE conditions: 
Rinse capillary with de-ionized water in between each run using syringe pump. 
7 kV injection for 7 s 








Aβ1-40 Oligomer Formation Assay With BTA-1 for Analysis Via LIF-ME  
BTA-1 stock solution: 
1) Prepare a 1 mg/mL stock solution of BTA-1 by adding ~1 mg BTA-1 to ~1 mL 100% DMSO.  
2) Dilute stock solution to 0.0064 mg/mL (4160 µM) in 40 mM Tris-HCl (pH 8.0). 
50 µM (0.22 mg/mL) Aβ1-40 Sample Concentration: 
1) Take vial containing 0.0625 mg Aβ1-40 out of -80°C freezer. Add 5 mM NaOH such that the 
ratio of NaOH:40 mM Tris-HCl is 500:10000, assuming a 0.22 mg/mL final concentration (ie. 
add 14.2 µL 5 mM NaOH). 
2) Let Aβ1-40 solution sit in 5 mM NaOH for 5 min. 
3) Bring up to 0.22 mg/mL in 40 mM Tris-HCl supplemented with 5 mM NaCl by adding the 
appropriate amount of 4.4 M NaCl to the tube. The final total volume should be 284 µL (ie. add 
269.5 µL 40 mM Tris-HCl and 0.33 µL 4.4 M NaCl). 
4) Agitate sample at 25°C and 800 rpm. At various time points, take aliquot and combine with 
BTA-1 for final Aβ1-40 and BTA-1 concentrations of 0.021 mg/mL (4.8 µM) and 0.0058 mg/mL 
(24.2 µM), respectively. The final BTA-1 concentration in solution (24.2 µM) should be 5 times 
the final Aβ1-40 concentration (4.84 µM).  Analyze sample via LIF-ME. 
ME conditions: 
1% PHEA dissolved in 40 mM Tris-HCl used for separation matrix 
40 mM Tris-HCl used for buffer 
200-600 V/cm injection for 10-20 s 






Aβ1-40 Oligomer Formation Assay With Thioflavin T for Analysis Via Fluorometer  
Thioflavin T (ThT) stock solution: 
1) Prepare a 2.32 mM ThT stock in de-ionized water. 
2) Solution is stable in 20°C freezer for 2-6 months. 
3) On day of experiment, dilute ThT stock to 26.8 µM in 40 mM Tris-HCl (pH 8.0).  
50 µM (0.22 mg/mL) Aβ1-40 Sample Concentration: 
1) Take vial containing 0.0625 mg Aβ1-40 out of -80°C freezer. Add 5 mM NaOH such that the 
ratio of NaOH:40 mM Tris-HCl is 500:10000, assuming a 0.22 mg/mL final concentration (ie. 
add 14.2 µL 5 mM NaOH). 
2) Let Aβ1-40 solution sit in 5 mM NaOH for 5 min. 
3) Bring up to 0.22 mg/mL in 40 mM Tris-HCl supplemented with 5 mM NaCl by adding the 
appropriate amount of 4.4 M NaCl to the tube. The final total volume should be 284 µL (ie. add 
269.5 µL 40 mM Tris-HCl and 0.33 µL 4.4 M NaCl). 
4) Agitate sample at 25°C and 800 rpm. At various time points, take aliquot and combine with 
ThT for final Aβ1-40 and ThT concentrations of 0.021 mg/mL (4.8 µM) and 0.0077 mg/mL (24.2 
µM), respectively (ie. add 19.4 µL Aβ1-40 to 180.6 µL 26.8 µM ThT). Use 1.5 mL quartz cuvette 
for analyses. 
5) Monitor fluorescence at the onset of aggregation and at times between 5 and 28 hours 
following the onset of aggregation using a Shimadzu RF-Mini-150 fluorometer (Columbia, MD) 







Protocol for Labeling Aβ1-40 with BODIPY  
Step 1:  Prepare 100 µl of 0.5 mg/ml Aβ pre-treated with HFIP in 0.1 M sodium bicarbonate, pH 
 8.3 on ice.  
Step 2: Add 7.5 µl dye –BODIPY-FL (Invitrogen D6140 MW = 491.20 g/mol)  
 BODIPY was dissolved in sequencing grade DMF at 10 mg/mL from dried aliquots in -
 20oC freezer 
Step 3: Incubate on ice for 1.5 hours 
Step 4: Stop the reaction by adding 10 µL of freshly prepared 1.5 M hydroxylamine, pH 8.5, 
 (To prepare hydroxylamine soln. carefully, add only ½ volume of sodium bicarbonate 
 soln. then pH) 
Step 5: Incubate on ice an additional 30 minutes 
Step 6: Rinse Centricon 3kDa with 40 mM Tris, pH 8.0, Add Reaction soln. dilute to 500 µl 
Spin at 14 krpm in microcentrifuge in refrigerator for 20 min; repeat 5 more times to 
change buffer to Tris and separate unreacted dye - should be approx. 100µl volume at end 
Step 7: Store at -80oC until need 
To figure concentration of dye BODIPY-FL: 
Use Beer’s Law    A = є × path length × concentration   
A = Absorbance maxima 502 nm  shifts to 504 nm after conjugation 
ε = 75,000 cm-1 M-1 
Path length is typically 1 cm (on nanodrop path length can change so use protein:dye program) 
Solve for dye concentration in M (moles/L)     c = ε x path length/ A   
To figure concentration of protein (This requires additional steps) 




ε = 1490 cm-1 M-1  at 280 nm    
Some of the absorbance at 280 nm will be due to the BODIPY dye  
 Therefore A280nm x 0.0573 = Adye  
To Solve for concentration of Aβ in M (moles/L)     c = ε x path length/ (A280nm - Adye) 
(Caution on attributing 280nm to Aβ concentration the extinction coefficient will change 
depending on the oligomeric/monomer state- therefore this method has been somewhat 
inconsistent) 
We do know that approx. 30% of total protein we started with is lost during our labeling 
procedures. 
Double-check your numbers for Aβ 
Determination of degree of labeling 















Aβ1-40/BODIPY-Aβ1-40 Oligomer Time Course Protocol for Analysis Via LIF-CE 
50 µM (0.22 mg/mL) Aβ1-40 Sample Concentration: 
1) Take vial containing 0.0625 mg Aβ1-40 out of -80°C freezer. Add 5 mM NaOH such that the 
ratio of NaOH:40 mM Tris-HCl is 500:10000, assuming a 0.22 mg/mL final concentration (ie. 
add 14.2 µL 5 mM NaOH). 
2) Let Aβ1-40 solution sit in 5 mM NaOH for 5 min. 
3) Bring up to 0.22 mg/mL in 40 mM Tris-HCl supplemented with 5 mM NaCl by adding the 
appropriate amount of 4.4 M NaCl to the tube. The final total volume should be ~284 µL (ie. add 
269.5 µL 40 mM Tris-HCl and 0.33 µL 4.4 M NaCl). 
4) Add BODIPY-Aβ1-40 to unlabeled Aβ1-40 such that final total concentration is ~50 µM Aβ. 
NOTE: See excel spreadsheet for exact volumes. 
5) Agitate sample at 25°C and 800 rpm. At various time points, take 7 µL sample and analyze 
via LIF-CE. 
CE conditions: 
Rinse capillary with de-ionized water in between each run using syringe pump. 
1.5% PHEA separation matrix in 0.1% PHEA coated capillary 
7 kV injection for 7 s 









Chip System 488 nm Laser Alignment and Operation 
NOTE:  Always wear safety glasses which are resistant to laser wavelength (orange lenses in 
container on the wall). Always close the curtain around the chip system when conducting 
experiments. Light put out by the laser can damage skin and eyes! Never shine the laser towards 
yourself or your eyes! 
488 nm Laser Operation: 
-Align laser so it is shining into the back of the microscope. 
-Ensure the 488 nm filter cube is in the correct position. 
-Ensure both filter wheels are in the “O” position. 
-Ensure the microscope is on the “Eye” port. 
-Ensure the key switch for the laser is in the “off” position (vertical up and down). 
-The “interlock” light should be green. 
-Plug in the laser fan. 
-Turn the key switch to the “on” position (horizontal side to side). 
-The laser will warm up and you will hear a click when it turns on.  
-Use the remote interface to turn the discharge switch to “On” and the run switch to “On”. 
-Turn off the laser by switching the remote interface discharge switch to “off”, run switch to 









488 nm Laser Alignment: 
NOTE: Before turning the laser on, ensure that the microscope objective is near well “D” of the 
microchip. Also, ensure the microscope is on the “Eye” port. 
 
-Turn on the 488 nm laser. 
-You should see a dot for the laser in the microchip well. You will need a source of light 
(flashlight) in order to see the laser dot on the microchip. Adjust the stage of the microscope so 
that the dot for the laser is in the middle of the microchip well and as close to well “D” as 
possible. 
 
-Record the position of the gauges on each side of the microscope stage. 
-Record the position of the actual laser on the table. 









Chip System High Voltage Power Supply Operation 
NOTE:  Always be cautious when operating the high voltage power supply. NEVER touch the 
stage or microchip when the high voltage power supply is enabled. This will result in 
electrocution! 
High Voltage Power Supply (HVPS) Operation: 
-See directions from George on using the metal chip holder and plastic cover. Never try to pull 
your chip out of the metal holder. This will break the chip! Instead, remove entire metal holder 
from stage to remove chip from stage. 
-Place the electrodes for each HVPS wire into the microchip wells as follows: 
 
-Ensure the electrodes are submerged in buffer within each well. In proper placement will result 
in loss of current. 
-Turn on the HVPS by pushing the button on the front of the HVPS box. 
-Click the “Sequence” icon on the desktop. 
-You can create your own program by going to “tools, simple sequence wizard”. 
-Press the  icon to toggle between offline and online status. 
-The  icon should be highlighted. This means the high voltage is not enabled. 
-Press the  icon to enable high voltage. Do NOT touch any part of the stage or microchip! 




-You can monitor the output of voltage and current for each well. The voltage values should 
equal what you set the program for and the current values should remain relatively steady. 
























Chip System Microscope Parts  
Microscope ports: 
There are 3 ports located on the microscope base: 
1) Eye-Put on this when want to look through eyepiece at microchip 
2) R-Right side port-Put on this when want to operate CCD camera (Hamamatsu) 
3) L-Left side port-Put on this when want to operate CCD camera (Andor) 
4) Aux-We will not use this port 
Microscope should be set on “Eye” by default. 
NOTE: Never turn the knob to R or L with the CCD camera ON and the overhead lights ON. 
This will burnout the CCD camera! 
Filter cube wheel positions: 
There are 2 positions on the filter cube wheel: 
C) Closed 
O) Open 
Filter wheels should be set to “C” by default. 
There are 6 filter cube positions within the filter wheel. 
The 488 nm laser filter cube is in position 6 on the lower filter wheel. 
 NOTE: Excitation filter = 470 nm and emission filter = 500 nm long pass  
The 355 nm laser filter cube is in position 5 on the lower filter wheel. 
 NOTE: Excitation filter = 355 nm and emission filter is interchangeable with either 430 






Chip System UV Laser Alignment and Operation 
NOTE:  Always wear safety glasses which are UV resistant (orange lenses in container on the 
wall). Always close the curtain around the chip system when conducting experiments with the 
UV laser. Light put out by the UV laser can damage skin and eyes! Never shine the laser towards 
yourself or your eyes! 
UV Laser Operation: 
-Align laser so it is shining into the back of the microscope. 
-Ensure the 355 nm filter cube is in the correct position. 
-Ensure both filter wheels are in the “O” position. 
-Ensure the microscope is on the “Eye” port. 
-Ensure the key switch is in the “off” position (vertical up and down). 
-Turn on the power button on the back of the power supply box (Coherent) for the UV laser. 
-Click the “OPSL” icon on the desktop. This is the user interface to operate the UV laser from 
the computer. 
-Wait until the “system fault” light is not red and the “interlock OK” light is yellow. The laser is 
now warmed up. 
-Turn the key switch to the “on” position (horizontal side to side). 
-The “laser on” light should be green indicating that the laser is on. 
-You can adjust the laser power using the “control” tab. Click “local” and set the power in the 
white box in the top part of the user interface.  






UV Laser Alignment: 
NOTE: Before turning the UV laser on, ensure that the microscope objective is near well “D” of 
the microchip. Also, ensure the microscope is on the “Eye” port. 
-Turn on the UV laser and adjust power to ~10? 
-You should see a dot for the laser in the microchip well. You will need a source of light 
(flashlight) in order to see the laser dot on the microchip. Adjust the stage of the microscope so 
that the dot for the laser is in the middle of the microchip well and as close to well “D” as 
possible. 
 
-Record the position of the gauges on each side of the microscope stage. 
-Record the position of the actual UV laser on the table. 









Existing techniques are limited in the ability to detect insulin and Aβ oligomers due to the 
fact that these early aggregates are transient, present at low concentrations, and difficult to 
isolate. A literature review was conducted by the author in the Fall of 2009 and later published in 
the International Journal of Molecular Sciences. This publication gave a broad overview of the 
techniques suitable for the determination of Aβ oligomer size and was thus reproduced in the 
literature review porition (Chapter 1) of this dissertation. The author contributed to more than 
50% of the work necessary to write this published review paper.  
The present work has demonstrated the potential for CE and ME to detect the native 
aggregation of insulin and Aβ proteins, in particular the formation of oligomers and aggregates. 
Specifically, we have demonstrated that UV-CE is capable of monitoring native aggregation and 
provides a size range for the oligomeric and aggregate species produced. LIF-CE is capable of 
detecting physiologically relevant concentrations of FITC-insulin and FAM-Aβ but the 
fluorescent dye necessary for these analyses interferes with native aggregation and thus could 
give inexact information about the amount of oligomers and aggregates formed. Chapter 3 
outlines studies conducted using CE to detect insulin oligomers and aggregates. This information 
was published in Fall 2011 in the International Journal of Molecular Sciences. Again, since this 
author contributed to writing over 50% of this publication, this publication was reproduced in 
Chapter 3 as a part of this dissertation.  
 
 
 
